

**CUMULATIVE
SUPPLEMENT 9
SEPTEMBER 2003**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

23rd EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2003

HYMAN, PHELPS
&MCNAMARA, P.C.
WASHINGTON, DC

DEMCO

earch

- 1.0 INT
- 1.1
- 1.2
- 1.3
- 1.4
- 1.5
- 1.6
- 1.7

DRUG PI

PATEL

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

23RD EDITION

Cumulative Supplement 9

September 2003

CONTENTS

		PAGE
1.0	INTRODUCTION	iii
1.1	How to Use the Cumulative Supplement	iii
1.2	Applicant Name Changes.....	iv
1.3	Nitroglycerin, Film, Extended Release; Transdermal 23 rd Annual Edition.....	v
1.4	NDA Patent 30-month Rule.....	vi
1.5	Availability of the Edition.....	vi
1.6	Report of Counts for the Prescription Drug Product List.....	vii
1.7	Cumulative Supplement Change Legend	viii
DRUG PRODUCT LISTS		1-1
	Prescription Drug Product List.....	2-1
	OTC Drug Product List.....	
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List.....	3-1
	Orphan Product Designations and Approvals List	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		A-1
	A. Patent and Exclusivity Lists	B-1
	B. Patent and Exclusivity Terms.....	

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

23rd EDITION

CUMULATIVE SUPPLEMENT 9

September 2003

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 23rd Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, are for exportation, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 23rd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 24th Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section A, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

AAIPHARMA INC (AAIPHARMA)	AAIPHARMA LLC (AAIPHARMA LLC)
BAYER CORP (BAYER)	BAYER PHARMACEUTICALS CORP (BAYER PHARMS)
BAYER CORP CONSUMER CARE DIV (BAYER CORP CONSUMER)	BAYER CORP CONSUMER CARE LLC (BAYER)
BAYER CORP PHARMACEUTICALS DIV (BAYER)	BAYER PHARMACEUTICALS CORP (BAYER PHARMS)
ESI LEDERLE INC (ESI LEDERLE)	CLONMEL HEALTHCARE INC (CLONMEL HEALTHCARE)
LEK SERVICES INC (LEK SVCS)	LEK PHARMACEUTICALS DD (LEK PHARM DD)
LEK LJUBLJANA PHARMACEUTICAL AND CHEMICAL CO (LEK LJUBLJANA)	LEK PHARMACEUTICALS DD (LEK PHARM DD)
LEK PHARMACEUTICAL AND CHEMICAL DD (LEK PHARM)	LEK PHARMACEUTICALS DD (LEK PHARM DD)
NEOSAN PHARMACEUTICALS (NEOSAN PHARMS)	AAIPHARMA LLC (AAIPHARMA LLC)
ORGANON INC (ORGANON INC)	ORGANON USA INC (ORGANON USA INC)
ORGANON INC SUB AKZO INC (ORGANON)	ORGANON USA INC (ORGANON USA INC)
ORGANON INC SUB AKZO NOBEL INC (ORGANON INC)	ORGANON USA INC (ORGANON USA INC)
SIDMAK LABORATORIES INC (SIDMAK LABS)	PLIVA INC (PLIVA)
SYNTEX (USA) INC LLC (SYNTEX USA INC)	ROCHE PALO ALTO LLC (ROCHE PALO)
WALLACE LABORATORIES DIV CARTER WALLACE INC (WALLACE LABS)	MEDPOINTE PHARMACEUTICALS MEDPOINTE HEALTHCARE INC (MEDPOINTE PHARM HLC)
WALLACE PHARMACEUTICALS DIV CARTER WALLACE INC (WALLACE PHARMS)	MEDPOINTE PHARMACEUTICALS MEDPOINTE HEALTHCARE INC (MEDPOINTE PHARM HLC)

1.3 NITROGLYCERIN, FILM, EXTENDED RELEASE; TRANSDERMAL 23RD ANNUAL EDITION

The *Approved Drug Products with Therapeutic Equivalence Evaluations 23rd annual edition*, page 3-265 omitted the 3 character Therapeutic Equivalence (TE) Codes for Nitroglycerin, Film, Extended Release; Transdermal products. The correct codes are listed below by product name, applicant holder, TE code, strength, NDA number, and product number.

<u>PRODUCT</u> <u>NAME</u>	<u>APPLICANT</u>	<u>TE</u> <u>CODE</u>	<u>STRENGTH</u>	<u>NDA</u>	<u>PRODUCT</u>
MINITRAN	3M	AB1	0.1MG/HR	N89771	001
MINITRAN	3M	AB1	0.2MG/HR	N89772	001
MINITRAN	3M	AB1	0.4MG/HR	N89773	001
MINITRAN	3M	AB1	0.6MG/HR	N89774	001
NITRO-DUR	KEY PHARMS	AB1	0.1MG/HR	N20145	001
NITRO-DUR	KEY PHARMS	AB1	0.2MG/HR	N20145	002
NITRO-DUR	KEY PHARMS	AB1	0.4MG/HR	N20145	004
NITRO-DUR	KEY PHARMS	AB1	0.6MG/HR	N20145	005
NITROGLYCERIN	HERCON LABS	AB2	0.2MG/HR	N89884	001
NITROGLYCERIN	HERCON LABS	AB2	0.4MG/HR	N89885	001
NITROGLYCERIN	HERCON LABS	AB2	0.6MG/HR	N89886	001

NITROGLYCERIN	MYLAN	AB2	0.1MG/HR	N75033	001
NITROGLYCERIN	MYLAN	AB2	0.2MG/HR	N74609	001
NITROGLYCERIN	MYLAN	AB2	0.4MG/HR	N74607	001

1.4 NDA PATENT 30-MONTH RULE

The Food and Drug Administration has amended its patent submission and listing requirements for new drug applications (NDAs). This final rule became effective on August 18, 2003. The final rule, among other things, limits to one per ANDA or 505(b)(2) application the maximum number of statutory 30-month stays of approval to which an innovator will be entitled when multiple patents are submitted for the same NDA.

Patents listed prior to August 18, 2003 will be designated by a “#” sign and are considered listed under the previous regulations that permitted multiple 30-month stays for an NDA. Patents listed after the effective date of the final rule will not have the # designation displayed and are considered listed under the new rule.

1.5 AVAILABILITY OF THE EDITION

The 23rd Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
 Government Printing Office
 P.O. Box 371954
 Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800 or toll free 866-512-1800. The cost is \$108.00 annually. A GPO Orange Book Subscription form is provided at the end of each cumulative supplement.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at <http://www.fda.gov/cder/ob>. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the monthly cumulative supplements.

The Internet version of the Orange Book annual edition is at
<http://www.fda.gov/cder/orange/adp.htm>

The Internet version of the monthly supplement is at
<http://www.fda.gov/cder/orange/supplement/cspreface.htm>

There are ASCII text files of the Orange Book drug product data at
<http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are zipped into zipobtxt.exe.

The files are updated concurrently with the publication of the monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 23rd annual edition of the 2002 Orange Book Patent and Exclusivity List is at <http://www.fda.gov/cder/orange/23bookpub.pdf>

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at <http://www.fda.gov/cder/orange/supplement/patents.pdf>

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at <http://www.fda.gov/cder/orange/docket.pdf>. It is updated monthly as soon as available and as otherwise needed.

The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at: <http://www.fda.gov/cder/orange/patdecl.pdf>
<http://www.fda.gov/cder/orange/patdecl.htm>

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2002) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2002</u>	<u>JUN 2003</u>	<u>SEP 2003</u>	<u>DEC 2003</u>
DRUG PRODUCTS LISTED	10465	10514	10624	
SINGLE SOURCE	2420 (23.1%)	2417 (23.0%)	2406	
MULTISOURCE	7939 (75.9%)	7989 (76.0%)	8110	
THERAPEUTICALLY	7659 (73.2%)	7708 (73.3%)	7830 (73.7%)	
EQUIVALENT				
NOT THERAPEUTICALLY	280 (2.7%)	281 (2.7%)	280 (2.6%)	
EQUIVALENT				
EXCEPTIONS ¹	106 (1.0%)	108 (1.0%)	108 (1.0%)	
NEW MOLECULAR ENTITIES	6	6	6	
APPROVED				
NUMBER OF APPLICANTS	598	604	602	

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

- WDAG Withdrawn. The applicant holder has notified the FDA in writing that the product is no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
- WDRP Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

SOLUTION; ORAL

ACETAMINOPHEN AND BUTALBITAL AND CAFFEINE

+ MIKART 325MG/15ML;50MG/15ML;40MG/15ML N40387 001 JAN 31, 2003 JAN NEWA

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AB VINTAGE PHARMS 325MG;50MG;40MG N40511 001 AUG 27, 2003 AUG NEWA

AB 500MG;50MG;40MG N40513 001 AUG 25, 2003 AUG NEWA

BUTALBITAL, APAP, AND CAFFEINE

AB AXIOM PHARM 325MG;50MG;40MG N89536 001 FEB 16, 1988 MAY CAHN

ESGIC-PLUS

AB + MIKART 500MG;50MG;40MG N89451 001 MAY 23, 1988 AUG CTNA

FIORICET

AB + WATSON PHARMS 325MG;50MG;40MG N88616 001 NOV 09, 1984 APR CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL; ACETAMINOPHEN; CAFFEINE AND CODEINE PHOSPHATE

AB ABLE 325MG;50MG;40MG;30MG N76528 001 AUG 21, 2003 AUG NEWA

FIORICET W/ CODEINE

AB + WATSON PHARMS 325MG;50MG;40MG;30MG N20232 001 JUL 30, 1992 MAR CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL

PHENAPHEN W/ CODEINE NO. 3

@ ROBINS AH 325MG;30MG N84445 001 JUN DISC

PHENAPHEN W/ CODEINE NO. 4

@ ROBINS AH 325MG;60MG N84446 001 JUN DISC

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA ANDRX PHARMS 300MG;15MG N40443 001 JAN 22, 2003 JAN NEWA

AA 300MG;30MG N40443 002 JAN 22, 2003 JAN NEWA

AA 300MG;60MG N40443 003 JAN 22, 2003 JAN NEWA

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA + DURAMED PHARM BARR 300MG;15MG N40223 001 NOV 18, 1997 AUG CRLD

AA RANBAXY 300MG;60MG N87083 001 JAN CAHN

ACETAMINOPHEN W/ CODEINE PHOSPHATE #3

AA RANBAXY 300MG;30MG N85868 001 JAN CAHN

CODRIX

+ ANDRX PHARMS 500MG;30MG N40441 001 MAR 27, 2003 MAR NEWA

+ 500MG;15MG N40447 001 FEB 26, 2003 FEB NEWA

+ 500MG;60MG N40488 001 MAR 28, 2003 MAR NEWA

TYLENOL W/ CODEINE NO. 1

@ ORTHO MCNEIL PHARM 300MG;7.5MG N85055 001 AUG DISC

TYLENOL W/ CODEINE NO. 2

@ ORTHO MCNEIL PHARM 300MG;15MG N85055 002 AUG DISC

TYLENOL W/ CODEINE NO. 4

@ ORTHO MCNEIL PHARM 300MG;60MG N85055 004 AUG DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	+	MALLINCKRODT	500MG/15ML;10MG/15ML	N40508 001	AUG 29, 2003	AUG	NEWA
>A>		+	MIKART	325MG/15ML;7.5MG/15ML	N40482 001	SEP 25, 2003	SEP NEWA
AA			500MG/15ML;5MG/15ML	N81226 001	OCT 27, 1992	AUG	CTEC
AA	+		500MG/15ML;5MG/15ML	N89557 001	APR 29, 1992	AUG	CTEC
TABLET; ORAL							
AA		ABLE	500MG;7.5MG	N40490 001	MAY 21, 2003	MAY	NEWA
AA			650MG;7.5MG	N40474 001	JAN 02, 2003	JAN	NEWA
AA		ANDRX PHARMS	500MG;5MG	N40493 001	MAY 28, 2003	MAY	NEWA
AA			660MG;10MG	N40495 001	MAY 28, 2003	MAY	NEWA
AA			750MG;7.5MG	N40494 001	MAY 28, 2003	MAY	NEWA
AA		AXIOM PHARM	500MG;5MG	N40236 001	SEP 25, 1997	MAY	CAHN
AA			650MG;10MG	N40240 001	NOV 26, 1997	MAY	CAHN
AA			650MG;7.5MG	N40240 002	NOV 26, 1997	MAY	CAHN
AA			750MG;7.5MG	N40236 002	SEP 25, 1997	MAY	CAHN
AA		MIKART	325MG;7.5MG	N40432 001	JAN 22, 2003	JAN	NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

AA		AXIOM PHARM	500MG;5MG	N40219 001	JAN 22, 1998	MAY	CAHN
TABLET; ORAL							
>A>	AA	WATSON LABS	325MG;7.5MG	N40535 001	SEP 05, 2003	SEP	NEWA
>A>	AA		325MG;10MG	N40535 002	SEP 05, 2003	SEP	NEWA
PERCOCET							
>D>		+	ENDO PHARMS	325MG;7.5MG	N40434 001	NOV 23, 2001	SEP CFTG
>D>		+		325MG;10MG	N40434 002	NOV 23, 2001	SEP CFTG
>A>	AA	+		325MG;7.5MG	N40434 001	NOV 23, 2001	SEP CFTG
>A>	AA	+		325MG;10MG	N40434 002	NOV 23, 2001	SEP CFTG

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

PROPOXYPHENE HCL AND ACETAMINOPHEN

AA		VINTAGE PHARMS	650MG;65MG	N40507 001	JUL 30, 2003	JUL	NEWA
----	--	----------------	------------	------------	--------------	-----	------

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

>A>		+	AAIPHARMA	500MG;100MG	N76429 001	SEP 10, 2003	SEP NEWA
-----	--	---	-----------	-------------	------------	--------------	----------

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

DIAMOX

AB		DURAMED PHARM BARR	500MG	N12945 001		JUN	CAHN
		+	500MG	N12945 003	APR 25, 1995	JUN	CAHN
TABLET; ORAL							
AB		DURAMED PHARM BARR	125MG	N08943 001		JUN	CAHN
AB	+		250MG	N08943 002		JUN	CAHN

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

AP + DURAMED PHARM BARR EQ 500MG BASE/VIAL N09388 001 DEC 05, 1990 JUN CAHN

ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE

SUSPENSION/DROPS; OTIC

NEO-CORT-DOME

@ BAYER PHARMS 2%;1%;EQ 0.35% BASE N50238 001 JUN DISC

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

AB AAIPHARMA 200MG N74833 001 APR 22, 1997 APR CAHN

TABLET; ORAL

@ CLONMEL HLTHCARE 400MG N74834 001 APR 24, 1997 JUL DISC

@ 800MG N74834 002 APR 24, 1997 JUL DISC

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE

+ BAXTER HLTHCARE EQ 500MG BASE/VIAL N74885 001 DEC 19, 1997 AUG CAHN

EQ 1GM BASE/VIAL N74885 002 DEC 19, 1997 AUG CAHN

ACYCLOVIR SODIUM

AP BAXTER HLTHCARE EQ 500MG BASE/VIAL N74913 001 OCT 15, 1997 AUG CAHN

AP EQ 1GM BASE/VIAL N74913 002 OCT 15, 1997 AUG CAHN

ALBUMIN HUMAN

INJECTABLE; INJECTION

OPTISON

+ AMERSHAM HLTH 10MG/ML N20899 001 DEC 31, 1997 JUN CAHN

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN NOVEX EQ 0.5% BASE N76391 001 APR 01, 2003 APR NEWA

SYRUP; ORAL

PROVENTIL

@ SCHERING EQ 2MG BASE/5ML N18062 001 JAN 19, 1983 AUG DISC

TABLET; ORAL

ALBUTEROL SULFATE

@ CLONMEL HLTHCARE EQ 2MG BASE N72859 001 DEC 20, 1989 JUN DISC

@ EQ 4MG BASE N72860 001 DEC 20, 1989 JUN DISC

AB + MYLAN EQ 2MG BASE N72893 001 JAN 17, 1991 AUG CRLD

AB + EQ 4MG BASE N72894 001 JAN 17, 1991 AUG CRLD

PROVENTIL

@ SCHERING EQ 2MG BASE N17853 001 MAY 07, 1982 AUG DISC

@ EQ 4MG BASE N17853 002 MAY 07, 1982 AUG DISC

ALENDRONATE SODIUM

SOLUTION; ORAL

>A> FOSAMAX

>A> + MERCK EQ 70MG ACID/75ML N21575 001 SEP 17, 2003 SEP NEWA

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ALFENTA

AP + AKORN EQ 0.5MG BASE/ML N19353 001 DEC 29, 1986 MAR CAHN

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

UROXATRAL

+ SANOFI SYN RES 10MG N21287 001 JUN 12, 2003 JUN NEWA

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB VINTAGE PHARMS 100MG N75798 001 JUN 27, 2003 JUN NEWA

AB 300MG N75798 002 JUN 27, 2003 JUN NEWA

ALMOTRIPTAN MALATE

TABLET; ORAL

AXERT

JANSSEN ORTHO

EQ 6.25MG BASE N21001 001 MAY 07, 2001 APR CAHN

+ EQ 12.5MG BASE N21001 002 MAY 07, 2001 APR CAHN

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION

INFUVITE ADULT

+ SABEX 2002 2 IU/ML;40MG/ML;12UGM/ML;40 IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;0.03MG/ML

N21163 001 MAY 18, 2000 JUN CPOT

INJECTABLE; IV (INFUSION)

+ SABEX 2002 2 IU/ML;40MG/ML;12UGM/ML;40 IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;30UGM/ML

N21559 001 JUN 16, 2003 JUN NEWA

ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

INJECTABLE; INJECTION

CERNEVIT-12

@ BAXTER HLTHCARE

11.2 IU/VIAL;125MG/VIAL;60UGM/VIAL;200 IU/VIAL;5.5MG/VIAL;414UGM/VIAL;46MG/VIAL;17.25MG/VIAL;4.53MG/VIAL;4.14 MG/VIAL;3.51MG/VIAL;3,500 IU/VIAL

N20924 001 APR 06, 1999 MAR DISC

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

@ CLONMEL HLTHCARE

0.25MG N74174 001 OCT 19, 1993 JUN DISC

@ 0.5MG N74174 002 OCT 19, 1993 JUN DISC

	@	1MG	N74174 003	OCT 19, 1993	JUN	DISC
	@	2MG	N74174 004	OCT 19, 1993	JUN	DISC
TABLET, EXTENDED RELEASE; ORAL						
XANAX XR						
		PHARMACIA AND UPJOHN 0.5MG	N21434 001	JAN 17, 2003	JAN	NEWA
		1MG	N21434 002	JAN 17, 2003	JAN	NEWA
		2MG	N21434 003	JAN 17, 2003	JAN	NEWA
	+	3MG	N21434 004	JAN 17, 2003	JAN	NEWA
<u>AMANTADINE HYDROCHLORIDE</u>						
CAPSULE; ORAL						
AMANTADINE HCL						
AB		GENEVA PHARMS 100MG	N71293 001	FEB 18, 1987	APR	CAHN
<u>AMCINONIDE</u>						
CREAM; TOPICAL						
AMCINONIDE						
AB		ALTANA 0.1%	N76065 001	MAY 15, 2003	MAY	NEWA
AB		TARO PHARM INDS 0.1%	N76229 001	MAY 31, 2002	MAY	CTEC
AT		0.1%	N76229 001	MAY 31, 2002	APR	NEWA
CYCLOCORT						
AT	+	FUJISAWA HLTHCARE 0.1%	N18116 002		APR	CFTG
AB	+	0.1%	N18116 002		MAY	CTEC
OINTMENT; TOPICAL						
AMCINONIDE						
AB		TARO PHARM INDS 0.1%	N76367 001	MAR 19, 2003	MAR	NEWA
<u>AMINO ACIDS</u>						
INJECTABLE; INJECTION						
PREMASOL 10% IN PLASTIC CONTAINER						
		BAXTER HLTHCARE 10% (10GM/100ML)	N75880 002	JUN 19, 2003	JUN	NEWA
PREMASOL 6% IN PLASTIC CONTAINER						
		BAXTER HLTHCARE 6% (6GM/100ML)	N75880 001	JUN 19, 2003	JUN	NEWA
<u>AMINOCAPROIC ACID</u>						
INJECTABLE; INJECTION						
AMINOCAPROIC ACID						
	@	BAXTER HLTHCARE 250MG/ML	N18590 001	OCT 29, 1982	AUG	CAHN
	@	ELKINS SINN 250MG/ML	N18590 001	OCT 29, 1982	JUN	DISC
<u>AMINOPHYLLINE</u>						
INJECTABLE; INJECTION						
AMINOPHYLLINE						
AP	+	ABBOTT 25MG/ML	N87601 001	JUL 23, 1982	JUN	CRLD
	@	ELKINS SINN 25MG/ML	N87239 001		JUN	DISC
<u>AMIODARONE HYDROCHLORIDE</u>						
INJECTABLE; INJECTION						
AMIODARONE HCL						
AP		APOTEX 50MG/ML	N76394 001	APR 25, 2003	APR	NEWA
>A>	AP	SICOR PHARMS 50MG/ML	N76163 001	SEP 05, 2003	SEP	NEWA
CORDARONE						
AP	+	WYETH PHARMS INC 50MG/ML	N20377 001	AUG 03, 1995	MAR	CAHN

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HCL

>D>	AB + EON	400MG	N75315 002	JUN 30, 2000	SEP	CRLD
>A>	AB	400MG	N75315 002	JUN 30, 2000	SEP	CRLD
>D>	+ TARO	100MG	N75424 002	DEC 18, 2002	SEP	CRLD
>A>		100MG	N75424 002	DEC 18, 2002	SEP	CRLD
>D>	AB	400MG	N76362 001	NOV 29, 2002	SEP	CRLD
>A>	AB +	400MG	N76362 001	NOV 29, 2002	SEP	CRLD
	CORDARONE					
AB	WYETH PHARMS INC	200MG	N18972 001	DEC 24, 1985	MAR	CAHN

AMITRIPTYLINE HYDROCHLORIDE

CONCENTRATE; ORAL

ENDEP

@ ROCHE 40MG/ML

N85749 001 JUN DISC

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

ETRAFON 2-10

@ SCHERING 10MG;2MG

N14713 007 MAR DISC

ETRAFON 2-25

@ SCHERING 25MG;2MG

N14713 004 MAR DISC

ETRAFON-FORTE

@ SCHERING 25MG;4MG

N14713 006 MAR DISC

AMLEXANOX

PASTE; DENTAL

APHTHASOL

+ ACCESS PHARMS 5%

N20511 001 DEC 17, 1996 JUL CAHN

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB TARO EQ 12% BASE

N75883 001 APR 10, 2003 APR NEWA

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXIL

AB GLAXOSMITHKLINE 50MG/ML

N62226 005 JUL CRLD

WYMOX

@ WYETH AYERST 125MG/5ML

N62131 001 JUN DISC

@ 250MG/5ML

N62131 002 JUN DISC

TABLET, FOR SUSPENSION; ORAL

DISPERMOX

RANBAXY 200MG

N65080 002 AUG 11, 2003 AUG NEWA

+ 400MG

N65080 001 AUG 11, 2003 AUG NEWA

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLECAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS; ORAL
PREVPAC

+ TAP PHARM 500MG;500MG;30MG N50757 001 DEC 02, 1997 MAY CDFR

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB RANBAXY 200MG/5ML;EQ 28.5MG BASE/5ML N65132 001 MAR 19, 2003 MAR NEWA
AB 400MG/5ML;EQ 57MG BASE/5ML N65132 002 MAR 19, 2003 MAR NEWAAMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE;DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

SHIRE LABS 2.5MG;2.5MG;2.5MG;2.5MG N21303 001 OCT 11, 2001 JAN CAHN

ADDERALL XR 15

SHIRE LABS 3.75MG;3.75MG;3.75MG;3.75MG N21303 006 MAY 22, 2002 JAN CAHN

ADDERALL XR 20

SHIRE LABS 5MG;5MG;5MG;5MG N21303 002 OCT 11, 2001 JAN CAHN

ADDERALL XR 25

SHIRE LABS 6.25MG;6.25MG;6.25MG;6.25MG N21303 004 MAY 22, 2002 JAN CAHN

ADDERALL XR 30

+ SHIRE LABS 7.5MG;7.5MG;7.5MG;7.5MG N21303 003 OCT 11, 2001 JAN CAHN

ADDERALL XR 5

SHIRE LABS 1.25MG;1.25MG;1.25MG;1.25MG N21303 005 MAY 22, 2002 JAN CAHN

TABLET; ORAL

ADDERALL 12.5

AB SHIRE LABS 3.125MG;3.125MG;3.125MG;3.125MG N11522 012 AUG 31, 2000 MAR CFTG

ADDERALL 15

AB SHIRE LABS 3.75MG;3.75MG;3.75MG;3.75MG N11522 013 AUG 31, 2000 MAR CFTG

ADDERALL 7.5

AB SHIRE LABS 1.875MG;1.875MG;1.875MG;1.875MG N11522 011 AUG 31, 2000 MAR CFTG

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>A> AB ABRICA PHARMS 1.25MG;1.25MG;1.25MG;1.25MG N40472 001 SEP 30, 2003 SEP NEWA

>A> AB 2.5MG;2.5MG;2.5MG;2.5MG N40472 002 SEP 30, 2003 SEP NEWA

>A> AB 5MG;5MG;5MG;5MG N40472 003 SEP 30, 2003 SEP NEWA

>A> AB 7.5MG;7.5MG;7.5MG;7.5MG N40472 004 SEP 30, 2003 SEP NEWA

AB BARR 1.875MG;1.875MG;1.875MG;1.875MG N40422 005 MAR 19, 2003 MAR NEWA

AB 3.125MG;3.125MG;3.125MG;3.125MG N40422 006 MAR 19, 2003 MAR NEWA

AB 3.75MG;3.75MG;3.75MG;3.75MG N40422 007 MAR 19, 2003 MAR NEWA

>A> AB MUTUAL PHARM 1.25MG;1.25MG;1.25MG;1.25MG N40480 001 SEP 09, 2003 SEP NEWA

>A> AB 1.875MG;1.875MG;1.875MG;1.875MG N40480 002 SEP 09, 2003 SEP NEWA

>A> AB 2.5MG;2.5MG;2.5MG;2.5MG N40480 003 SEP 09, 2003 SEP NEWA

>A> AB 3.125MG;3.125MG;3.125MG;3.125MG N40480 004 SEP 09, 2003 SEP NEWA

>A> AB 3.75MG;3.75MG;3.75MG;3.75MG N40480 005 SEP 09, 2003 SEP NEWA

>A> AB 5MG;5MG;5MG;5MG N40480 006 SEP 09, 2003 SEP NEWA

>A> AB 7.5MG;7.5MG;7.5MG;7.5MG N40480 007 SEP 09, 2003 SEP NEWA

AB WATSON LABS 1.25MG;1.25MG;1.25MG;1.25MG N40456 001 MAY 06, 2003 MAY NEWA

AB 2.5MG;2.5MG;2.5MG;2.5MG N40456 002 MAY 06, 2003 MAY NEWA

AB 5MG;5MG;5MG;5MG N40456 003 MAY 06, 2003 MAY NEWA

AB 7.5MG;7.5MG;7.5MG;7.5MG N40456 004 MAY 06, 2003 MAY NEWA

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

@ BAXTER HLTHCARE	EQ 125MG BASE/VIAL	N62692 001	JUN 24, 1986	AUG	CAHN
@	EQ 250MG BASE/VIAL	N62692 002	JUN 24, 1986	AUG	CAHN
@	EQ 500MG BASE/VIAL	N62692 003	JUN 24, 1986	AUG	CAHN
@	EQ 1GM BASE/VIAL	N62692 004	JUN 24, 1986	AUG	CAHN
@	EQ 2GM BASE/VIAL	N62692 005	JUN 24, 1986	AUG	CAHN
@	EQ 10GM BASE/VIAL	N62692 006	JUN 24, 1986	AUG	CAHN

OMNIPEN-N

@ WYETH AYERST	EQ 125MG BASE/VIAL	N60626 001		JUN	DISC
@	EQ 250MG BASE/VIAL	N60626 002		JUN	DISC
@	EQ 500MG BASE/VIAL	N60626 003		JUN	DISC
@	EQ 1GM BASE/VIAL	N60626 004		JUN	DISC
@	EQ 2GM BASE/VIAL	N60626 005		JUN	DISC

TOTACILLIN-N

AP + GLAXOSMITHKLINE	EQ 125MG BASE/VIAL	N60677 001		JUN	CRLD
AP +	EQ 250MG BASE/VIAL	N60677 002		JUN	CRLD
AP +	EQ 500MG BASE/VIAL	N60677 003		JUN	CRLD
AP +	EQ 1GM BASE/VIAL	N60677 004		JUN	CRLD
AP +	EQ 2GM BASE/VIAL	N60677 005		JUN	CRLD

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

OMNIPEN (AMPICILLIN)

@ WYETH AYERST	250MG	N60624 001		JUN	DISC
@	500MG	N60624 002		JUN	DISC

FOR SUSPENSION; ORAL

@ WYETH AYERST	100MG/ML	N60625 001		JUN	DISC
@	125MG/5ML	N60625 002		JUN	DISC
@	250MG/5ML	N60625 003		JUN	DISC

PRINCIPEN

APOTHECON	EQ 100MG BASE/ML	N61394 001		JUN	CTEC
-----------	------------------	------------	--	-----	------

AMPRENAVIR

CAPSULE; ORAL

AGENERASE

GLAXOSMITHKLINE	50MG	N21007 001	APR 15, 1999	MAR	CMFD	
+	150MG	N21007 002	APR 15, 1999	MAR	CMFD	
SOLUTION; ORAL						
+	GLAXOSMITHKLINE	15MG/ML	N21039 001	APR 15, 1999	MAR	CMFD

APREPITANT

CAPSULE; ORAL

EMEND

MERCK	80MG	N21549 001	MAR 26, 2003	MAR	NEWA
+	125MG	N21549 002	MAR 26, 2003	MAR	NEWA

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN

+	ENCYSIVE	100MG/ML	N20883 001	JUN 30, 2000	JUN	CAHN
---	----------	----------	------------	--------------	-----	------

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON W/ ASA

@ AAIPHARMA LLC

325MG;65MG

N10996 005

JUL DISC

ATAZANAVIR SULFATE

CAPSULE; ORAL

REYATAZ

BRISTOL MYERS SQUIBB

EQ 100MG BASE

N21567 001 JUN 20, 2003 JUN NEWA

EQ 150MG BASE

N21567 002 JUN 20, 2003 JUN NEWA

+

EQ 200MG BASE

N21567 003 JUN 20, 2003 JUN NEWA

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

STRATTERA

@ LILLY

5MG

N21411 001 NOV 26, 2002 MAY DISC

ATROPINE

INJECTABLE; INJECTION

ATROPEN

+ MERIDIAN MEDCL TECHN

EQ 0.5MG SULFATE/0.7ML

N17106 003 JUN 19, 2003 JUL NEWA

+

EQ 1MG SULFATE/0.7ML

N17106 002 JUN 19, 2003 JUL NEWA

AZATHIOPRINE

TABLET; ORAL

AZASAN

AAIPHARMA LLC

25MG

N75252 002 FEB 03, 2003 FEB NEWA

AB

50MG

N75252 001 JUN 07, 1999 FEB NEWA

75MG

N75252 003 FEB 03, 2003 FEB NEWA

100MG

N75252 004 FEB 03, 2003 FEB NEWA

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OPTIVAR

+ MEDPOINTE

0.05%

N21127 001 MAY 22, 2000 APR CAHN

AZITHROMYCIN

TABLET; ORAL

ZITHROMAX

PFIZER

EQ 500MG BASE

N50784 001 MAY 24, 2002 AUG CRLD

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

BECLOVENT

@ GLAXOSMITHKLINE

0.042MG/INH

N18153 001

MAR DISC

AEROSOL, METERED; NASAL

BECONASE

@ GLAXOSMITHKLINE

0.042MG/INH

N18584 001

MAR DISC

VANCENASE

@ SCHERING

0.042MG/INH

N18521 001

MAR DISC

BENZYL PENICILLOYL-POLYLYSINE

INJECTABLE; INJECTION

PRE-PEN

+ HOLLISTER STIER LABS 60UMOLAR N50114 001 JUL CAHN

BETAMETHASONE

TABLET; ORAL

CELESTONE

@ SCHERING 0.6MG N12657 003 FEB DISC

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

ALPHATREX

AB + SAVAGE LABS EQ 0.05% BASE N19138 001 JUN 26, 1984 MAY CRLD

DIPROSONE

@ SCHERING EQ 0.05% BASE N17536 001 MAY DISC

GEL, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB ALTANA EQ 0.05% BASE N75276 001 MAY 13, 2003 MAY NEWA

DIPROLENE

AB + SCHERING EQ 0.05% BASE N19408 002 NOV 22, 1991 MAY CFTG

BETHANECHOL CHLORIDE

TABLET; ORAL

>A> BETHANECHOL CHLORIDE

>A> AA WOCKHARDT 5MG N40532 001 SEP 29, 2003 SEP NEWA

>A> AA 10MG N40533 001 SEP 29, 2003 SEP NEWA

>A> AA 25MG N40534 001 SEP 29, 2003 SEP NEWA

>A> AA 50MG N40518 001 SEP 29, 2003 SEP NEWA

URECHOLINE

>D> + ODYSSEY PHARMS 5MG N89095 001 DEC 19, 1985 SEP CFTG

>A> AA + 5MG N89095 001 DEC 19, 1985 SEP CFTG

>D> + 10MG N88440 001 MAY 29, 1984 SEP CFTG

>A> AA + 10MG N88440 001 MAY 29, 1984 SEP CFTG

>D> + 25MG N88441 001 MAY 29, 1984 SEP CFTG

>A> AA + 25MG N88441 001 MAY 29, 1984 SEP CFTG

>D> + 50MG N89096 001 DEC 19, 1985 SEP CFTG

>A> AA + 50MG N89096 001 DEC 19, 1985 SEP CFTG

BISOPROLOL FUMARATE

TABLET; ORAL

ZEBETA

AB DURAMED PHARM BARR 5MG N19982 002 JUL 31, 1992 JUN CAHN

AB + 10MG N19982 001 JUL 31, 1992 JUN CAHN

AB WYETH PHARMS INC 5MG N19982 002 JUL 31, 1992 MAR CAHN

AB + 10MG N19982 001 JUL 31, 1992 MAR CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ZIAC

AB DURAMED PHARM BARR 2.5MG;6.25MG N20186 003 MAR 26, 1993 JUN CAHN

AB 5MG;6.25MG N20186 001 MAR 26, 1993 JUN CAHN

AB	+		10MG;6.25MG		N20186 002	MAR 26, 1993	JUN	CAHN
AB		WYETH PHARMS INC	2.5MG;6.25MG		N20186 003	MAR 26, 1993	MAR	CAHN
AB			5MG;6.25MG		N20186 001	MAR 26, 1993	MAR	CAHN
AB	+		10MG;6.25MG		N20186 002	MAR 26, 1993	MAR	CAHN
<u>BLEOMYCIN SULFATE</u>								
INJECTABLE; INJECTION								
BLEOMYCIN SULFATE								
AP		GENSIA SICOR PHARMS	EQ 15 UNITS BASE/VIAL		N64084 001	JUN 01, 1996	AUG	CAHN
AP			EQ 30 UNITS BASE/VIAL		N64084 002	JUN 01, 1996	AUG	CAHN
<u>BORTEZOMIB</u>								
INJECTABLE; INTRAVENOUS								
VELCADE								
	+	MILLENNIUM PHARMS	3.5MG/VIAL		N21602 001	MAY 13, 2003	MAY	NEWA
<u>BRETYLIUM TOSYLATE</u>								
INJECTABLE; INJECTION								
BRETYLIUM TOSYLATE								
	@	BAXTER HLTHCARE	50MG/ML		N70545 001	MAY 14, 1986	AUG	CAHN
	@		50MG/ML		N70546 001	MAY 14, 1986	AUG	CAHN
	@	ELKINS SINN	50MG/ML		N70545 001	MAY 14, 1986	JUN	DISC
	@		50MG/ML		N70546 001	MAY 14, 1986	JUN	DISC
<u>BRIMONIDINE TARTRATE</u>								
SOLUTION/DROPS; OPHTHALMIC								
BRIMONIDINE TARTRATE								
>A>	AT	ALCON	0.2%		N76254 001	SEP 16, 2003	SEP	NEWA
>D>	+	BAUSCH AND LOMB	0.2%		N76260 001	MAY 28, 2003	SEP	CFTG
>A>	AT	+	0.2%		N76260 001	MAY 28, 2003	SEP	CFTG
	+		0.2%		N76260 001	MAY 28, 2003	MAY	NEWA
<u>BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>								
SYRUP; ORAL								
DIMETANE-DX								
	@	ROBINS AH	2MG/5ML;10MG/5ML;30MG/5ML		N19279 001	AUG 24, 1984	MAR	DISC
	@	MYPHETANE DX						
AA	+	MORTON GROVE	2MG/5ML;10MG/5ML;30MG/5ML		N88811 001	JUN 07, 1985	MAR	CTEC
<u>BUDESONIDE</u>								
>D>		AEROSOL, METERED; NASAL						
>D>		RHINOCORT						
>D>	+	ASTRAZENECA	0.032MG/INH		N20233 001	FEB 14, 1994	SEP	DISC
>A>	@		0.032MG/INH		N20233 001	FEB 14, 1994	SEP	DISC
<u>BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE</u>								
INJECTABLE; INJECTION								
DUOCAINE								
	+	AMPHASTAR	0.375% (37.5MG/10ML);1% (100MG/10ML)		N21496 001	MAY 23, 2003	MAY	NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

WELLBUTRIN XL

SMITHKLINE BEECHAM

150MG

N21515 001 AUG 28, 2003 AUG NEWA

+

300MG

N21515 002 AUG 28, 2003 AUG NEWA

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HCL

AB

EGIS

15MG

N75119 003 JAN 23, 2003 JAN NEWA

BUSULFAN

INJECTABLE; INJECTION

BUSULFEX

+ ESP PHARMA

6MG/ML

N20954 001 FEB 04, 1999 JUN CAHN

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS, ORAL

CAFCIT

+ MEAD JOHNSON

EQ 10MG BASE/ML

N20793 001 SEP 21, 1999 JUN CAHN

CALCITRIOL

INJECTABLE; INJECTION

CALCITRIOL

AP AAIPHARMA

0.001MG/ML

N75766 001 FEB 20, 2003 FEB NEWA

AP

0.002MG/ML

N75766 002 FEB 20, 2003 FEB NEWA

AP GENZIA SICOR PHARMS

0.001MG/ML

N75823 001 MAR 31, 2003 MAR NEWA

AP

0.002MG/ML

N75823 002 MAR 31, 2003 MAR NEWA

>A> AP LUITPOLD

0.001MG/ML

N75746 001 SEP 26, 2003 SEP NEWA

>A> AP

0.002MG/ML

N75746 002 SEP 26, 2003 SEP NEWA

>A> AP LYNE

0.001MG/ML

N76206 001 SEP 17, 2003 SEP NEWA

SOLUTION; ORAL

AA ROXANE

1UGM/ML

N76242 001 JUL 18, 2003 JUL NEWA

ROCALTROL

AA + ROCHE

1UGM/ML

N21068 001 NOV 20, 1998 JUL CFTG

CALCIUM ACETATE

CAPSULE; ORAL

PHOSLO

a NABI

EQ 84.5MG CALCIUM

N21160 001 APR 02, 2001 AUG CAHN

a

EQ 169MG CALCIUM

N21160 002 APR 02, 2001 AUG CAHN

PHOSLO GELCAPS

+ NABI

EQ 169MG CALCIUM

N21160 003 APR 02, 2001 AUG CAHN

TABLET; ORAL

PHOSLO

+ NABI

EQ 169MG CALCIUM

N19976 001 DEC 10, 1990 AUG CAHN

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE;SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INTRATHECAL

ELLIOTTS B SOLUTION

+ QOL MEDCL

0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/ML
;1.9MG/ML;7.3MG/ML;0.2MG/ML

N20577 001 SEP 27, 1996 MAY CAHN

CARBAMAZEPINE

TABLET; ORAL

>A>		TERIL						
>A>	AB	TARO	200MG		N76525 001	SEP 26, 2003	SEP	NEWA

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

STALEVO 100

		ORION PHARMA INC	25MG;200MG;100MG		N21485 002	JUN 11, 2003	JUN	NEWA
--	--	------------------	------------------	--	------------	--------------	-----	------

STALEVO 150

+		ORION PHARMA INC	37.5MG;200MG;150MG		N21485 003	JUN 11, 2003	JUN	NEWA
---	--	------------------	--------------------	--	------------	--------------	-----	------

STALEVO 50

		ORION PHARMA INC	12.5MG;200MG;50MG		N21485 001	JUN 11, 2003	JUN	NEWA
--	--	------------------	-------------------	--	------------	--------------	-----	------

CARBINOXAMINE MALEATE

SOLUTION; ORAL

CARBINOXAMINE MALEATE

+		MIKART	4MG/5ML		N40458 001	APR 25, 2003	APR	NEWA
---	--	--------	---------	--	------------	--------------	-----	------

TABLET; ORAL

+		MIKART	4MG		N40442 001	MAR 19, 2003	MAR	NEWA
---	--	--------	-----	--	------------	--------------	-----	------

CARBOPLATIN

INJECTABLE; IV (INFUSION)

PARAPLATIN

+		BRISTOL MYERS SQUIBB	EQ 50MG /5ML(10MG/ML)		N20452 001	JUL 14, 2003	JUL	NEWA
---	--	----------------------	-----------------------	--	------------	--------------	-----	------

+			EQ 150MG /15ML(10MG/ML)		N20452 002	JUL 14, 2003	JUL	NEWA
---	--	--	-------------------------	--	------------	--------------	-----	------

+			EQ 450MG /45ML(10MG/ML)		N20452 003	JUL 14, 2003	JUL	NEWA
---	--	--	-------------------------	--	------------	--------------	-----	------

CARVEDILOL

TABLET; ORAL

COREG

+		GLAXOSMITHKLINE	12.5MG		N20297 002	SEP 14, 1995	APR	CRLD
---	--	-----------------	--------	--	------------	--------------	-----	------

			25MG		N20297 001	SEP 14, 1995	APR	CRLD
--	--	--	------	--	------------	--------------	-----	------

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL

CEFADROXIL

AB		RANBAXY	EQ 125MG BASE/5ML		N65115 001	MAR 26, 2003	MAR	NEWA
----	--	---------	-------------------	--	------------	--------------	-----	------

AB			EQ 250MG BASE/5ML		N65115 002	MAR 26, 2003	MAR	NEWA
----	--	--	-------------------	--	------------	--------------	-----	------

AB			EQ 500MG BASE/5ML		N65115 003	MAR 26, 2003	MAR	NEWA
----	--	--	-------------------	--	------------	--------------	-----	------

DURICEF

AB		WARNER CHILCOTT	EQ 125MG BASE/5ML		N50527 002		MAR	CFTG
----	--	-----------------	-------------------	--	------------	--	-----	------

AB			EQ 250MG BASE/5ML		N50527 003		MAR	CFTG
----	--	--	-------------------	--	------------	--	-----	------

AB	+		EQ 500MG BASE/5ML		N50527 001		MAR	CFTG
----	---	--	-------------------	--	------------	--	-----	------

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

+		PURDUE PHARMA LP	200MG		N21222 001	AUG 29, 2001	MAY	CAHN
---	--	------------------	-------	--	------------	--------------	-----	------

CEFIXIME

FOR SUSPENSION; ORAL

SUPRAX

@ LEDERLE

100MG/5ML

N50622 001 APR 28, 1989 APR DISC

TABLET; ORAL

@ LEDERLE

200MG

N50621 001 APR 28, 1989 APR DISC

@

400MG

N50621 002 APR 28, 1989 APR DISC

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME SODIUM

>A> AP LUPIN

EQ 500MG BASE/VIAL

N65124 001 SEP 24, 2003 SEP NEWA

>A> AP

EQ 1GM BASE/VIAL

N65124 002 SEP 24, 2003 SEP NEWA

>A> AP

EQ 2GM BASE/VIAL

N65124 003 SEP 24, 2003 SEP NEWA

CLAFORAN

>D> AVENTIS PHARMS

EQ 1GM BASE/VIAL

N62659 001 JAN 13, 1987 SEP CTEC

>A> AP

EQ 1GM BASE/VIAL

N62659 001 JAN 13, 1987 SEP CTEC

>D>

EQ 2GM BASE/VIAL

N62659 002 JAN 13, 1987 SEP CTEC

>A> AP

EQ 2GM BASE/VIAL

N62659 002 JAN 13, 1987 SEP CTEC

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

AP BAXTER HLTHCARE

EQ 10GM BASE/VIAL

N65050 001 SEP 11, 2000 AUG CAHN

MEFOXIN IN PLASTIC CONTAINER

+ MERCK

EQ 20MG BASE/ML

N63182 001 JAN 25, 1993 MAR CRLD

+

EQ 40MG BASE/ML

N63182 002 JAN 25, 1993 MAR CRLD

CEFPODOXIME PROXETIL

TABLET; ORAL

CEFPODOXIME PROXETIL

AB RANBAXY

EQ 100MG BASE

N65083 001 AUG 20, 2003 AUG NEWA

AB

EQ 200MG BASE

N65083 002 AUG 20, 2003 AUG NEWA

VANTIN

AB PHARMACIA AND UPJOHN

EQ 100MG BASE

N50674 001 AUG 07, 1992 AUG CFTG

AB +

EQ 200MG BASE

N50674 002 AUG 07, 1992 AUG CFTG

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFIZOX

FUJISAWA HLTHCARE

EQ 1GM BASE/VIAL

N63294 002 MAR 31, 1994 AUG CAHN

EQ 2GM BASE/VIAL

N63294 003 MAR 31, 1994 AUG CAHN

CEFTRIAZONE SODIUM

INJECTABLE; IM-IV

CEFTRIAZONE

>A> AP LUPIN

EQ 250MG BASE/VIAL

N65125 001 SEP 30, 2003 SEP NEWA

>A> AP

EQ 500MG BASE/VIAL

N65125 002 SEP 30, 2003 SEP NEWA

>A> AP

EQ 1GM BASE/VIAL

N65125 003 SEP 30, 2003 SEP NEWA

>A> AP

EQ 2GM BASE/VIAL

N65125 004 SEP 30, 2003 SEP NEWA

ROCEPHIN

>D> + HLR

EQ 250MG BASE/VIAL

N50585 001 DEC 21, 1984 SEP CFTG

>A>	AP	+	EQ 250MG BASE/VIAL	N50585 001	DEC 21, 1984	SEP	CFTG
>D>		+	EQ 500MG BASE/VIAL	N50585 002	DEC 21, 1984	SEP	CFTG
>A>	AP	+	EQ 500MG BASE/VIAL	N50585 002	DEC 21, 1984	SEP	CFTG
>D>		+	EQ 1GM BASE/VIAL	N50585 003	DEC 21, 1984	SEP	CFTG
>A>	AP	+	EQ 1GM BASE/VIAL	N50585 003	DEC 21, 1984	SEP	CFTG
>D>		+	EQ 2GM BASE/VIAL	N50585 004	DEC 21, 1984	SEP	CFTG
>A>	AP	+	EQ 2GM BASE/VIAL	N50585 004	DEC 21, 1984	SEP	CFTG

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

AB	LUPIN		EQ 250MG BASE	N65135 001	JUL 25, 2003	JUL	NEWA
AB			EQ 500MG BASE	N65135 002	JUL 25, 2003	JUL	NEWA
AB	RANBAXY		EQ 125MG BASE	N65118 001	APR 25, 2003	APR	NEWA
AB			EQ 250MG BASE	N65118 002	APR 25, 2003	APR	NEWA
AB			EQ 500MG BASE	N65118 003	APR 25, 2003	APR	NEWA

CEPHALEXIN

>A> TABLET, FOR SUSPENSION; ORAL

>A> PANIXINE DISPERDOSE

>A>			EQ 125MG BASE	N65100 002	SEP 11, 2003	SEP	NEWA
>A>		+	EQ 250MG BASE	N65100 001	SEP 11, 2003	SEP	NEWA

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

CEPHALOTHIN SODIUM

+	BRISTOL		EQ 1GM BASE/VIAL	N62464 001	MAY 07, 1984	MAR	CRLD
+			EQ 2GM BASE/VIAL	N62464 002	MAY 07, 1984	MAR	CRLD
+			EQ 4GM BASE/VIAL	N62464 003	MAY 07, 1984	MAR	CRLD
	KEFLIN						
@	LILLY		EQ 1GM BASE/VIAL	N50482 001		MAR	DISC
@			EQ 2GM BASE/VIAL	N50482 002		MAR	DISC
@			EQ 4GM BASE/VIAL	N50482 003		MAR	DISC

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEPHAPIRIN SODIUM

@	BAXTER HLTHCARE		EQ 500MG BASE/VIAL	N62720 001	JUL 02, 1987	AUG	CAHN
@			EQ 1GM BASE/VIAL	N62720 002	JUL 02, 1987	AUG	CAHN
@			EQ 2GM BASE/VIAL	N62720 003	JUL 02, 1987	AUG	CAHN
@			EQ 20GM BASE/VIAL	N62720 004	JUL 02, 1987	AUG	CAHN

CHLORAMPHENICOL

CAPSULE; ORAL

MYCHEL

@ ARMENPHARM

250MG

N60851 001

JUL DISC

OINTMENT; OPHTHALMIC

CHLORAMPHENICOL

AT	+	ALTANA	1%	N60133 001		MAY	CRLD
		CHLOROMYCETIN					
@		PARKEDALE	1%	N50156 001		MAY	DISC
		CHLOROPTIC S.O.P.					
@		ALLERGAN	1%	N61187 001		JUN	DISC

CHLORAMPHENICOL

SOLUTION/DROPS; OPHTHALMIC

CHLOROPTIC

@ ALLERGAN	0.5%	N50091 001		JUN	DISC
------------	------	------------	--	-----	------

SOLUTION/DROPS; OTIC

CHLOROMYCETIN

@ PARKEDALE	0.5%	N50205 001		MAY	DISC
-------------	------	------------	--	-----	------

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL SODIUM SUCCINATE

@ GRUPPO LEPETIT	EQ 1GM BASE/VIAL	N62278 001		JUL	DISC
------------------	------------------	------------	--	-----	------

CHLOROQUINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARALEN HCL

@ SANOFI SYNTHELABO	EQ 40MG BASE/ML	N06002 002		JUN	DISC
---------------------	-----------------	------------	--	-----	------

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

AA	IMPAX LABS	EQ 300MG BASE	N40516 001	AUG 29, 2003	AUG	NEWA	
>D>	AA +	WATSON LABS	EQ 150MG BASE	N87979 001	DEC 21, 1982	SEP	DISC
>A>		@	EQ 150MG BASE	N87979 001	DEC 21, 1982	SEP	DISC
>D>	AA		EQ 300MG BASE	N88030 001	DEC 21, 1982	SEP	DISC
>A>		@	EQ 300MG BASE	N88030 001	DEC 21, 1982	SEP	DISC
>D>	AA	WEST WARD	EQ 150MG BASE	N83082 001		SEP	CRLD
>A>	AA +		EQ 150MG BASE	N83082 001		SEP	CRLD

CHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDOCLOR-150

@ MERCK	150MG;250MG	N16016 001		MAY	DISC
---------	-------------	------------	--	-----	------

ALDOCLOR-250

@ MERCK	250MG;250MG	N16016 002		MAY	DISC
---------	-------------	------------	--	-----	------

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HCL

AP	BAXTER HLTHCARE	25MG/ML	N83329 001		JUN	CAHN
----	-----------------	---------	------------	--	-----	------

TABLET; ORAL

@ LEDERLE

10MG	N84803 001		JUN	DISC
------	------------	--	-----	------

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

@ CLONMEL HLTHCARE	25MG	N87451 001		JUL	CAHN
--------------------	------	------------	--	-----	------

@

50MG	N87450 001		JUL	CAHN
------	------------	--	-----	------

<u>CHLORTHALIDONE</u>					
	TABLET; ORAL				
	THALITONE				
	@ MONARCH PHARMS	25MG	N19574 002	FEB 12, 1992	MAY DISC
<u>CICLOPIROX</u>					
	SHAMPOO; TOPICAL				
	LOPROX				
	+ MEDICIS	1%	N21159 001	FEB 28, 2003	FEB NEWA
<u>CIMETIDINE</u>					
	SOLUTION; ORAL				
	CIMETIDINE HCL				
AA	DURAMED PHARM BARR	300MG/5ML	N75110 001	JUN 18, 1998	AUG CAIN
<u>CIMETIDINE HYDROCHLORIDE</u>					
	SOLUTION; ORAL				
AA	+ ALPHARMA	EQ 300MG BASE/5ML	N74176 001	JUN 01, 1994	AUG CRLD
AA	DURAMED PHARM BARR	EQ 300MG BASE/5ML	N75110 001	JUN 18, 1998	AUG CAIN
	TAGAMET				
	@ GLAXOSMITHKLINE	EQ 300MG BASE/5ML	N17924 001		AUG DISC
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE</u>					
	TABLET; ORAL				
	CIPRO XR				
	+ BAYER PHARMS	425.2MG;EQ 574.9MG BASE	N21473 002	AUG 28, 2003	AUG NEWA
<u>CIPROFLOXACIN; DEXAMETHASONE</u>					
	SUSPENSION/DROPS; OTIC				
	CIPRODEX				
	+ ALCON	0.3%;0.1%	N21537 001	JUL 18, 2003	JUL NEWA
<u>CITRIC ACID; UREA, C-13</u>					
	FOR SOLUTION; TABLET, FOR SOLUTION; ORAL				
	IDKIT:HP				
	@ ORIDION	4GM;75MG	N21314 001	DEC 17, 2002	JUL DISC
<u>CLADRIBINE</u>					
	INJECTABLE; INJECTION				
	LEUSTATIN				
AP	+ ORTHO BIOTECH	1MG/ML	N20229 001	FEB 26, 1993	APR CTEC
<u>CLEMASTINE FUMARATE</u>					
	SYRUP; ORAL				
	CLEMASTINE FUMARATE				
AA	+ TEVA	EQ 0.5MG BASE/5ML	N73399 001	JUN 30, 1994	JUN CRLD
	TAVIST				
	@ NOVARTIS	EQ 0.5MG BASE/5ML	N18675 001	JUN 28, 1985	JUN DISC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HCL

AB	WATSON LABS	EQ 300MG BASE	N63083 002	MAR 18, 2003	MAR	NEWA
----	-------------	---------------	------------	--------------	-----	------

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

	@ BAXTER HLHCARE	EQ 150MG BASE/ML	N62806 001	OCT 15, 1987	AUG	CAHN
AP		EQ 150MG BASE/ML	N62889 001	APR 25, 1988	AUG	CAHN
	@	EQ 150MG BASE/ML	N63068 001	AUG 28, 1989	AUG	CAHN

CLOBETASOL PROPIONATE

LOTION; TOPICAL

CLOBEX

+	GALDERMA LABS LP	0.05%	N21535 001	JUL 24, 2003	JUL	NEWA
---	------------------	-------	------------	--------------	-----	------

CLOFIBRATE

CAPSULE; ORAL

ATROMID-S

	@ WYETH AYERST	500MG	N16099 002		JUN	DISC
--	----------------	-------	------------	--	-----	------

CLONAZEPAM

TABLET, ORALLY DISINTEGRATING; ORAL

KLONOPIN RAPIDLY DISINTEGRATING

	ROCHE	0.125MG	N20813 001	DEC 23, 1997	APR	CMFD
		0.25MG	N20813 002	DEC 23, 1997	APR	CMFD
		0.5MG	N20813 003	DEC 23, 1997	APR	CMFD
+		1MG	N20813 004	DEC 23, 1997	APR	CMFD
		2MG	N20813 005	DEC 23, 1997	APR	CMFD

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

	@ CLONMEL HLHCARE	3.75MG	N71742 001	DEC 14, 1987	JUN	DISC
	@	7.5MG	N71743 001	DEC 14, 1987	JUN	DISC
	@	15MG	N71744 001	DEC 14, 1987	JUN	DISC

CLOZAPINE

TABLET; ORAL

CLOZAPINE

	IVAX PHARMS	12.5MG	N74949 003	JUL 31, 2003	JUL	NEWA	
>D>	AB	100MG	N74949 002	NOV 26, 1997	SEP	CRLD	
>A>	AB +	100MG	N74949 002	NOV 26, 1997	SEP	CRLD	
	CLOZARIL						
>D>	AB +	NOVARTIS	100MG	N19758 002	SEP 26, 1989	SEP	CRLD
>A>	AB	100MG	N19758 002	SEP 26, 1989	SEP	CRLD	

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN VC W/ CODEINE

	@ WYETH AYERST	10MG/5ML;5MG/5ML;6.25MG/5ML	N08306 005	APR 02, 1984	JUN	DISC
--	----------------	-----------------------------	------------	--------------	-----	------

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH VC W/ CODEINE

AA + ALPHARMA 10MG/5ML;5MG/5ML;6.25MG/5ML N88764 001 OCT 31, 1984 JUN CRLD

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN W/ CODEINE

@ WYETH AYERST 10MG/5ML;6.25MG/5ML

N08306 004 APR 02, 1984 JUN DISC

PROMETH W/ CODEINE

AA + ALPHARMA 10MG/5ML;6.25MG/5ML N88763 001 OCT 31, 1984 JUN CRLD

COLESTIPOL HYDROCHLORIDE

TABLET; ORAL

COLESTID

+ PHARMACIA AND UPJOHN 1GM N20222 001 JUL 19, 1994 MAY CRLD

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

COPPER T MODEL TCU 380A

+ FEI 309MG/COPPER N18680 001 NOV 15, 1984 MAR CAHN

CORTISONE ACETATE

TABLET; ORAL

CORTISONE ACETATE

BP + PHARMACIA AND UPJOHN 25MG N08126 001 APR CRLD

CORTONE

@ MERCK 25MG N07750 003 APR DISC

COSYNTROPIN

INJECTABLE; INJECTION

CORTROSYN

+ AMPHASTAR 0.25MG/VIAL N16750 001 JUN CAHN

CROMOLYN SODIUM

SOLUTION/DROPS; OPHTHALMIC

CROMOPTIC

@ KING PHARMS 4% N75088 001 APR 27, 1999 MAY DISC

CYANOCOBALAMIN

GEL, METERED; NASAL

NASCOBAL

+ QUESTCOR PHARMS 0.5MG/INH N19722 001 NOV 05, 1996 JUN CAHN

INJECTABLE; INJECTION

CYANOCOBALAMIN

@ BAXTER HLTHCARE 1MG/ML N80515 002 AUG CAHN

@ ELKINS SINN 1MG/ML N80515 002 JUN DISC

>A> AP PHARMAFORCE 1MG/ML N40451 001 SEP 23, 2003 SEP NEWA

@ WYETH AYERST 0.1MG/ML N80554 001 JUN DISC

@ 1MG/ML N80554 002 JUN DISC

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

FLEXERIL

AA	MCNEIL CONS SPECLT	5MG	N17821 001		MAR	CMFD
		5MG	N17821 001		APR	CTEC

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

NEOSAR

	@ GENZIA SICOR PHARMS	100MG/VIAL	N40015 001	APR 29, 1993	AUG	DISC
AP		100MG/VIAL	N87442 001	FEB 16, 1982	AUG	CAHN
	@	200MG/VIAL	N40015 002	APR 29, 1993	AUG	DISC
AP		200MG/VIAL	N87442 002	FEB 16, 1982	AUG	CAHN
	@	500MG/VIAL	N40015 003	APR 29, 1993	AUG	DISC
AP		500MG/VIAL	N87442 003	FEB 16, 1982	AUG	CAHN
	@	1GM/VIAL	N40015 004	APR 29, 1993	AUG	DISC
AP		1GM/VIAL	N87442 004	JUL 08, 1983	AUG	CAHN
	@	2GM/VIAL	N40015 005	APR 29, 1993	AUG	DISC
AP		2GM/VIAL	N87442 005	MAR 30, 1989	AUG	CAHN

CYCLOSPORINE

CAPSULE; ORAL

GENGRAF

AB1	ABBOTT	25MG	N65003 001	MAY 12, 2000	FEB	CTNA
BX		50MG	N65003 002	MAY 12, 2000	FEB	CTNA
AB1		100MG	N65003 003	MAY 12, 2000	FEB	CTNA

EMULSION; OPHTHALMIC

RESTASIS

+	ALLERGAN	0.05%	N50790 001	DEC 23, 2002	MAR	CMS1
---	----------	-------	------------	--------------	-----	------

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HCL

>A>	AA	COREPHARMA	4MG	N40537 001	SEP 30, 2003	SEP	NEWA
-----	----	------------	-----	------------	--------------	-----	------

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AP	SICOR PHARMS	100MG/VIAL	N75206 001	DEC 30, 1998	JUL	CAHN
AP +		500MG/VIAL	N75206 002	DEC 30, 1998	JUL	CAHN
AP		1GM/VIAL	N75206 004	DEC 30, 1998	JUL	CAHN
AP		2GM/VIAL	N75206 003	DEC 30, 1998	JUL	CAHN

CYTOSAR-U

AP +	GENZIA SICOR PHARMS	100MG/VIAL	N16793 001		JUN	CAHN
AP +		500MG/VIAL	N16793 002		JUN	CAHN
AP +		1GM/VIAL	N16793 003	DEC 21, 1987	JUN	CAHN
AP +		2GM/VIAL	N16793 004	DEC 21, 1987	JUN	CAHN

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; IV (INFUSION)

SYNERCID

+	KING PHARMS	350MG/VIAL;150MG/VIAL	N50748 001	SEP 21, 1999	FEB	CAHN
---	-------------	-----------------------	------------	--------------	-----	------

	@	420MG/VIAL;180MG/VIAL	N50748 002	AUG 24, 2000	FEB	CAHN
>A>	<u>DAPTOMYCIN</u>					
>A>	INJECTABLE; IV (INFUSION)					
>A>	CUBICIN					
>A>		CUBIST	250MG/VIAL	N21572 001	SEP 12, 2003	SEP NEWA
>A>	+		500MG/VIAL	N21572 002	SEP 12, 2003	SEP NEWA
	<u>DEMECLOCYCLINE HYDROCHLORIDE</u>					
	TABLET; ORAL					
	DECLOMYCIN					
	@	WYETH PHARMS INC	75MG	N50261 001		MAR CAHN
			150MG	N50261 002		MAR CAHN
	+		300MG	N50261 003		MAR CAHN
	<u>DESIRUDIN</u>					
	INJECTABLE; SUBCUTANEOUS					
	IPRIVASK					
	+	AVENTIS PHARMS	15MG/VIAL	N21271 001	APR 04, 2003	APR NEWA
	<u>DESMOPRESSIN ACETATE</u>					
	SPRAY, METERED; NASAL					
	DESMOPRESSIN ACETATE					
AB	+	FERRING	0.01MG/SPRAY	N21333 001	SEP 16, 2002	MAY CMS1
	MINIRIN					
AB	+	FERRING	0.01MG/SPRAY	N21333 001	SEP 16, 2002	JUN CTNA
	<u>DESOGESTREL; ETHINYL ESTRADIOL</u>					
	TABLET; ORAL-21					
	ORTHO-CEPT					
	@	ORTHO MCNEIL PHARM	0.15MG;0.03MG	N20301 001	DEC 14, 1992	MAR DISC
	TABLET; ORAL-28					
AB	+	ORTHO MCNEIL PHARM	0.15MG;0.03MG	N20301 002	DEC 14, 1992	MAR CRLD
	<u>DESOXIMETASONE</u>					
	CREAM; TOPICAL					
	DESOXIMETASONE					
AB		CLAY PARK	0.25%	N76510 001	JUL 01, 2003	JUL NEWA
	<u>DEXAMETHASONE</u>					
	ELIXIR; ORAL					
	DECADRON					
	@	MERCK	0.5MG/5ML	N12376 002		APR DISC
	HEXADROL					
AA	+	ORGANON	0.5MG/5ML	N12674 001		APR CRLD
	<u>DEXAMETHASONE SODIUM PHOSPHATE</u>					
	INJECTABLE; INJECTION					
	DEXAMETHASONE					
AP		BAXTER HLTHCARE	EQ 4MG PHOSPHATE/ML	N84282 001		AUG CAHN
	DEXAMETHASONE SODIUM PHOSPHATE					
AP		AM PHARM	EQ 10MG PHOSPHATE/ML	N40491 001	APR 11, 2003	APR NEWA

FEB	CAHN	<u>DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE</u>						
		SOLUTION/DROPS; OPHTHALMIC						
		NEODECADRON						
		@ MERCK	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N50322 001			MAY	DISC
SEP	NEWA	<u>DEXTROAMPHETAMINE SULFATE</u>						
SEP	NEWA	CAPSULE, EXTENDED RELEASE; ORAL						
		DEXEDRINE						
		AB	GLAXOSMITHKLINE 5MG	N17078 001			JUL	CRLD
		AB	10MG	N17078 002			JUL	CRLD
MAR	CAHN	DEXTROAMPHETAMINE SULFATE						
MAR	CAHN	AB	MALLINCKRODT 5MG	N76353 001	MAY 06, 2003		MAY	NEWA
MAR	CAHN	AB	10MG	N76353 002	MAY 06, 2003		MAY	NEWA
		AB	15MG	N76353 003	MAY 06, 2003		MAY	NEWA
		<u>DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE</u>						
		SYRUP; ORAL						
APR	NEWA	PHENERGAN W/ DEXTROMETHORPHAN						
		@ WYETH AYERST	15MG/5ML;6.25MG/5ML	N11265 002	APR 02, 1984		JUN	DISC
		PROMETH W/ DEXTROMETHORPHAN						
		AA + ALPHARMA	15MG/5ML;6.25MG/5ML	N88762 001	OCT 31, 1984		JUN	CRLD
MAY	CMS1	<u>DIAZEPAM</u>						
		INJECTABLE; INJECTION						
JUN	CTNA	DIAZEPAM						
		@ BAXTER HLTHCARE	5MG/ML	N71308 001	JUL 17, 1987	AUG	CAHN	
		AP	5MG/ML	N71309 001	JUL 17, 1987	AUG	CAHN	
		AP	5MG/ML	N71310 001	JUL 17, 1987	AUG	CAHN	
		@ ELKINS SINN	5MG/ML	N70311 001	DEC 16, 1985	JUN	DISC	
MAR	DISC	@	5MG/ML	N70312 001	DEC 16, 1985	JUN	DISC	
		@	5MG/ML	N70313 001	DEC 16, 1985	JUN	DISC	
MAR	CRLD	TABLET; ORAL						
		@ CLONMEL HLTHCARE	5MG	N70227 001	SEP 26, 1985	AUG	DISC	
		@	10MG	N70228 001	SEP 26, 1985	AUG	DISC	
		<u>DICHLORPHENAMIDE</u>						
JUL	NEWA	TABLET; ORAL						
		DARANIDE						
		@ MERCK	50MG	N11366 001			MAY	DISC
		<u>DICLOXACILLIN SODIUM</u>						
APR	DISC	CAPSULE; ORAL						
		PATHOCIL						
APR	CRLD	@ WYETH AYERST	EQ 250MG BASE	N50011 002			JUN	DISC
		@	EQ 500MG BASE	N50011 003	MAR 28, 1983		JUN	DISC
		FOR SUSPENSION; ORAL						
		DICLOXACILLIN SODIUM						
		+ APOTHECON	EQ 62.5MG BASE/5ML	N61455 001			JUN	CTEC
AUG	CAHN	PATHOCIL						
		@ WYETH AYERST	EQ 62.5MG BASE/5ML	N50092 001			JUN	DISC
APR	NEWA							

DICYCLOMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DICYCLOMINE HCL (PRESERVATIVE-FREE)

AP	BEDFORD	10MG/ML	N40465 001	JUN 30, 2003	JUN	NEWA
----	---------	---------	------------	--------------	-----	------

DIENESTROL

CREAM; VAGINAL

DIENESTROL

@	ORTHO MCNEIL	0.01%	N06110 005		AUG	DISC
---	--------------	-------	------------	--	-----	------

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

AP	SABEX 2002	0.25MG/ML	N40481 001	AUG 21, 2003	AUG	NEWA
	@ WYETH AYERST	0.25MG/ML	N84386 001		JUN	DISC

TABLET; ORAL

AB	CARACO	0.125MG	N76363 001	JAN 31, 2003	JAN	NEWA
AB		0.25MG	N76363 002	JAN 31, 2003	JAN	NEWA

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

D.H.E. 45

AP +	XCEL PHARMS	1MG/ML	N05929 001		APR	CFTG
------	-------------	--------	------------	--	-----	------

DIHYDROERGOTAMINE MESYLATE

AP	BEDFORD	1MG/ML	N40453 001	JUN 09, 2003	JUN	NEWA
----	---------	--------	------------	--------------	-----	------

DIHYDROERGOTAMINE MESYLATE

AP	PADDOCK	1MG/ML	N40475 001	APR 28, 2003	APR	NEWA
----	---------	--------	------------	--------------	-----	------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

TAZTIA XT

AB4	ANDRX PHARMS	120MG	N75401 001	APR 10, 2003	APR	NEWA
AB4		180MG	N75401 002	APR 10, 2003	APR	NEWA
AB4		240MG	N75401 003	APR 10, 2003	APR	NEWA
AB4		300MG	N75401 004	APR 10, 2003	APR	NEWA
AB4		360MG	N75401 005	APR 10, 2003	APR	NEWA

TIAZAC

AB4 +	BIOVAIL	120MG	N20401 001	SEP 11, 1995	APR	CFTG
AB4		120MG	N20401 001	SEP 11, 1995	AUG	CRLD
AB4 +		180MG	N20401 002	SEP 11, 1995	APR	CFTG
AB4		180MG	N20401 002	SEP 11, 1995	AUG	CRLD
AB4 +		240MG	N20401 003	SEP 11, 1995	APR	CFTG
AB4		240MG	N20401 003	SEP 11, 1995	AUG	CRLD
AB4 +		300MG	N20401 004	SEP 11, 1995	APR	CFTG
AB4		300MG	N20401 004	SEP 11, 1995	AUG	CRLD
AB4 +		360MG	N20401 005	SEP 11, 1995	APR	CFTG
AB4		360MG	N20401 005	SEP 11, 1995	AUG	CRLD

INJECTABLE; INJECTION

DILTIAZEM HCL

AP +	BEDFORD	5MG/ML	N74617 001	FEB 28, 1996	AUG	CRLD
------	---------	--------	------------	--------------	-----	------

DILTIAZEM HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CARDIZEM LA

+	BIOVAIL	120MG	N21392 001	FEB 06, 2003	FEB	NEWA
+		180MG	N21392 002	FEB 06, 2003	FEB	NEWA
+		240MG	N21392 003	FEB 06, 2003	FEB	NEWA
+		300MG	N21392 004	FEB 06, 2003	FEB	NEWA
+		360MG	N21392 005	FEB 06, 2003	FEB	NEWA
+		420MG	N21392 006	FEB 06, 2003	FEB	NEWA

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL

TIAMATE

@	MERCK	EQ 120MG HCL	N20506 001	OCT 04, 1996	MAY	DISC
@		EQ 180MG HCL	N20506 002	OCT 04, 1996	MAY	DISC
@		EQ 240MG HCL	N20506 003	OCT 04, 1996	MAY	DISC

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

@	BAXTER HLTHCARE	50MG/ML	N84767 001		AUG	CAHN
+	STERIS	50MG/ML	N80615 001		JUN	CTEC
@	WYETH AYERST	50MG/ML	N84316 001		JUN	DISC

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL

RIMSO-50

AT	+	EDWARDS LIFESCIENCES	50%	N17788 001		JUL	CAHN
----	---	----------------------	-----	------------	--	-----	------

DIMYRISTOYL LECITHIN; PERFLEXANE

INJECTABLE; INTRAVENOUS

IMAGENT

+	IMCOR	0.92MG/VIAL;0.092MG/VIAL	N21191 001	MAY 31, 2002	AUG	CAHN
---	-------	--------------------------	------------	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DIPHENHYDRAMINE HCL

AP		BAXTER HLTHCARE	50MG/ML	N80817 002		JUN	CAHN
	@		50MG/ML	N83183 001		AUG	CAHN
	@	WYETH AYERST	50MG/ML	N80577 001		JUN	DISC

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

AB		CLONMEL HLTHCARE	25MG	N88999 001	FEB 05, 1991	JUL	CAHN
	@		25MG	N88999 001	FEB 05, 1991	AUG	DISC
AB			50MG	N89000 001	FEB 05, 1991	JUL	CAHN
AB			75MG	N89001 001	FEB 05, 1991	JUL	CAHN
	@		75MG	N89001 001	FEB 05, 1991	AUG	DISC

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HCL

@ BAXTER HLTHCARE

EQ 12.5MG BASE/ML

N74381 001 SEP 26, 1996 AUG CAHN

@ ELKINS SINN

EQ 12.5MG BASE/ML

N74381 001 SEP 26, 1996 JUN DISC

DOLASETRON MESYLATE MONOHYDRATE

INJECTABLE; INJECTION

ANZEMET

>D> AVENTIS PHARMS

EQ 12.5MG BASE/0.625ML

N20624 002 SEP 11, 1997 SEP CPOT

>A>

EQ 12.5MG BASE/0.625ML(20MG/ML)

N20624 002 SEP 11, 1997 SEP CPOT

EQ 12.5MG BASE/0.625ML

N20624 002 SEP 11, 1997 JUL CPOT

>D> +

EQ 20MG BASE/ML

N20624 001 SEP 11, 1997 SEP CPOT

>A> +

EQ 100MG BASE/5ML(20MG/ML)

N20624 001 SEP 11, 1997 SEP CPOT

>A> +

EQ 500MG BASE/25ML(20MG/ML)

N20624 003 DEC 11, 2001 SEP NEWA

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HCL

@ BAXTER HLTHCARE

40MG/ML

N18398 001 JUN DISC

@

80MG/ML

N18398 002 MAR 22, 1982 JUN DISC

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOPRAM

AP + BAXTER HLTHCARE CORP

20MG/ML

N14879 001 JAN CAHN

DOXAPRAM HCL

AP BEDFORD

20MG/ML

N76266 001 JAN 10, 2003 JAN NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ADRIAMYCIN RDF

@ PHARMACIA AND UPJOHN

150MG/VIAL

N50467 004 JUL 22, 1987 JUL DISC

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB AXIOM PHARM

EQ 50MG BASE

N65041 001 APR 28, 2000 MAY CAHN

AB

EQ 100MG BASE

N65041 002 APR 28, 2000 MAY CAHN

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

AB AXIOM PHARM

EQ 50MG BASE

N61717 001 MAY CAHN

AB

EQ 100MG BASE

N61717 002 MAY CAHN

CAPSULE, COATED PELLETS; ORAL

DORYX

FAULDING

EQ 75MG BASE

N50582 002 AUG 13, 2001 FEB NEWA

INJECTABLE; INJECTION

DOXY 100

+ AM PHARM PARTNERS

EQ 100MG BASE/VIAL

N62475 001 DEC 09, 1983 MAR CRLD

DOXYCYCLINE HYCLATE

INJECTABLE; INJECTION

DOXY 200

	+	AM PHARM PARTNERS	EQ 200MG BASE/VIAL	N62475 002	DEC 09, 1983	MAR	CRLD
		DOXYCYCLINE					
		@ BAXTER HLHCARE	EQ 100MG BASE/VIAL	N62450 001	OCT 27, 1983	AUG	CAHN
		@	EQ 200MG BASE/VIAL	N62450 002	OCT 27, 1983	AUG	CAHN
		DOXYCYCLINE HYCLATE					
		@ BAXTER HLHCARE	EQ 100MG BASE/VIAL	N62992 001	FEB 16, 1989	AUG	CAHN
		@	EQ 200MG BASE/VIAL	N62992 002	FEB 16, 1989	AUG	CAHN
		VIBRAMYCIN					
		@ PFIZER	EQ 100MG BASE/VIAL	N50442 002		MAR	DISC
		@	EQ 200MG BASE/VIAL	N50442 001		MAR	DISC

TABLET; ORAL

DOXYCYCLINE HYCLATE

AB		AXIOM PHARM	EQ 100MG BASE	N62269 002	NOV 08, 1982	MAY	CAHN
AB		WEST WARD	EQ 100MG BASE	N65095 001	JUL 02, 2003	JUL	NEWA
		DOXYCYCLINE HYLATE					
		@ AXIOM PHARM	EQ 50MG BASE	N62269 003		MAY	CAHN

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

REVERSOL

		@ ORGANON	10MG/ML	N89624 001	MAY 13, 1988	MAY	DISC
--	--	-----------	---------	------------	--------------	-----	------

ELETRIPTAN HYDROBROMIDE

TABLET; ORAL

RELPAK

		PFIZER IRELAND	EQ 20MG BASE	N21016 001	DEC 26, 2002	MAR	CAHN
		+	EQ 40MG BASE	N21016 002	DEC 26, 2002	MAR	CAHN

EMTRICITABINE

CAPSULE; ORAL

EMTRIVA

		+	GILEAD	200MG	N21500 001	JUL 02, 2003	JUL	NEWA
--	--	---	--------	-------	------------	--------------	-----	------

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB		IVAX PHARMS	5MG;12.5MG	N75736 001	MAR 25, 2003	MAR	NEWA
AB			10MG;25MG	N75736 002	MAR 25, 2003	MAR	NEWA

ENFUVRTIDE

INJECTABLE; SUBCUTANEOUS

FUZEON

		+	ROCHE	90MG/VIAL	N21481 001	MAR 13, 2003	MAR	NEWA
--	--	---	-------	-----------	------------	--------------	-----	------

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

LOVENOX

		+	AVENTIS	300MG/3ML	N20164 009	JAN 23, 2003	JAN	NEWA
--	--	---	---------	-----------	------------	--------------	-----	------

<u>EPINEPHRINE</u>					
INJECTABLE; IM-SC					
TWINJECT					
+	HOLLISTER STIER LABS	0.3MG /DELIVERY	N20800 001	MAY 30, 2003	MAY NEWA
<u>EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE</u>					
INJECTABLE; INJECTION					
DURANEST					
@	DENTSPLY PHARM	0.005MG/ML;1.5%	N21384 001		MAR DISC
<u>EPINEPHRINE; LIDOCAINE HYDROCHLORIDE</u>					
INJECTABLE; INJECTION					
LIDOCAINE HCL AND EPINEPHRINE					
@	ELKINS SINN	0.01MG/ML;1%	N80406 001		JUN DISC
@		0.01MG/ML;2%	N80406 002		JUN DISC
<u>EPROSARTAN MESYLATE</u>					
TABLET; ORAL					
TEVETEN					
	BIOVAIL	EQ 300MG BASE	N20738 004	DEC 22, 1997	JUL CAHN
		EQ 400MG BASE	N20738 005	DEC 22, 1997	JUL CAHN
+		EQ 600MG BASE	N20738 006	MAY 27, 1999	JUL CAHN
<u>EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE</u>					
TABLET; ORAL					
TEVETEN HCT					
	BIOVAIL	600MG;12.5MG	N21268 001	NOV 01, 2001	JUL CAHN
+		600MG;25MG	N21268 002	NOV 01, 2001	JUL CAHN
<u>ERGOTAMINE TARTRATE</u>					
TABLET; SUBLINGUAL					
ERGOMAR					
+	HARVEST PHARMS	2MG	N87693 001	FEB 24, 1983	MAR CAHN
<u>ERYTHROMYCIN</u>					
SOLUTION; TOPICAL					
STATICIN					
+	WESTWOOD SQUIBB	1.5%	N50526 001		APR CTEC
<u>ERYTHROMYCIN LACTOBIONATE</u>					
INJECTABLE; INJECTION					
ERYTHROMYCIN					
@	ELKINS SINN	EQ 500MG BASE/VIAL	N62563 001	MAR 28, 1985	JUN DISC
@		EQ 1GM BASE/VIAL	N62563 002	MAR 28, 1985	JUN DISC
ERYTHROMYCIN LACTOBIONATE					
AP	BAXTER HLTHCARE	EQ 500MG BASE/VIAL	N62993 001	MAY 09, 1989	AUG CAHN
AP		EQ 1GM BASE/VIAL	N62993 002	MAY 09, 1989	AUG CAHN
<u>ESMOLOL HYDROCHLORIDE</u>					
INJECTABLE; INJECTION					
BREVIBLOC					
+	BAXTER HLTHCARE CORP	10MG/ML	N19386 006	FEB 25, 2003	JUN NEWA

	+		20MG/ML	N19386 007	MAY 28, 2003	JUN	NEWA
		BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER					
	+	BAXTER HLTHCARE CORP	2GM/100ML	N19386 005	JAN 27, 2003	MAR	NEWA
		BREVIBLOC IN PLASTIC CONTAINER					
	+	BAXTER HLTHCARE CORP	1GM/100ML	N19386 004	FEB 16, 2001	MAR	NEWA

ESTRADIOL

		FILM, EXTENDED RELEASE; TRANSDERMAL					
		CLIMARA					
BX	+	BERLEX LABS	0.0375MG/24HR	N20375 005	MAY 27, 2003	JUN	NEWA
	+		0.06MG/24HR	N20375 006	MAY 27, 2003	JUN	NEWA
		TABLET; ORAL					
		ESTRADIOL					
		@ CLONMEL HLTHCARE	0.5MG	N40275 001	DEC 29, 1998	AUG	DISC
		@	1MG	N40275 002	DEC 29, 1998	AUG	DISC
		@	2MG	N40275 003	DEC 29, 1998	AUG	DISC

ESTRADIOL ACETATE

		INSERT, EXTENDED RELEASE; VAGINAL					
		FEMRING					
		GALEN LTD	0.05MG/24HR	N21367 001	MAR 20, 2003	MAR	NEWA
	+		0.1MG/24HR	N21367 002	MAR 20, 2003	MAR	NEWA

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

		INJECTABLE; INTRAMUSCULAR					
		LUNELLE					
		@ PHARMACIA AND UPJOHN	5MG/0.5ML;25MG/0.5ML	N20874 001	OCT 05, 2000	AUG	DISC

ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE

		INJECTABLE; INJECTION					
		DEPO-TESTADIOL					
		@ PHARMACIA AND UPJOHN	2MG/ML;50MG/ML	N17968 001		MAY	WDAG

ESTRADIOL; NORGESTIMATE

		TABLET; ORAL					
		PREFEST					
	+	KING PHARMS	1MG;1MG;0.09MG	N21040 001	OCT 22, 1999	MAY	CTNA

ESTROGENS, CONJUGATED

		CREAM; TOPICAL, VAGINAL					
		PREMARIN					
	+	WYETH PHARMS INC	0.625MG/GM	N20216 001		MAR	CAHN
		INJECTABLE; INJECTION					
	+	WYETH PHARMS INC	25MG/VIAL	N10402 001		MAR	CAHN
		TABLET; ORAL					
		WYETH PHARMS INC	0.3MG	N04782 003		MAR	CAHN
			0.45MG	N04782 006	JUL 16, 2003	JUL	NEWA
	+		0.625MG	N04782 004		MAR	CAHN
			0.9MG	N04782 005	JAN 26, 1984	MAR	CAHN
	+		1.25MG	N04782 001		MAR	CAHN
	+		2.5MG	N04782 002		MAR	CAHN

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPHASE (PREMARIN;CYCRIN 14/14)

@ WYETH PHARMS INC 0.625MG;0.625MG;5MG

N20303 002 DEC 30, 1994 MAR CAHN

PREMPHASE 14/14

+ WYETH PHARMS INC 0.625MG;0.625MG;5MG

N20527 002 NOV 17, 1995 MAR CAHN

PREMPRO

+ WYETH PHARMS INC 0.3MG;1.5MG

N20527 005 JUN 04, 2003 JUN NEWA

+ 0.45MG;1.5MG

N20527 004 MAR 12, 2003 MAR NEWA

+ 0.625MG;0.625MG;2.5MG;2.5MG

N20527 001 NOV 17, 1995 MAR CAHN

+ 0.625MG;0.625MG;5MG;5MG

N20527 003 JAN 09, 1998 MAR CAHN

PREMPRO (PREMARIN;CYCRIN)

@ WYETH PHARMS INC 0.625MG;0.625MG;2.5MG;2.5MG

N20303 001 DEC 30, 1994 MAR CAHN

ESTROGENS, ESTERIFIED

TABLET; ORAL

MENEST

MONARCH PHARMS 0.3MG

N84951 001 JAN CRLD

ETHACRYNIC ACID

TABLET; ORAL

EDECIN

+ MERCK 25MG

N16092 001 MAY CRLD

@ 50MG

N16092 002 MAY DISC

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

ETHAMBUTOL HCL

AB + WEST WARD 400MG

N75095 002 NOV 30, 1999 JUN CRLD

MYAMBUTOL

@ LEDERLE 100MG

N16320 001 JUN DISC

@ 400MG

N16320 003 JUN DISC

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

DEMULEN 1/35-28

AB + GD SEARLE LLC 0.035MG;1MG

N18160 001 JUL CRLD

ETHINYL ESTRADIOL; ETONOGESTREL

RING; VAGINAL

NUVARING

+ ORGANON USA INC 0.015MG;0.12MG

N21187 001 OCT 03, 2001 JUN CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

>A> SEASONALE

>A> + BARR 0.03MG;0.15MG

N21544 001 SEP 05, 2003 SEP NEWA

TABLET; ORAL-21

ALESSE

AB1 + WYETH PHARMS INC 0.02MG;0.1MG

N20683 001 MAR 27, 1997 MAR CAHN

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1 BARR 0.02MG;0.1MG

N75862 001 APR 29, 2003 APR NEWA

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21						
	NORDETTE-21					
AB +	WYETH PHARMS INC	0.03MG;0.15MG	N18668 001	MAY 10, 1982	MAR	CAHN
	TRIPHASIL-21					
AB +	WYETH PHARMS INC	0.03MG;0.04MG;0.03MG;0.05MG;0.125MG; ;0.075MG	N19192 001	NOV 01, 1984	MAR	CAHN
TABLET; ORAL-28						
	ALESSE					
AB1	WYETH PHARMS INC	0.02MG;0.1MG	N20683 002	MAR 27, 1997	MAR	CAHN
	LEVONORGESTREL AND ETHINYL ESTRADIOL					
AB1	BARR	0.02MG;0.1MG	N75862 002	APR 29, 2003	APR	NEWA
	NORDETTE-28					
AB	WYETH PHARMS INC	0.03MG;0.15MG	N18782 001	JUL 21, 1982	MAR	CAHN
	TRIPHASIL-28					
AB	WYETH PHARMS INC	0.03MG;0.04MG;0.03MG;0.05MG;0.125MG; ;0.075MG	N19190 001	NOV 01, 1984	MAR	CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21						
	BREVICON 21-DAY					
AB +	WATSON LABS	0.035MG;0.5MG	N17566 001		AUG	CRLD
	MODICON 21					
	@ ORTHO MCNEIL PHARM	0.035MG;0.5MG	N17488 001		AUG	DISC
	ORTHO-NOVUM 1/35-21					
	@ ORTHO MCNEIL PHARM	0.035MG;1MG	N17489 002		AUG	DISC
	ORTHO-NOVUM 10/11-21					
	@ ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG	N18354 001	JAN 11, 1982	AUG	DISC
	ORTHO-NOVUM 7/7/7-21					
	@ ORTHO MCNEIL PHARM	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0 .75MG	N18985 001	APR 04, 1984	AUG	DISC
	TRI-NORINYL 21-DAY					
	@ WATSON LABS	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0 .5MG	N18977 001	APR 13, 1984	MAR	CPOT
	@	0.035MG,0.035MG;0.5MG,1MG	N18977 001	APR 13, 1984	FEB	DISC
TABLET; ORAL-28						
	ORTHO-NOVUM 7/7/7-28					
AB +	ORTHO MCNEIL PHARM	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0 .75MG	N18985 002	APR 04, 1984	FEB	CRLD
	OVCON-35					
+	WARNER CHILCOTT	0.035MG;0.4MG	N17716 001		JAN	CRLD
	OVCON-50					
+	WARNER CHILCOTT	0.05MG;1MG	N17576 001		JAN	CRLD
	TRI-NORINYL 28-DAY					
+	WATSON LABS	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0 .5MG	N18977 002	APR 13, 1984	MAR	CPOT
+		0.035MG,0.035MG;0.5MG,1MG	N18977 002	APR 13, 1984	JAN	CRLD

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL		FEMHRT							
	+	GALEN CHEM	0.005MG;1MG	N21065 002	OCT 15, 1999	MAY	CAHN		
TABLET; ORAL-21		ESTROSTEP 21							
	@	GALEN CHEM	0.02MG;0.03MG;0.035MG;1MG;1MG;1MG	N20130 001	OCT 09, 1996	APR	CAHN		
		JUNEL 1.5/30							
AB		BARR	0.03MG;1.5MG	N76381 001	MAY 30, 2003	MAY	NEWA		
		JUNEL 1/20							
AB		BARR	0.02MG;1MG	N76380 001	MAY 30, 2003	MAY	NEWA		
		LOESTRIN 21 1.5/30							
	+	GALEN CHEM	0.03MG;1.5MG	N17875 001		APR	CAHN		
AB	+		0.03MG;1.5MG	N17875 001		MAY	CFTG		
		LOESTRIN 21 1/20							
	+	GALEN CHEM	0.02MG;1MG	N17876 001		APR	CAHN		
AB	+		0.02MG;1MG	N17876 001		MAY	CFTG		
TABLET; ORAL-28		ESTROSTEP FE							
	+	GALEN CHEM	0.02MG;0.03MG;0.035MG;1MG;1MG;1MG	N20130 002	OCT 09, 1996	APR	CAHN		
		JUNEL FE 1.5/30							
>A>	AB	BARR	0.03MG;1.5MG	N76064 001	SEP 18, 2003	SEP	NEWA		
		JUNEL FE 1/20							
>A>	AB	BARR	0.02MG;1MG	N76081 001	SEP 18, 2003	SEP	NEWA		
		LOESTRIN FE 1.5/30							
AB	+	GALEN CHEM	0.03MG;1.5MG	N17355 001		APR	CAHN		
		LOESTRIN FE 1/20							
AB	+	GALEN CHEM	0.02MG;1MG	N17354 001		APR	CAHN		

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21		LO/OVRAL							
AB	+	WYETH PHARMS INC	0.03MG;0.3MG	N17612 001		MAR	CAHN		
		OGESTREL 0.5/50-21							
AB		WATSON LABS	0.05MG;0.5MG	N75406 001	DEC 15, 1999	FEB	CAHN		
		OVRAL							
AB	+	WYETH PHARMS INC	0.05MG;0.5MG	N16672 001		MAR	CAHN		
TABLET; ORAL-28		LO/OVRAL-28							
AB		WYETH PHARMS INC	0.03MG;0.3MG	N17802 001		MAR	CAHN		
		OGESTREL 0.5/50-28							
AB		WATSON LABS	0.05MG;0.5MG	N75406 002	DEC 15, 1999	FEB	CAHN		
		OVRAL-28							
AB		WYETH PHARMS INC	0.05MG;0.5MG	N16806 001		MAR	CAHN		

ETHIONAMIDE

TABLET; ORAL		TRECATOR-SC							
	+	WYETH PHARMS INC	250MG	N13026 002		MAR	CAHN		

ETHOTOIN

TABLET; ORAL

PEGANONE

+ OVATION PHARMS

250MG

N10841 001

MAR CAHN

@

500MG

N10841 003

MAR CAHN

ETIDRONATE DISODIUM

TABLET; ORAL

DIDRONEL

AB PROCTER AND GAMBLE

200MG

N17831 001

JUL CTEC

AB +

400MG

N17831 002

JUL CTEC

ETIDRONATE DISODIUM

AB GENPHARM

200MG

N75800 001 JAN 24, 2003

JAN NEWA

AB

400MG

N75800 002 JAN 24, 2003

JAN NEWA

ETODOLAC

CAPSULE; ORAL

LODINE

AB WYETH PHARMS INC

200MG

N18922 002 JAN 31, 1991

MAR CAHN

AB +

300MG

N18922 003 JAN 31, 1991

MAR CAHN

TABLET; ORAL

AB WYETH PHARMS INC

400MG

N18922 004 JUL 29, 1993

MAR CAHN

AB +

500MG

N18922 005 JUN 28, 1996

MAR CAHN

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

AB TARO

400MG

N76174 001 MAR 13, 2003

MAR NEWA

AB

500MG

N76174 002 MAR 13, 2003

MAR NEWA

AB

600MG

N76174 003 MAR 13, 2003

MAR NEWA

LODINE XL

AB + WYETH PHARMS INC

400MG

N20584 001 OCT 25, 1996

MAR CAHN

AB +

500MG

N20584 003 JAN 20, 1998

MAR CAHN

AB +

600MG

N20584 002 OCT 25, 1996

MAR CAHN

ETOPOSIDE

INJECTABLE; INJECTION

ETOPOSIDE

AP SICOR PHARMS

20MG/ML

N74284 001 FEB 10, 1994

JUL CAHN

AP

20MG/ML

N74529 001 JUL 24, 1996

JUL CAHN

TOPOSAR

AP GENSLA SICOR PHARMS

20MG/ML

N74166 001 FEB 27, 1995

JUL CAHN

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

AP BAXTER HLTHCARE

10MG/ML

N75488 001 APR 16, 2001

AUG CAHN

FAMOTIDINE PRESERVATIVE FREE

AP BAXTER HLTHCARE

10MG/ML

N75486 001 APR 16, 2001

JUN CAHN

FELBAMATE

SUSPENSION; ORAL

FELBATOL

+ MEDPOINTE

600MG/5ML

N20189 003 JUL 29, 1993

MAR CAHN

FELBAMATE

TABLET; ORAL

MEDPOINTE 400MG

+ 600MG

N20189 001 JUL 29, 1993 MAR CAHN

N20189 002 JUL 29, 1993 MAR CAHN

FENOFIBRATE

CAPSULE; ORAL

FENOFIBRATE (MICRONIZED)

TEVA 67MG

134MG

+ 200MG

N75753 001 SEP 03, 2002 MAR CTEC

N75753 002 APR 09, 2002 MAR CTEC

N75753 003 APR 09, 2002 MAR CRLD

TRICOR (MICRONIZED)

a ABBOTT 67MG

N19304 002 FEB 09, 1998 MAR DISC

a 134MG

N19304 003 JUN 30, 1999 MAR DISC

a 200MG

N19304 004 JUN 30, 1999 MAR DISC

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

AP + BAXTER HLTHCARE EQ 0.05MG BASE/ML

N19101 001 JUL 11, 1984 AUG CAHN

FERRIC AMMONIUM CITRATE

FOR SOLUTION; ORAL

FERRISELTZ

a OTSUKA 600MG/PACKET

N20292 001 OCT 14, 1997 AUG CAHN

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HCL

AB IMPAX PHARMS 100MG

URISPAS

N76234 001 AUG 28, 2003 AUG NEWA

+ ORTHO MCNEIL PHARM 100MG

N16769 001 MAR CAHN

AB + 100MG

N16769 001 AUG CFTG

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

AB GENEVA PHARMS 50MG

N76030 001 OCT 28, 2002 JUN CAHN

AB 100MG

N76030 002 OCT 28, 2002 JUN CAHN

AB 150MG

N76030 003 OCT 28, 2002 JUN CAHN

AB RANBAXY 50MG

N76421 001 MAR 28, 2003 MAR NEWA

AB 100MG

N76421 002 MAR 28, 2003 MAR NEWA

AB 150MG

N76421 003 MAR 28, 2003 MAR NEWA

AB ROXANE 50MG

N76278 001 JAN 14, 2003 JAN NEWA

AB 100MG

N76278 002 JAN 14, 2003 JAN NEWA

AB 150MG

N76278 003 JAN 14, 2003 JAN NEWA

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARA

AP	+	BERLEX	50MG/VIAL	N20038 001	APR 18, 1991	AUG	CFTG
		FLUDARABINE PHOSPHATE					
AP		GENSIA SICOR PHARMS	50MG/VIAL	N76349 001	AUG 28, 2003	AUG	NEWA

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

AB		BARR	0.1MG	N40425 001	JAN 21, 2003	JAN	NEWA
----	--	------	-------	------------	--------------	-----	------

FLUNISOLIDE

SPRAY, METERED; NASAL

NASAREL

+ IVAX RES

0.029MG/SPRAY

N20409 001	MAR 08, 1995	JUL	CPOT
------------	--------------	-----	------

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

AB1		ALPHARMA US PHARM	0.05%	N73085 001	FEB 14, 1992	MAY	CTEC
AB1		FOUGERA	0.05%	N73030 001	OCT 17, 1994	MAY	CTEC
AB1		TARO	0.05%	N19117 001	JUN 26, 1984	MAY	CTEC
AB1			0.05%	N71500 001	JUN 10, 1987	MAY	CTEC
AB1		TEVA	0.05%	N72488 001	FEB 06, 1989	MAY	CTEC

FLUOCINONIDE EMULSIFIED BASE

AB2		ALPHARMA US PHARM	0.05%	N74204 001	JUN 13, 1995	MAY	CTEC
AB2		DRAXIS HLTH	0.05%	N72494 001	JAN 19, 1989	MAY	CTEC
AB2		TARO	0.05%	N72494 001	JAN 19, 1989	JUN	CAHN
AB2		TEVA	0.05%	N72490 001	FEB 07, 1989	MAY	CTEC

LIDEX

AB1	+	MEDICIS	0.05%	N16908 002		MAY	CTEC
-----	---	---------	-------	------------	--	-----	------

LIDEX-E

AB2	+	MEDICIS	0.05%	N16908 003		MAY	CRLD
-----	---	---------	-------	------------	--	-----	------

FLUORESCEIN SODIUM

INJECTABLE; INJECTION

FUNDUSCEIN-25

@ NOVARTIS

25%

N17869 001		JAN	DISC
------------	--	-----	------

FLUOROURACIL

INJECTABLE; INJECTION

ADRUCIL

AP		GENSIA SICOR PHARMS	50MG/ML	N40023 001	OCT 18, 1991	JUL	CAHN
AP	+		50MG/ML	N81225 001	AUG 28, 1991	JUL	CAHN
		FLUOROURACIL					
AP		SICOR PHARMS	50MG/ML	N40333 001	JAN 27, 2000	JUL	CAHN
AP			50MG/ML	N40334 001	FEB 25, 2000	JUL	CAHN

SOLUTION; TOPICAL

FLUROPLEX

@ ALLERGAN HERBERT

1%

N16765 001		JUN	DISC
------------	--	-----	------

	<u>FLUPHENAZINE DECANOATE</u>							
	INJECTABLE; INJECTION							
	FLUPHENAZINE DECANOATE							
	@ KING PHARMS	25MG/ML		N74966 001	APR 16, 1998	MAY	DISC	
	<u>FLURANDRENOLIDE</u>							
	LOTION; TOPICAL							
	CORDRAN							
	+ OCLASSEN	0.05%		N13790 001		MAY	CTEC	
	<u>FLUTAMIDE</u>							
	CAPSULE; ORAL							
	FLUTAMIDE							
AB	GENPHARM	125MG		N76224 001	MAY 09, 2003	MAY	NEWA	
	<u>FLUVOXAMINE MALEATE</u>							
	TABLET; ORAL							
	FLUVOXAMINE MALEATE							
AB	GENEVA PHARMS	25MG		N75887 001	JAN 05, 2001	APR	CAHN	
AB		50MG		N75887 002	JAN 05, 2001	APR	CAHN	
AB		100MG		N75887 003	JAN 05, 2001	APR	CAHN	
	<u>FOLIC ACID</u>							
	INJECTABLE; INJECTION							
	FOLIC ACID							
AP	+ AM PHARM PARTNERS	5MG/ML		N89202 001	FEB 18, 1986	JUN	CRLD	
	FOLVITE							
AP	+ WYETH PHARMS INC	5MG/ML		N05897 008		MAR	CAHN	
	@	5MG/ML		N05897 008		JUN	DISC	
	TABLET; ORAL							
	@ WYETH PHARMS INC	1MG		N05897 004		MAR	CAHN	
	<u>FUROSEMIDE</u>							
	INJECTABLE; INJECTION							
	FUROSEMIDE							
	@ BAXTER HLTHCARE	10MG/ML		N18267 001		JUN	DISC	
AP		10MG/ML		N71439 001	SEP 14, 1990	AUG	CAHN	
	TABLET; ORAL							
AB	CLONMEL HLTHCARE	20MG		N18415 001	JUL 27, 1982	JUL	CAHN	
	@	20MG		N18415 001	JUL 27, 1982	AUG	DISC	
AB		40MG		N18415 002	JUL 27, 1982	JUL	CAHN	
	@	40MG		N18415 002	JUL 27, 1982	AUG	DISC	
AB		80MG		N18415 003	NOV 26, 1984	JUL	CAHN	
	@	80MG		N18415 003	NOV 26, 1984	AUG	DISC	
	<u>GABAPENTIN</u>							
	CAPSULE; ORAL							
>A>	GABAPENTIN							
>A>	AB	PUREPAC PHARM	100MG	N75350 001	SEP 12, 2003	SEP	NEWA	
>A>	AB		300MG	N75350 002	SEP 12, 2003	SEP	NEWA	
>A>	AB		400MG	N75350 003	SEP 12, 2003	SEP	NEWA	

GABAPENTIN

CAPSULE; ORAL

NEURONTIN

>D>		PFIZER PHARMS	100MG	N20235 001	DEC 30, 1993	SEP	CFTG
>A>	AB		100MG	N20235 001	DEC 30, 1993	SEP	CFTG
>D>			300MG	N20235 002	DEC 30, 1993	SEP	CFTG
>A>	AB		300MG	N20235 002	DEC 30, 1993	SEP	CFTG
>D>		+	400MG	N20235 003	DEC 30, 1993	SEP	CFTG
>A>	AB	+	400MG	N20235 003	DEC 30, 1993	SEP	CFTG

GALANTAMINE HYDROBROMIDE

TABLET; ORAL

REMINYL

	+	JANSSEN PHARMA	EQ 4MG BASE	N21169 001	FEB 28, 2001	APR	CRLD
			EQ 12MG BASE	N21169 003	FEB 28, 2001	APR	CRLD

GANCICLOVIR

CAPSULE; ORAL

CYTOVENE

AB		ROCHE PALO	250MG	N20460 001	DEC 22, 1994	JUN	CFTG
AB	+		500MG	N20460 002	DEC 12, 1997	JUN	CFTG

GANCICLOVIR

AB		RANBAXY	250MG	N76457 001	JUN 27, 2003	JUN	NEWA
AB			500MG	N76457 002	JUN 27, 2003	JUN	NEWA

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

CYTOVENE IV

AP	+	ROCHE PALO	EQ 500MG BASE/VIAL	N19661 001	JUN 23, 1989	JUL	CFTG
----	---	------------	--------------------	------------	--------------	-----	------

GANCICLOVIR SODIUM

AP		BEDFORD	EQ 500MG BASE/VIAL	N76222 001	JUL 16, 2003	JUL	NEWA
----	--	---------	--------------------	------------	--------------	-----	------

GATIFLOXACIN

INJECTABLE; INJECTION

TEQUIN

	+	BRISTOL MYERS SQUIBB	EQ 2MG /ML(200MG/100ML)	N21062 001	DEC 17, 1999	APR	CRLD
	+		EQ 2MG /ML(400MG/200ML)	N21062 002	DEC 17, 1999	APR	CRLD
	+		EQ 10MG /ML(200MG)	N21062 003	DEC 17, 1999	APR	CRLD

SOLUTION/DROPS; OPHTHALMIC

ZYMAR

	+	ALLERGAN	0.3%	N21493 001	MAR 28, 2003	MAR	NEWA
--	---	----------	------	------------	--------------	-----	------

GEFITINIB

TABLET; ORAL

IRESSA

	+	ASTRAZENECA	250MG	N21399 001	MAY 05, 2003	MAY	NEWA
--	---	-------------	-------	------------	--------------	-----	------

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

		@ CLONMEL HLTHCARE	600MG	N74270 001	SEP 27, 1993	AUG	DISC
--	--	--------------------	-------	------------	--------------	-----	------

GEMIFLOXACIN MESYLATE

TABLET; ORAL

FACTIVE

+ GENESOFT PHARMS	EQ 320MG BASE	N21158 001	APR 04, 2003	MAY	CAHN
+ LG LIFE	EQ 320MG BASE	N21158 001	APR 04, 2003	APR	NEWA

GEMTUZUMAB OZOGAMICIN

INJECTABLE; INJECTION

MYLOTARG

+ WYETH PHARMS INC	5MG/VIAL	N21174 001	MAY 17, 2000	MAR	CAHN
--------------------	----------	------------	--------------	-----	------

GENTAMICIN SULFATE

CREAM; TOPICAL

GARAMYCIN

@ SCHERING	EQ 0.1% BASE	N60462 001		FEB	DISC
------------	--------------	------------	--	-----	------

GENTAMICIN SULFATE

AT + FOUGERA	EQ 0.1% BASE	N62531 001	JUL 05, 1984	FEB	CRLD
--------------	--------------	------------	--------------	-----	------

INJECTABLE; INJECTION

AP + AM PHARM PARTNERS	EQ 10MG BASE/ML	N62356 001	MAR 04, 1982	JUN	CRLD
------------------------	-----------------	------------	--------------	-----	------

@ BAXTER HLTHCARE	EQ 10MG BASE/ML	N62251 002		JUN	DISC
-------------------	-----------------	------------	--	-----	------

@	EQ 40MG BASE/ML	N62251 001		JUN	DISC
---	-----------------	------------	--	-----	------

OINTMENT; OPHTHALMIC

GARAMYCIN

@ SCHERING	EQ 0.3% BASE	N50425 001		APR	DISC
------------	--------------	------------	--	-----	------

GENTAMICIN SULFATE

+ AKORN	EQ 0.3% BASE	N64093 001	AUG 31, 1995	APR	CRLD
---------	--------------	------------	--------------	-----	------

GLIMEPIRIDE

TABLET; ORAL

AMARYL

+ AVENTIS PHARMS	1MG	N20496 001	NOV 30, 1995	JAN	CRLD
------------------	-----	------------	--------------	-----	------

	4MG	N20496 003	NOV 30, 1995	JAN	CRLD
--	-----	------------	--------------	-----	------

GLIPIZIDE

TABLET, EXTENDED RELEASE; ORAL

>A>	GLIPIZIDE				
-----	-----------	--	--	--	--

>A>	AB	WATSON LABS	5MG	N76467 001	SEP 08, 2003	SEP	NEWA
-----	----	-------------	-----	------------	--------------	-----	------

GLUCOTROL XL

>D>		PFIZER	5MG	N20329 001	APR 26, 1994	SEP	CFTG
-----	--	--------	-----	------------	--------------	-----	------

>A>	AB		5MG	N20329 001	APR 26, 1994	SEP	CFTG
-----	----	--	-----	------------	--------------	-----	------

GLYBURIDE

TABLET; ORAL

GLYBURIDE (MICRONIZED)

AB	HIKMA	1.5MG	N75890 001	JUL 31, 2003	JUL	NEWA
----	-------	-------	------------	--------------	-----	------

AB		3MG	N75890 002	JUL 31, 2003	JUL	NEWA
----	--	-----	------------	--------------	-----	------

AB		6MG	N75890 003	JUL 31, 2003	JUL	NEWA
----	--	-----	------------	--------------	-----	------

GLYCOPYRROLATE

INJECTABLE; INJECTION

ROBINUL

AP + BAXTER HLTHCARE CORP	0.2MG/ML	N17558 001		AUG	CAHN
---------------------------	----------	------------	--	-----	------

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION

FACTREL

+ BAXTER HLTHCARE CORP	EQ 0.1MG BASE/VIAL	N18123 001	SEP 30, 1982	MAY	CAHN
@	EQ 0.2MG BASE/VIAL	N18123 002	SEP 30, 1982	MAY	CAHN
@	EQ 0.5MG BASE/VIAL	N18123 003	SEP 30, 1982	MAY	CAHN

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

A.P.L.

@ FERRING	5,000 UNITS/VIAL	N17055 001		JUL	CAHN
@	10,000 UNITS/VIAL	N17055 002		JUL	CAHN
@	20,000 UNITS/VIAL	N17055 003		JUL	CAHN
@ WYETH AYERST	5,000 UNITS/VIAL	N17055 001		JUN	DISC
@	10,000 UNITS/VIAL	N17055 002		JUN	DISC

CHORIONIC GONADOTROPIN

>D> AP + STERIS	5,000 UNITS/VIAL	N17016 006		SEP	DISC
>A> @	5,000 UNITS/VIAL	N17016 006		SEP	DISC

GRANISETRON HYDROCHLORIDE

SOLUTION; ORAL

KYTRIL

+ ROCHE	EQ 2MG BASE/10ML	N21238 001	JUN 27, 2001	JUL	CMFD
---------	------------------	------------	--------------	-----	------

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL

RAXAR

@ OTSUKA	EQ 200MG BASE	N20695 001	NOV 06, 1997	MAY	DISC
@	EQ 400MG BASE	N20695 002	MAY 14, 1998	MAY	DISC
@	EQ 600MG BASE	N20695 003	MAY 14, 1998	MAY	DISC

GUANABENZ ACETATE

TABLET; ORAL

GUANABENZ ACETATE

AB + WATSON LABS	EQ 8MG BASE	N74025 002	FEB 28, 1994	JUN	CRLD
WYTENSIN					
@ WYETH AYERST	EQ 4MG BASE	N18587 001	SEP 07, 1982	JUN	DISC
@	EQ 8MG BASE	N18587 002	SEP 07, 1982	JUN	DISC

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

@ KING PHARMS	EQ 50MG BASE/ML	N75176 001	FEB 09, 2000	MAY	DISC
@	EQ 100MG BASE/ML	N75176 002	FEB 09, 2000	MAY	DISC

HEPARIN SODIUM

INJECTABLE; INJECTION

HEP-LOCK

AP + BAXTER HLTHCARE	10 UNITS/ML	N17037 007		JUN	CAHN
AP +	100 UNITS/ML	N17037 006		JUN	CAHN
HEP-LOCK U/P					
AP BAXTER HLTHCARE	10 UNITS/ML	N17037 010	JUN 10, 1983	JUN	CAHN

AP		100 UNITS/ML	N17037 011	JUN 10, 1983	JUN	CAHN
	HEPARIN LOCK FLUSH					
	@ BAXTER HLTHCARE CORP	10 UNITS/ML	N17007 008		MAY	CAHN
	@	100 UNITS/ML	N17007 009		MAY	CAHN
	HEPARIN SODIUM					
AP	BAXTER HLTHCARE	1,000 UNITS/ML	N17037 001		JUN	CAHN
AP		5,000 UNITS/ML	N17037 002		JUN	CAHN
AP		5,000 UNITS/0.5ML	N17037 013	APR 07, 1986	JUN	CAHN
AP		10,000 UNITS/ML	N17037 003		JUN	CAHN
	@ BAXTER HLTHCARE CORP	1,000 UNITS/ML	N17007 001		MAY	CAHN
	@	2,500 UNITS/ML	N17007 007		MAY	CAHN
	@	5,000 UNITS/ML	N17007 002		MAY	CAHN
	@	5,000 UNITS/0.5ML	N17007 010		MAY	CAHN
	@	7,500 UNITS/ML	N17007 003		MAY	CAHN
	@	10,000 UNITS/ML	N17007 004		MAY	CAHN
	@	15,000 UNITS/ML	N17007 005		MAY	CAHN
	@	20,000 UNITS/ML	N17007 006		MAY	CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	AXIOM PHARM	1.5MG/5ML;5MG/5ML	N40285 001	JUL 19, 1999	MAY	CAHN
----	-------------	-------------------	------------	--------------	-----	------

HYALURONIDASE

INJECTABLE; INJECTION

WYDASE

	@ BAXTER HLTHCARE	150 UNITS/ML	N06343 002		AUG	CAHN
	@	150 UNITS/VIAL	N06343 006		AUG	CAHN
	@	1,500 UNITS/VIAL	N06343 005		AUG	CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HCL

	@ CLONMEL HLTHCARE	25MG	N86243 001		AUG	DISC
	@	50MG	N86242 002		AUG	DISC

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB	CLONMEL HLTHCARE	25MG	N87059 001		JUL	CAHN
AB		50MG	N87068 001		JUL	CAHN
	@	100MG	N87060 001		JUL	CAHN

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

	@ CLONMEL HLTHCARE	15MG;250MG	N72507 001	JUN 02, 1989	JUL	DISC
	@	25MG;250MG	N72508 001	JUN 02, 1989	JUL	DISC
	@	30MG;500MG	N72509 001	JUN 02, 1989	JUL	DISC
	@	50MG;500MG	N72510 001	JUN 02, 1989	JUL	DISC

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR HCT

SANKYO

12.5MG;20MG

N21532 002 JUN 05, 2003 JUN NEWA

12.5MG;40MG

N21532 003 JUN 05, 2003 JUN NEWA

+

25MG;40MG

N21532 005 JUN 05, 2003 JUN NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

INDERIDE-40/25

AB WYETH PHARMS INC

25MG;40MG

N18031 001

MAR CAHN

INDERIDE-80/25

AB + WYETH PHARMS INC

25MG;80MG

N18031 002

MAR CAHN

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCT

NOVARTIS

25MG;160MG

N20818 003 JAN 17, 2002 JUL NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

AB TEVA

7.5MG;200MG

N76023 001 APR 11, 2003 APR NEWA

VICOPROFEN

AB + ABBOTT

7.5MG;200MG

N20716 001 SEP 23, 1997 APR CFTG

HYDROCORTISONE

LOTION; TOPICAL

HYDROCORTISONE

AT VINTAGE PHARMS

2.5%

N40417 001 JUL 30, 2003 JUL NEWA

HYDROCORTISONE CYPIONATE

SUSPENSION; ORAL

CORTEF

@ PHARMACIA AND UPJOHN

EQ 10MG BASE/5ML

N09900 001

AUG DISC

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

HYDROCORTONE

@ MERCK

EQ 50MG BASE/ML

N12052 001

APR DISC

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

HYDROCORTISONE SODIUM SUCCINATE

@ BAXTER HLTHCARE

EQ 100MG BASE/VIAL

N86619 001

AUG CAHN

@

EQ 250MG BASE/VIAL

N87567 001

AUG CAHN

@

EQ 500MG BASE/VIAL

N87568 001

AUG CAHN

@

EQ 1GM BASE/VIAL

N87569 001

AUG CAHN

HYDROCORTISONE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-CORT-DOME

@ BAYER PHARMS

0.5%;EQ 3.5MG BASE/GM

N50237 006 JUN 05, 1984 JUN DISC

@

1%;EQ 3.5MG BASE/GM

N50237 005 JUN 05, 1984 JUN DISC

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT ALCON

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

N62423 001 AUG 25, 1983 FEB CMFD

SUSPENSION/DROPS; OPHTHALMIC

AT ALCON UNIVERSAL

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

N62874 001 MAY 11, 1988 FEB CMFD

SUSPENSION/DROPS; OTIC

AT ALCON UNIVERSAL

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

N62488 001 NOV 06, 1985 FEB CMFD

HYDROFLUMETHIAZIDE

TABLET; ORAL

DIUCARDIN

@ WYETH AYERST

50MG

N83383 001

JUN DISC

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

SALUTENSIN

@ SHIRE LABS

50MG;0.125MG

N12359 003

JUL DISC

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROMORPHONE HCL

AP FAULDING

10MG/ML

N76444 001 APR 25, 2003 APR NEWA

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE

@ ELKINS SINN

50MG/ML

N85551 002

JUN DISC

HYDROXYZINE HCL

@ ELKINS SINN

25MG/ML

N85551 001

JUN DISC

TABLET; ORAL

ATARAX

@ PFIZER

10MG

N10392 001

FEB DISC

@

25MG

N10392 004

FEB DISC

@

50MG

N10392 006

FEB DISC

@

100MG

N10392 005

FEB DISC

HYDROXYZINE HCL

AB + SIDMAK LABS NJ

10MG

N88617 001 JAN 10, 1986 FEB CRLD

AB +

25MG

N88618 001 JAN 10, 1986 FEB CRLD

AB +

50MG

N88619 001 JAN 10, 1986 FEB CRLD

@

100MG

N81054 001 SEP 25, 1995 FEB DISC

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

@ ROCHE

EQ 2.5MG BASE

N21455 001 MAY 16, 2003 JUL DISC

	+	EQ 2.5MG BASE		N21455 001	MAY 16, 2003	MAY	NEWA
		<u>IFOSFAMIDE</u>					
		INJECTABLE; INJECTION					
		IFOSFAMIDE					
>A>	+	AM PHARM PARTNERS	1GM/VIAL	N76078 001	MAY 28, 2002	SEP	CTNA
>A>	+		3GM/VIAL	N76078 002	MAY 28, 2002	SEP	CTNA
>D>		IFOSFAMIDE					
>D>	+	AM PHARM PARTNERS	1GM/VIAL	N76078 001	MAY 28, 2002	SEP	CTNA
>D>	+		3GM/VIAL	N76078 002	MAY 28, 2002	SEP	CTNA
		<u>IMATINIB MESYLATE</u>					
		CAPSULE; ORAL					
		GLEEVEC					
	@	NOVARTIS	50MG	N21335 001	MAY 10, 2001	JUN	DISC
		TABLET; ORAL					
		NOVARTIS	100MG	N21588 001	APR 18, 2003	APR	NEWA
	+		400MG	N21588 002	APR 18, 2003	APR	NEWA
>D>		<u>INULIN</u>					
>D>		INJECTABLE; INJECTION					
>D>		INULIN AND SODIUM CHLORIDE					
>D>	+	QUESTCOR PHARMS	100MG/ML	N02282 001		SEP	DISC
>A>	@		100MG/ML	N02282 001		SEP	DISC
		<u>IOPAMIDOL</u>					
		INJECTABLE; INJECTION					
		IOPAMIDOL					
	@	BAXTER HLTHCARE	41%	N74629 001	NOV 06, 1996	AUG	CAHN
	@		51%	N74629 004	MAR 31, 1998	AUG	CAHN
	@		61%	N74629 002	NOV 06, 1996	AUG	CAHN
	@		76%	N74629 003	NOV 06, 1996	AUG	CAHN
	@	ELKINS SINN PHARM	41%	N74629 001	NOV 06, 1996	JUN	DISC
	@		51%	N74629 004	MAR 31, 1998	JUN	DISC
	@		61%	N74629 002	NOV 06, 1996	JUN	DISC
	@		76%	N74629 003	NOV 06, 1996	JUN	DISC
		<u>IOVERSOL</u>					
		INJECTABLE; INJECTION					
		OPTIRAY 240					
	@	MALLINCKRODT	51%	N20923 001	MAY 28, 1998	JUN	DISC
		OPTIRAY 300					
	+	MALLINCKRODT	64%	N20923 004	MAY 13, 1999	JUN	NEWA
		OPTIRAY 320					
	@	MALLINCKRODT	68%	N20923 002	MAY 29, 1998	JUN	DISC
		<u>IPRATROPIUM BROMIDE</u>					
		SPRAY, METERED; NASAL					
		ATROVENT					
AB	+	BOEHRINGER INGELHEIM	0.021MG/SPRAY	N20393 001	OCT 20, 1995	MAR	CFTG
AB	+		0.042MG/SPRAY	N20394 001	OCT 20, 1995	MAR	CFTG
		IPRATROPIUM BROMIDE					
AB		BAUSCH AND LOMB	0.021MG/SPRAY	N76025 001	MAR 31, 2003	MAR	NEWA
AB			0.042MG/SPRAY	N76103 001	MAR 31, 2003	MAR	NEWA

AB	DEY	0.021MG/SPRAY	N75552 001	MAR 31, 2003	MAR	NEWA
AB		0.042MG/SPRAY	N75553 001	MAR 31, 2003	MAR	NEWA
AB	NOVEX	0.021MG/SPRAY	N76156 001	APR 18, 2003	APR	NEWA
AB		0.042MG/SPRAY	N76155 001	APR 18, 2003	APR	NEWA
<u>ISONIAZID</u>						
TABLET; ORAL						
ISONIAZID						
	@ AXIOM PHARM	100MG	N80136 001		MAY	CAHN
AA		300MG	N83633 001		MAY	CAHN
<u>ISOPROTERENOL HYDROCHLORIDE</u>						
INJECTABLE; INJECTION						
ISOPROTERENOL HCL						
	@ BAXTER HLTHCARE	0.2MG/ML	N83486 001		JUN	DISC
<u>ISOSORBIDE DINITRATE</u>						
CAPSULE, EXTENDED RELEASE; ORAL						
DILATRATE-SR						
BC	+ SCHWARZ PHARMA	40MG	N19790 001	SEP 02, 1988	JUN	CRLD
	+	40MG	N19790 001	SEP 02, 1988	JUL	CTEC
ISORDIL						
	@ WYETH AYERST	40MG	N12882 002	JUL 29, 1988	JUN	DISC
TABLET; ORAL						
AB	BIOVAIL	5MG	N12093 007	JUL 29, 1988	JUN	CAHN
AB		10MG	N12093 002	JUL 29, 1988	JUN	CAHN
AB		20MG	N12093 006	JUL 29, 1988	JUN	CAHN
AB	+	30MG	N12093 005	JUL 29, 1988	JUN	CAHN
AB		40MG	N12093 001	JUL 29, 1988	JUN	CAHN
AB	WYETH PHARMS INC	5MG	N12093 007	JUL 29, 1988	MAR	CAHN
AB		10MG	N12093 002	JUL 29, 1988	MAR	CAHN
AB		20MG	N12093 006	JUL 29, 1988	MAR	CAHN
AB	+	30MG	N12093 005	JUL 29, 1988	MAR	CAHN
AB		40MG	N12093 001	JUL 29, 1988	MAR	CAHN
TABLET; SUBLINGUAL						
AB	BIOVAIL	2.5MG	N12940 004	JUL 29, 1988	JUN	CAHN
AB		5MG	N12940 003	JUL 29, 1988	JUN	CAHN
	+	10MG	N12940 005	JUL 29, 1988	JUN	CAHN
AB	WYETH PHARMS INC	2.5MG	N12940 004	JUL 29, 1988	MAR	CAHN
AB		5MG	N12940 003	JUL 29, 1988	MAR	CAHN
	+	10MG	N12940 005	JUL 29, 1988	MAR	CAHN
<u>ISOTRETINOIN</u>						
CAPSULE; ORAL						
CLARAVIS						
AB	BARR	10MG	N76356 001	APR 11, 2003	APR	NEWA
AB		20MG	N76135 002	APR 11, 2003	APR	NEWA
AB		40MG	N76135 001	APR 11, 2003	APR	NEWA
SOTRET						
	RANBAXY	30MG	N76503 001	JUN 20, 2003	JUN	NEWA

ISRADIPINE

CAPSULE; ORAL

DYNACIRC

RELIANT PHARMS 2.5MG

N19546 001 DEC 20, 1990 MAY CAHN

+ 5MG

N19546 002 DEC 20, 1990 MAY CAHN

TABLET, EXTENDED RELEASE; ORAL

DYNACIRC CR

+ RELIANT PHARMS 5MG

N20336 001 JUN 01, 1994 MAY CAHN

+ 10MG

N20336 002 JUN 01, 1994 MAY CAHN

KANAMYCIN SULFATE

INJECTABLE; INJECTION

KANAMYCIN

@ BAXTER HLTHCARE EQ 75MG BASE/2ML

N62324 001 AUG CAHN

@ EQ 500MG BASE/2ML

N62324 002 AUG CAHN

@ EQ 1GM BASE/3ML

N62324 003 AUG CAHN

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

AB CLONMEL HLTHCARE 75MG

N74014 003 JAN 29, 1993 JUN CAHN

AB + TEVA 75MG

N73517 001 DEC 22, 1992 JUN CRLD

ORUDIS

@ WYETH AYERST 25MG

N18754 001 JUL 31, 1987 JUN DISC

@ 50MG

N18754 002 JAN 09, 1986 JUN DISC

@ 75MG

N18754 003 JAN 09, 1986 JUN DISC

CAPSULE, EXTENDED RELEASE; ORAL

ORUVAIL

AB WYETH PHARMS INC 100MG

N19816 003 FEB 08, 1995 MAR CAHN

AB 150MG

N19816 002 FEB 08, 1995 MAR CAHN

AB + 200MG

N19816 001 SEP 24, 1993 MAR CAHN

KETOROLAC TROMETHAMINE

SOLUTION/DROPS; OPHTHALMIC

ACULAR LS

+ ALLERGAN 0.4%

N21528 001 MAY 30, 2003 MAY NEWA

LACTULOSE

SOLUTION; ORAL

CHRONULAC

@ AVENTIS PHARMS 10GM/15ML

N17884 001 AUG DISC

CONSTULOSE

AA + ALPHARMA 10GM/15ML

N70288 001 AUG 15, 1988 AUG CRLD

LACTULOSE

AA VISTAPHARM 10GM/15ML

N74138 001 SEP 30, 1992 MAR CAHN

SOLUTION; ORAL, RECTAL

AA NOVEX 10GM/15ML

N76645 001 JUL 28, 2003 JUL NEWA

LAMIVUDINE

TABLET; ORAL

EPIVIR

>A> GLAXOSMITHKLINE 300MG

N20564 003 JUN 24, 2002 SEP NEWA

LEFLUNOMIDE

TABLET; ORAL

ARAVA

+ AVENTIS PHARMS	20MG	N20905 002	SEP 10, 1998	MAR	CRLD
@	100MG	N20905 003	SEP 10, 1998	MAR	DISC

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

@ ELKINS SINN	EQ 50MG BASE/VIAL	N70480 001	JAN 02, 1987	JUN	DISC
@	EQ 100MG BASE/VIAL	N81224 001	JUN 03, 1994	JUN	DISC

LEUPROLIDE ACETATE

INJECTABLE; SUBCUTANEOUS

ELIGARD

+ ATRIX	30MG/VIAL	N21488 001	FEB 13, 2003	FEB	NEWA
---------	-----------	------------	--------------	-----	------

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

XOPENEX

+ SEPRACOR	EQ 0.0103% BASE	N20837 003	JAN 30, 2002	JUL	CPOT
+ SEPRACOR	EQ 0.25% BASE	N20837 004	JUL 18, 2003	JUL	NEWA

LEVETIRACETAM

SOLUTION; ORAL

KEPPRA

+ UCB	100MG/ML	N21505 001	JUL 15, 2003	JUL	NEWA
-------	----------	------------	--------------	-----	------

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETAXON

@ ALCON	EQ 0.5% BASE	N21114 001	FEB 23, 2000	JUL	CAHN
+ MEDPOINTE	EQ 0.5% BASE	N21114 001	FEB 23, 2000	MAR	CAHN

LEVONORGESTREL

IMPLANT; IMPLANTATION

LEVONORGESTREL

BX + WYETH PHARMS INC	75MG/IMPLANT	N20627 001	AUG 15, 1996	MAR	CAHN
@	75MG/IMPLANT	N20627 001	AUG 15, 1996	JUN	DISC
NORPLANT II					
BX + POPULATION COUNCIL	75MG/IMPLANT	N20544 001	NOV 01, 1996	JUN	CRLD
NORPLANT SYSTEM IN PLASTIC CONTAINER					
+ WYETH PHARMS INC	36MG/IMPLANT	N20088 001	DEC 10, 1990	MAR	CAHN
@	36MG/IMPLANT	N20088 001	DEC 10, 1990	JUN	DISC

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVO-DROMORAN

@ ICN	2MG	N08720 001	DEC 19, 1991	FEB	DISC
LEVORPHANOL TARTRATE					
+ ROXANE	2MG	N74278 001	MAR 31, 2000	FEB	CRLD

LEVOTHYROXINE SODIUM

TABLET; ORAL

LEVO-T

MAR	CRLD	BX	ALARA PHARM	0.025MG	N21342 001	MAR 01, 2002	APR	CAHN
MAR	DISC	BX		0.05MG	N21342 002	MAR 01, 2002	APR	CAHN
		BX		0.075MG	N21342 003	MAR 01, 2002	APR	CAHN
		BX		0.088MG	N21342 004	MAR 01, 2002	APR	CAHN
		BX		0.1MG	N21342 005	MAR 01, 2002	APR	CAHN
		BX		0.112MG	N21342 006	MAR 01, 2002	APR	CAHN
JUN	DISC	BX		0.125MG	N21342 007	MAR 01, 2002	APR	CAHN
JUN	DISC	BX		0.15MG	N21342 008	MAR 01, 2002	APR	CAHN
		BX		0.175MG	N21342 009	MAR 01, 2002	APR	CAHN
		BX		0.2MG	N21342 010	MAR 01, 2002	APR	CAHN
		BX +		0.3MG	N21342 011	MAR 01, 2002	APR	CAHN

LEVOLET

FEB	NEWA	BX	VINTAGE PHARMS	0.025MG	N21137 001	JUN 06, 2003	JUN	NEWA
		BX		0.05MG	N21137 002	JUN 06, 2003	JUN	NEWA
		BX		0.075MG	N21137 003	JUN 06, 2003	JUN	NEWA
		BX		0.088MG	N21137 004	JUN 06, 2003	JUN	NEWA
		BX		0.1MG	N21137 005	JUN 06, 2003	JUN	NEWA
JUL	CPOT	BX		0.112MG	N21137 006	JUN 06, 2003	JUN	NEWA
JUL	NEWA	BX		0.125MG	N21137 007	JUN 06, 2003	JUN	NEWA
		BX		0.137MG	N21137 008	JUN 06, 2003	JUN	NEWA
		BX		0.15MG	N21137 009	JUN 06, 2003	JUN	NEWA
		BX		0.175MG	N21137 010	JUN 06, 2003	JUN	NEWA
JUL	NEWA	BX		0.2MG	N21137 011	JUN 06, 2003	JUN	NEWA
		BX		0.3MG	N21137 012	JUN 06, 2003	JUN	NEWA

LIDOCAINE

SOLUTION; TOPICAL

XYLOCAINE

JUL	CAHN	@	ASTRAZENECA	5%	N14127 001		AUG	DISC
-----	------	---	-------------	----	------------	--	-----	------

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL

		@	ELKINS SINN	1%	N80407 001		JUN	DISC
		@		2%	N80407 002		JUN	DISC
MAR	CAHN	@	WYETH AYERST	1%	N83083 001		JUN	DISC
JUN	DISC	@		2%	N83083 002		JUN	DISC

LIDOCAINE HCL PRESERVATIVE FREE

JUN	CRLD	@	ELKINS SINN	1%	N84625 001		JUN	DISC
MAR	CAHN	@		2%	N84625 002		JUN	DISC

JELLY; TOPICAL

LIDOCAINE HCL

		AT	AKORN	2%	N40433 001	FEB 12, 2003	FEB	NEWA
--	--	----	-------	----	------------	--------------	-----	------

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

EMLA

FEB	DISC	AB +	ASTRAZENECA	2.5%;2.5%	N19941 001	DEC 30, 1992	AUG	CFTG
-----	------	------	-------------	-----------	------------	--------------	-----	------

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

LIDOCAINE AND PRILOCAINE

AB	ALTANA	2.5%;2.5%	N76453 001	AUG 18, 2003	AUG	NEWA
AB	ATRIX	2.5%;2.5%	N76320 001	AUG 27, 2003	AUG	NEWA
>A>	HI TECH PHARMA	2.5%;2.5%	N76290 001	SEP 25, 2003	SEP	NEWA

LISINAPRIL

TABLET; ORAL

LISINAPRIL

AB	RANBAXY	30MG	N75944 006	FEB 11, 2003	FEB	NEWA
AB	WEST WARD	30MG	N76063 006	JUN 27, 2003	JUN	NEWA
	ZESTRIL					
AB	ASTRAZENECA	30MG	N19777 006	JAN 20, 1999	APR	CRLD

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

AB	ROXANE	150MG	N17812 002	JAN 28, 1987	FEB	CTEC
AB	WEST WARD	150MG	N76243 002	FEB 24, 2003	FEB	NEWA
	TABLET, EXTENDED RELEASE; ORAL					
	ESKALITH CR					
AB +	GLAXOSMITHKLINE	450MG	N18152 001	MAR 29, 1982	JUN	CFTG
	LITHIUM CARBONATE					
AB	ABLE	300MG	N76382 001	APR 21, 2003	APR	NEWA
AB	BARR	450MG	N76366 001	AUG 21, 2003	AUG	NEWA
AB	WEST WARD	450MG	N76490 001	JUN 17, 2003	JUN	NEWA

LORATADINE

SYRUP; ORAL

CLARITIN

@	SCHERING	1MG/ML	N20641 001	OCT 10, 1996	MAY	DISC
	TABLET; ORAL					
@	SCHERING	10MG	N19658 001	APR 12, 1993	MAY	DISC
	TABLET, ORALLY DISINTEGRATING; ORAL					
	CLARITIN REDITABS					
@	SCHERING	10MG	N20704 001	DEC 23, 1996	MAY	DISC

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM INTENSOL

+	ROXANE	2MG/ML	N72755 001	JUN 28, 1991	MAY	CRLD
	INJECTABLE; INJECTION					
	ATIVAN					
AP +	BAXTER HLTHCARE CORP	2MG/ML	N18140 001		FEB	CAHN
AP +		4MG/ML	N18140 002		FEB	CAHN
	TABLET; ORAL					
AB	BIOVAIL	0.5MG	N17794 001		JUN	CAHN
AB		1MG	N17794 002		JUN	CAHN
AB +		2MG	N17794 003		JUN	CAHN

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

INVERSINE

+ TARGACEPT

2.5MG

N10251 001

APR CAHN

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

AB + MYLAN

EQ 100MG BASE

N71081 001

SEP 03, 1986

MAY CRLD

MECLOMEN

@ PARKE DAVIS

EQ 50MG BASE

N18006 001

MAY DISC

@

EQ 100MG BASE

N18006 002

MAY DISC

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HCL

AB GENEVA PHARMS

250MG

N76175 001

FEB 20, 2002

APR CAHN

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

AB COPLEY PHARM

40MG/ML

N75681 001

MAY 05, 2003

MAY NEWA

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION

REPRONEX

BX + FERRING

75 IU/VIAL;75 IU/VIAL

N21047 001

AUG 27, 1999

MAY CRLD

@

150 IU/VIAL;150 IU/VIAL

N21047 002

AUG 27, 1999

MAY DISC

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HCL

@ BAXTER HLTHCARE

25MG/ML

N88279 001

JUN 15, 1984

AUG CAHN

@

50MG/ML

N88280 001

JUN 15, 1984

AUG CAHN

@

75MG/ML

N88281 001

JUN 15, 1984

AUG CAHN

@

100MG/ML

N88282 001

JUN 15, 1984

AUG CAHN

AP BAXTER HLTHCARE CORP

25MG/ML

N80455 007

MAY CAHN

AP 50MG/ML

N80455 008

MAY CAHN

AP 75MG/ML

N80455 009

MAY CAHN

AP 100MG/ML

N80455 010

MAY CAHN

TABLET; ORAL

AXIOM PHARM

AA 50MG

N80448 001

MAY CAHN

AA 100MG

N80448 002

MAY CAHN

@ WYETH AYERST

50MG

N80454 001

JUN DISC

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERGAN

@ BAXTER HLTHCARE CORP

25MG/ML;25MG/ML

N11730 001

MAY CAHN

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION

WYAMINE SULFATE

@ BAXTER HLTHCARE CORP EQ 15MG BASE/ML N08248 002 FEB CAHN

@ EQ 30MG BASE/ML N08248 001 FEB CAHN

MEPROBAMATE

TABLET; ORAL

EQUANIL

@ WYETH AYERST 200MG N10028 005 JUN DISC

@ 400MG N10028 004 JUN DISC

MEPROBAMATE

+ ROXANE 600MG N84332 001 JUN CRLD

MILTOWN

AA + MEDPOINTE 600MG N83919 001 APR CAHN

@ MEDPOINTE PHARM HLC 600MG N83919 001 JUN DISC

MERCAPTOPYRINE

TABLET; ORAL

PURINETHOL

+ TEVA 50MG N09053 002 AUG CAHN

MESORIDAZINE BESYLATE

TABLET; ORAL

SERENTIL

@ NOVARTIS EQ 10MG BASE N16774 001 JUN DISC

@ EQ 50MG BASE N16774 003 JUN DISC

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21

NORINYL 1+50 21-DAY

AB + WATSON LABS 0.05MG;1MG N13625 002 AUG CRLD

ORTHO-NOVUM 1/50 21

@ ORTHO MCNEIL PHARM 0.05MG;1MG N12728 004 AUG DISC

METAXALONE

TABLET; ORAL

SKELAXIN

JONES PHARMA INC 400MG N13217 001 JUN CAHN

+ 800MG N13217 003 AUG 30, 2002 JUN CAHN

METFORMIN HYDROCHLORIDE

>A> SOLUTION; ORAL

>A> RIOMET

>A> + RANBAXY 500MG/5ML N21591 001 SEP 11, 2003 SEP NEWA

TABLET; ORAL

METFORMIN HCL

AB PUREPAC PHARM 1GM N76033 003 JAN 24, 2002 FEB CMS1

TABLET, EXTENDED RELEASE; ORAL

GLUCOPHAGE XR

BRISTOL MYERS SQUIBB 500MG N21202 001 OCT 13, 2000 AUG CRLD

+ 750MG N21202 004 APR 11, 2003 APR NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

SB PHARMCO

500MG;EQ 1MG BASE

N21410 001 OCT 10, 2002 APR CAHN

500MG;EQ 2MG BASE

N21410 002 OCT 10, 2002 APR CAHN

+

500MG;EQ 4MG BASE

N21410 003 OCT 10, 2002 APR CAHN

500MG;EQ 4MG BASE

N21410 003 OCT 10, 2002 AUG CRLD

1GM;EQ 2MG BASE

N21410 004 AUG 25, 2003 AUG NEWA

+

1GM;EQ 4MG BASE

N21410 005 AUG 25, 2003 AUG NEWA

METHADONE HYDROCHLORIDE

INJECTABLE; INJECTION

DOLOPHINE HCL

+ AAIPHARMA

10MG/ML

N21624 001 APR CAHN

+ ROXANE

10MG/ML

N21624 001 FEB CMS1

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

AB + MIKART

50MG

N40062 002 JAN 27, 1994 JUN CRLD

NEPTAZANE

@ LEDERLE

25MG

N11721 002 NOV 25, 1991 JUN DISC

@

50MG

N11721 001 JUN DISC

METHENAMINE HIPPURATE

TABLET; ORAL

METHENAMINE HIPPURATE

AB COREPHARMA

1GM

N76411 001 JUN 20, 2003 JUN NEWA

METHIMAZOLE

TABLET; ORAL

TAPAZOLE

AB LILLY

10MG

N07517 004 JUN CRLD

METHOCARBAMOL

INJECTABLE; INJECTION

ROBAXIN

AP + BAXTER HLTHCARE CORP

100MG/ML

N11790 001 AUG CAHN

TABLET; ORAL

METHOCARBAMOL

AA ABLE

500MG

N40413 001 MAR 17, 2003 MAR NEWA

AA

750MG

N40413 002 MAR 17, 2003 MAR NEWA

@ CLONMEL HLTHCARE

500MG

N85961 001 JUN DISC

@

750MG

N85963 001 JUN DISC

AA LANNETT

500MG

N84756 002 MAR 31, 2003 MAR NEWA

AA VINTAGE PHARMS

500MG

N40489 001 JAN 29, 2003 JAN NEWA

AA

750MG

N40489 002 JAN 29, 2003 JAN NEWA

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE LPF

AP + WYETH PHARMS INC

EQ 25MG BASE/ML

N11719 007 MAR 31, 1982 MAR CAHN

METHOTREXATE SODIUM

	INJECTABLE; INJECTION				
	METHOTREXATE SODIUM				
	@ WYETH PHARMS INC	EQ 2.5MG BASE/ML	N11719 004		MAR CAHN
	+	EQ 20MG BASE/VIAL	N11719 001		MAR CAHN
AP	+	EQ 25MG BASE/ML	N11719 005		MAR CAHN
	@	EQ 50MG BASE/VIAL	N11719 003		MAR CAHN
	@	EQ 100MG BASE/VIAL	N11719 006		MAR CAHN
	METHOTREXATE SODIUM PRESERVATIVE FREE				
AP	+	WYETH PHARMS INC	EQ 1GM BASE/VIAL	N11719 009	APR 07, 1988 MAR CAHN

METHSCOPOLAMINE BROMIDE

	TABLET; ORAL				
	PAMINE FORTE				
	+	BRADLEY PHARMS	5MG	N08848 002	MAR 25, 2003 MAR NEWA

METHYCLOTHIAZIDE

	TABLET; ORAL				
	AQUATENSEN				
	@ MEDPOINTE PHARM HLC	5MG	N17364 001		JUN DISC

METHYLDOPA

	TABLET; ORAL				
	ALDOMET				
	@ MERCK	125MG	N13400 003		MAY DISC
	@	250MG	N13400 001		MAY DISC
	METHYLDOPA				
	@ CLONMEL HLTHCARE	125MG	N70070 003	OCT 15, 1985	JUN DISC

METHYLDOPATE HYDROCHLORIDE

	INJECTABLE; INJECTION				
	METHYLDOPATE HCL				
	@ BAXTER HLTHCARE	50MG/ML	N70291 001	JUL 01, 1986	AUG CAHN
	@ ELKINS SINN	50MG/ML	N70291 001	JUL 01, 1986	JUN DISC

METHYLPHENIDATE HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE; ORAL				
	METADATE CD				
	CELLTECH PHARMS	10MG	N21259 003	MAY 27, 2003	JUL NEWA
BX		20MG	N21259 001	APR 03, 2001	JUL CRLD
BX	+	30MG	N21259 002	JUN 19, 2003	JUL CTEC
	+	30MG	N21259 002	JUN 19, 2003	JUN NEWA
	RITALIN LA				
BX	NOVARTIS	30MG	N21284 002	JUN 05, 2002	JUL CTEC
	TABLET, CHEWABLE; ORAL				
	METHYLIN				
	MALLINCKRODT	2.5MG	N21475 001	APR 15, 2003	APR NEWA
		5MG	N21475 002	APR 15, 2003	APR NEWA
	+	10MG	N21475 003	APR 15, 2003	APR NEWA

<u>METHYLPHENIDATE HYDROCHLORIDE</u>									
TABLET, EXTENDED RELEASE; ORAL									
CONCERTA									
	+	MCNEIL CONS SPECT	18MG		N21121 001	AUG 01, 2000	MAY	CAHN	
	+		27MG		N21121 004	APR 01, 2002	MAY	CAHN	
	+		36MG		N21121 002	AUG 01, 2000	MAY	CAHN	
	+		54MG		N21121 003	DEC 08, 2000	MAY	CAHN	
<u>METHYLPREDNISOLONE</u>									
TABLET; ORAL									
MEDROL									
		@ PHARMACIA AND UPJOHN	2MG		N11153 002		JUL	DISC	
<u>METHYLPREDNISOLONE ACETATE</u>									
OINTMENT; TOPICAL									
MEDROL ACETATE									
		@ PHARMACIA AND UPJOHN	0.25%		N12421 001		JUN	DISC	
<u>METHYSERGIDE MALEATE</u>									
TABLET; ORAL									
SANSERT									
		@ NOVARTIS	2MG		N12516 001		JUN	DISC	
<u>METOCLOPRAMIDE HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
REGLAN									
AP	+	BAXTER HLTHCARE CORP	EQ 5MG BASE/ML		N17862 001		AUG	CAHN	
		@	EQ 10MG BASE/ML		N17862 004	MAY 28, 1987	AUG	CAHN	
SOLUTION; ORAL									
METOCLOPRAMIDE									
AA		VISTAPHARM	EQ 5MG BASE/5ML		N75051 001	JAN 26, 2001	APR	CAHN	
TABLET; ORAL									
METOCLOPRAMIDE HCL									
		@ CLONMEL HLTHCARE	EQ 10MG BASE		N72639 001	MAY 09, 1991	JUN	DISC	
<u>METOLAZONE</u>									
TABLET; ORAL									
ZAROXOLYN									
		CELLTECH PHARMS	2.5MG		N17386 001		JUL	CRLD	
	+		5MG		N17386 002		JUL	CRLD	
<u>METOPROLOL TARTRATE</u>									
INJECTABLE; INJECTION									
METOPROLOL TARTRATE									
AP		BEDFORD LABS	1MG/ML		N76495 001	JUL 07, 2003	JUL	NEWA	
<u>METRONIDAZOLE</u>									
TABLET; ORAL									
METRONIDAZOLE									
AB		ABLE	250MG		N76519 001	JUN 27, 2003	JUN	NEWA	
AB			500MG		N76519 002	JUN 27, 2003	JUN	NEWA	

METRONIDAZOLE

TABLET, EXTENDED RELEASE; ORAL

FLAGYL ER

AB +	GD SEARLE LLC	750MG	N20868 001	NOV 26, 1997	JUN	CFTG
	METRONIDAZOLE					
AB	ABLE	750MG	N76462 001	JUN 25, 2003	JUN	NEWA

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION

MEZLIN

@ BAYER PHARMS

EQ 1GM BASE/VIAL

N50549 001

JUN DISC

@

EQ 2GM BASE/VIAL

N50549 002

JUN DISC

@

EQ 3GM BASE/VIAL

N50549 003

JUN DISC

@

EQ 4GM BASE/VIAL

N50549 004

JUN DISC

@

EQ 20GM BASE/VIAL

N50549 005 MAR 02, 1988

JUN DISC

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HCL

AP BAXTER HLTHCARE

EQ 1MG BASE/ML

N75243 001

JUN 20, 2000 JUN CAHN

AP

EQ 5MG BASE/ML

N75243 002

JUN 20, 2000 JUN CAHN

SYRUP; ORAL

>A> AA HI TECH PHARMA

EQ 2MG BASE/ML

N75958 001

SEP 04, 2003 SEP NEWA

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HCL

>A>

>A> AB EON 2.5MG

N76514 001

SEP 11, 2003 SEP NEWA

>A> AB 5MG

N76514 002

SEP 11, 2003 SEP NEWA

>A> AB MYLAN 2.5MG

N76577 001

SEP 10, 2003 SEP NEWA

>A> AB 5MG

N76577 002

SEP 10, 2003 SEP NEWA

>A> AB 10MG

N76577 003

SEP 10, 2003 SEP NEWA

PROAMATINE

>D> SHIRE PHARM 2.5MG

N19815 001

SEP 06, 1996 SEP CFTG

>A> AB 2.5MG

N19815 001

SEP 06, 1996 SEP CFTG

>D> + 5MG

N19815 002

SEP 06, 1996 SEP CFTG

>A> AB + 5MG

N19815 002

SEP 06, 1996 SEP CFTG

>D> 10MG

N19815 003

MAR 20, 2002 SEP CFTG

>A> AB 10MG

N19815 003

MAR 20, 2002 SEP CFTG

MIGLUSTAT

CAPSULE; ORAL

ZAVESCA

+ ACTELION PHARMS 100MG

N21348 001

JUL 31, 2003 JUL NEWA

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP BAXTER HLTHCARE

EQ 1MG BASE/ML

N75530 001

MAY 28, 2002 JUN CAHN

JUN	CFTG	AP	BIONICHE (CANADA)	EQ 1MG BASE/ML	N76428 001	JUN 16, 2003	JUN	NEWA
			MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
		AP	BAXTER HLTHCARE	EQ 20MG BASE/100ML	N75510 001	MAY 28, 2002	AUG	CAHN
			MILRINONE LACTOSE IN 5% DEXTROSE					
		AP	BAXTER HLTHCARE	EQ 20MG BASE/100ML	N76259 001	AUG 08, 2002	AUG	CAHN
			PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER					
JUN	NEWA	AP +	SANOFI SYNTHELABO	EQ 20MG BASE/100ML	N20343 003	AUG 09, 1994	MAY	CRLD

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCIN

JUN	DISC	AB	WYETH PHARMS INC	EQ 50MG BASE	N50649 001	MAY 31, 1990	MAR	CAHN
JUN	DISC	AB		EQ 75MG BASE	N50649 003	FEB 12, 2001	MAR	CAHN
JUN	DISC	AB +		EQ 100MG BASE	N50649 002	MAY 31, 1990	MAR	CAHN

MINOCYCLINE HCL

JUN	DISC	AB	TEVA	EQ 75MG BASE	N63009 002	AUG 12, 2003	AUG	NEWA
-----	------	----	------	--------------	------------	--------------	-----	------

INJECTABLE; INJECTION

MINOCIN

		+	WYETH PHARMS INC	EQ 100MG BASE/VIAL	N50444 001		MAR	CAHN
--	--	---	------------------	--------------------	------------	--	-----	------

TABLET; ORAL

MINOCYCLINE HCL

JUN	CAHN		MEDICIS	EQ 50MG BASE	N65131 001	APR 16, 2003	AUG	CAHN
-----	------	--	---------	--------------	------------	--------------	-----	------

JUN	CAHN			EQ 75MG BASE	N65131 002	APR 16, 2003	AUG	CAHN
-----	------	--	--	--------------	------------	--------------	-----	------

SEP	NEWA	+		EQ 100MG BASE	N65131 003	APR 16, 2003	AUG	CAHN
-----	------	---	--	---------------	------------	--------------	-----	------

			PAR PHARM	EQ 50MG BASE	N65131 001	APR 16, 2003	APR	NEWA
--	--	--	-----------	--------------	------------	--------------	-----	------

				EQ 75MG BASE	N65131 002	APR 16, 2003	APR	NEWA
--	--	--	--	--------------	------------	--------------	-----	------

		+		EQ 100MG BASE	N65131 003	APR 16, 2003	APR	NEWA
--	--	---	--	---------------	------------	--------------	-----	------

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

SEP	NEWA	AB	ALPHAPHARM	15MG	N76176 001	JUN 19, 2003	JUN	NEWA
-----	------	----	------------	------	------------	--------------	-----	------

SEP	NEWA	AB		30MG	N76176 002	JUN 19, 2003	JUN	NEWA
-----	------	----	--	------	------------	--------------	-----	------

SEP	NEWA	AB		45MG	N76176 003	JUN 19, 2003	JUN	NEWA
-----	------	----	--	------	------------	--------------	-----	------

SEP	NEWA	AB	AMIDE PHARM	15MG	N76241 001	JUN 25, 2003	JUN	NEWA
-----	------	----	-------------	------	------------	--------------	-----	------

SEP	CFTG	AB		30MG	N76241 002	JUN 25, 2003	JUN	NEWA
-----	------	----	--	------	------------	--------------	-----	------

SEP	CFTG	AB		45MG	N76241 003	JUN 25, 2003	JUN	NEWA
-----	------	----	--	------	------------	--------------	-----	------

SEP	CFTG	AB	ANDRX PHARMS	15MG	N76336 001	JUN 20, 2003	JUN	NEWA
-----	------	----	--------------	------	------------	--------------	-----	------

SEP	CFTG	AB		30MG	N76336 002	JUN 20, 2003	JUN	NEWA
-----	------	----	--	------	------------	--------------	-----	------

SEP	CFTG	AB		45MG	N76336 003	JUN 20, 2003	JUN	NEWA
-----	------	----	--	------	------------	--------------	-----	------

SEP	CFTG	AB	EON	15MG	N76219 001	JUN 19, 2003	JUN	NEWA
-----	------	----	-----	------	------------	--------------	-----	------

		AB		30MG	N76219 002	JUN 19, 2003	JUN	NEWA
--	--	----	--	------	------------	--------------	-----	------

		AB		45MG	N76219 003	JUN 19, 2003	JUN	NEWA
--	--	----	--	------	------------	--------------	-----	------

		AB	GENEVA PHARMS	15MG	N76189 001	JUN 19, 2003	JUN	NEWA
--	--	----	---------------	------	------------	--------------	-----	------

		AB		30MG	N76189 002	JUN 19, 2003	JUN	NEWA
--	--	----	--	------	------------	--------------	-----	------

JUL	NEWA	AB		45MG	N76189 003	JUN 19, 2003	JUN	NEWA
-----	------	----	--	------	------------	--------------	-----	------

		AB	MYLAN	15MG	N76122 001	JUN 19, 2003	JUN	NEWA
--	--	----	-------	------	------------	--------------	-----	------

		AB		30MG	N76122 002	JUN 19, 2003	JUN	NEWA
--	--	----	--	------	------------	--------------	-----	------

		AB		45MG	N76122 003	JUN 19, 2003	JUN	NEWA
--	--	----	--	------	------------	--------------	-----	------

		AB	PUREPAC PHARM	15MG	N76308 001	JUN 20, 2003	JUN	NEWA
--	--	----	---------------	------	------------	--------------	-----	------

JUN	CAHN	AB		30MG	N76308 002	JUN 20, 2003	JUN	NEWA
-----	------	----	--	------	------------	--------------	-----	------

		AB		45MG	N76308 003	JUN 20, 2003	JUN	NEWA
--	--	----	--	------	------------	--------------	-----	------

		AB	ROXANE	15MG	N76270 001	JUN 19, 2003	JUN	NEWA
--	--	----	--------	------	------------	--------------	-----	------

AB		30MG	N76270 002	JUN 19, 2003	JUN	NEWA
AB		45MG	N76270 003	JUN 19, 2003	JUN	NEWA
AB	TEVA	15MG	N76119 001	JAN 24, 2003	JAN	NEWA
AB		30MG	N76119 002	JAN 24, 2003	JAN	NEWA
AB		45MG	N76119 003	JUN 19, 2003	JUN	NEWA
AB	WATSON LABS	15MG	N76312 001	JUN 19, 2003	JUN	NEWA
AB		30MG	N76312 002	JUN 19, 2003	JUN	NEWA
AB		45MG	N76312 003	JUN 19, 2003	JUN	NEWA
	REMERON					
AB +	ORGANON	15MG	N20415 001	JUN 14, 1996	JAN	CFTG
AB		30MG	N20415 002	JUN 14, 1996	JAN	CFTG

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

AP	BAXTER HLTHCARE	5MG/VIAL	N64180 001	DEC 23, 1999	AUG	CAHN
AP		20MG/VIAL	N64180 002	DEC 23, 1999	AUG	CAHN

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HCL

AB	TEVA	7.5MG	N76204 001	MAY 08, 2003	MAY	NEWA
AB		15MG	N76204 002	MAY 08, 2003	MAY	NEWA

UNIVASC

AB	SCHWARZ PHARMA	7.5MG	N20312 001	APR 19, 1995	MAY	CFTG
AB +		15MG	N20312 002	APR 19, 1995	MAY	CFTG

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AVINZA

BX +	LIGAND	30MG	N21260 001	MAR 20, 2002	JUN	CAHN
BX +		60MG	N21260 002	MAR 20, 2002	JUN	CAHN
+		90MG	N21260 003	MAR 20, 2002	JUN	CAHN
+		120MG	N21260 004	MAR 20, 2002	JUN	CAHN

INJECTABLE; INJECTION

DURAMORPH PF

AP +	BAXTER HLTHCARE	1MG/ML	N18565 002	SEP 18, 1984	AUG	CAHN
	INFUMORPH					
+	BAXTER HLTHCARE	10MG/ML	N18565 003	JUL 19, 1991	AUG	CAHN
+		25MG/ML	N18565 004	JUL 19, 1991	AUG	CAHN

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

	@ CLONMEL HLTHCARE	15MG	N75407 001	JAN 28, 2000	JUL	DISC
AB	MALLINCKRODT	15MG	N76412 001	JUL 31, 2003	JUL	NEWA
AB		30MG	N76412 002	JUL 31, 2003	JUL	NEWA
AB		60MG	N76412 003	JUL 31, 2003	JUL	NEWA
AB		100MG	N76438 001	JUL 03, 2003	JUL	NEWA
AB		200MG	N76438 002	JUL 03, 2003	JUL	NEWA

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VIGAMOX

+	ALCON	0.5%	N21598 001	APR 15, 2003	APR	NEWA
---	-------	------	------------	--------------	-----	------

MUPIROCIN

OINTMENT; TOPICAL

MUPIROCIN

BX	CLAY PARK LABS	2%	N50788 001	DEC 04, 2002	JAN	CTEC
BX	JOHNSON AND JOHNSON	2%	N50788 001	DEC 04, 2002	APR	CAHN

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

CELLCEPT

+	ROCHE PALO	250MG	N50722 001	MAY 03, 1995	FEB	CAHN
---	------------	-------	------------	--------------	-----	------

SUSPENSION; ORAL

+	ROCHE PALO	200MG/ML	N50759 001	OCT 01, 1998	FEB	CAHN
---	------------	----------	------------	--------------	-----	------

TABLET; ORAL

+	ROCHE PALO	500MG	N50723 001	JUN 19, 1997	FEB	CAHN
---	------------	-------	------------	--------------	-----	------

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION

+	ROCHE PALO	500MG/VIAL	N50758 001	AUG 12, 1998	FEB	CAHN
---	------------	------------	------------	--------------	-----	------

NABUMETONE

TABLET; ORAL

NABUMETONE

AB	IVAX PHARMS	500MG	N76009 001	JAN 24, 2003	JAN	NEWA
AB		750MG	N76009 002	JAN 24, 2003	JAN	NEWA

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIN

@	ALLERGAN HERBERT	1%	N19599 001	FEB 29, 1988	JUN	DISC
---	------------------	----	------------	--------------	-----	------

GEL; TOPICAL

@	ALLERGAN HERBERT	1%	N19356 001	JUN 18, 1990	JUN	DISC
---	------------------	----	------------	--------------	-----	------

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HCL

@	KING PHARMS	10MG/ML	N74471 001	MAR 19, 1998	MAY	DISC
---	-------------	---------	------------	--------------	-----	------

@		20MG/ML	N74471 002	MAR 19, 1998	MAY	DISC
---	--	---------	------------	--------------	-----	------

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

@	BAXTER HLTHCARE	0.4MG/ML	N70496 001	SEP 24, 1986	AUG	CAHN
---	-----------------	----------	------------	--------------	-----	------

@	ELKINS SINN	0.4MG/ML	N70299 001	SEP 24, 1986	JUN	DISC
---	-------------	----------	------------	--------------	-----	------

@	ELKINS SINN PHARM	0.4MG/ML	N70298 001	SEP 24, 1986	JUN	DISC
---	-------------------	----------	------------	--------------	-----	------

NALOXONE HCL

@	BAXTER HLTHCARE	0.02MG/ML	N71272 001	MAY 24, 1988	AUG	CAHN
---	-----------------	-----------	------------	--------------	-----	------

@		1MG/ML	N71273 001	MAY 24, 1988	AUG	CAHN
---	--	--------	------------	--------------	-----	------

@		1MG/ML	N71274 001	MAY 24, 1988	AUG	CAHN
---	--	--------	------------	--------------	-----	------

@		1MG/ML	N71287 001	MAY 24, 1988	AUG	CAHN
---	--	--------	------------	--------------	-----	------

@	ELKINS SINN	0.02MG/ML	N71272 001	MAY 24, 1988	JUN	DISC
---	-------------	-----------	------------	--------------	-----	------

@		1MG/ML	N71273 001	MAY 24, 1988	JUN	DISC
---	--	--------	------------	--------------	-----	------

@		1MG/ML	N71274 001	MAY 24, 1988	JUN	DISC
---	--	--------	------------	--------------	-----	------

	@	1MG/ML		N71287 001	MAY 24, 1988	JUN	DISC	>A>
<u>NANDROLONE DECANOATE</u>								
INJECTABLE; INJECTION								
DECA-DURABOLIN								
	@	ORGANON USA INC	50MG/ML	N13132 001	JUN 12, 1986	MAY	DISC	>A>
	@		100MG/ML	N13132 002	JUN 12, 1986	MAY	DISC	>A>
	@		200MG/ML	N13132 003	JUN 12, 1986	MAY	DISC	>A>
NANDROLONE DECANOATE								
	+	STERIS	50MG/ML	N86385 001	JAN 13, 1984	MAY	CRLD	>A>
	+		100MG/ML	N86598 001	JAN 13, 1984	MAY	CRLD	>A>
	+		200MG/ML	N88128 001	DEC 05, 1983	MAY	CRLD	>A>
<u>NAPROXEN SODIUM</u>								
TABLET; ORAL								
NAPROXEN SODIUM								
AB		ABLE	EQ 250MG BASE	N76544 001	AUG 22, 2003	AUG	NEWA	>A>
AB			EQ 500MG BASE	N76544 002	AUG 22, 2003	AUG	NEWA	>A>
TABLET, EXTENDED RELEASE; ORAL								
NAPRELAN								
AB	+	ELAN PHARM	EQ 375MG BASE	N20353 001	JAN 05, 1996	APR	CFTG	>A>
AB	+		EQ 500MG BASE	N20353 002	JAN 05, 1996	MAR	CFTG	>A>
AB	+	ELAN PHARMA	EQ 375MG BASE	N20353 001	JAN 05, 1996	JUN	CAHN	>D>
AB	+		EQ 500MG BASE	N20353 002	JAN 05, 1996	JUN	CAHN	>A>
	@		EQ 750MG BASE	N20353 003	JAN 05, 1996	JUN	CAHN	>D>
NAPROXEN SODIUM								
AB		ANDRX PHARMS	EQ 375MG BASE	N75416 002	APR 23, 2003	APR	NEWA	>D>
AB			EQ 500MG BASE	N75416 001	AUG 27, 2002	MAR	NEWA	>A>
<u>NEFAZODONE HYDROCHLORIDE</u>								
TABLET; ORAL								
>A>	NEFAZODONE HCL							
>A>	AB	DR REDDYS LABS INC	50MG	N76309 001	SEP 16, 2003	SEP	NEWA	>A>
>A>	AB		100MG	N76309 002	SEP 16, 2003	SEP	NEWA	>A>
>A>	AB		150MG	N76309 003	SEP 16, 2003	SEP	NEWA	>A>
>A>	AB		200MG	N76309 004	SEP 16, 2003	SEP	NEWA	>A>
>A>	AB		250MG	N76309 005	SEP 16, 2003	SEP	NEWA	>A>
>A>	AB	EON	50MG	N76302 001	SEP 16, 2003	SEP	NEWA	>A>
>A>	AB		100MG	N76302 002	SEP 16, 2003	SEP	NEWA	>A>
>A>	AB		150MG	N76302 003	SEP 16, 2003	SEP	NEWA	>A>
>A>	AB		200MG	N76302 004	SEP 16, 2003	SEP	NEWA	>A>
>A>	AB		250MG	N76302 005	SEP 16, 2003	SEP	NEWA	>A>
>A>	AB	GENEVA PHARMS	50MG	N76072 001	SEP 16, 2003	SEP	NEWA	>A>
>A>	AB		100MG	N76072 002	SEP 16, 2003	SEP	NEWA	>A>
>A>	AB		150MG	N76072 003	SEP 16, 2003	SEP	NEWA	>A>
>A>	AB		200MG	N76072 004	SEP 16, 2003	SEP	NEWA	>A>
>A>	AB		250MG	N76072 005	SEP 16, 2003	SEP	NEWA	>A>
>A>	AB	IVAX PHARMS	50MG	N75763 001	SEP 16, 2003	SEP	NEWA	>A>
>A>	AB		100MG	N75763 002	SEP 16, 2003	SEP	NEWA	>A>
>A>	AB		150MG	N75763 003	SEP 16, 2003	SEP	NEWA	>A>
>A>	AB		200MG	N75763 004	SEP 16, 2003	SEP	NEWA	>A>
>A>	AB		250MG	N75763 005	SEP 16, 2003	SEP	NEWA	>A>
>A>	AB	MYLAN	100MG	N76129 002	SEP 16, 2003	SEP	NEWA	>A>

>A>	AB		150MG	N76129 003	SEP 16, 2003	SEP	NEWA
>A>	AB		200MG	N76129 004	SEP 16, 2003	SEP	NEWA
>A>	AB		250MG	N76129 005	SEP 16, 2003	SEP	NEWA
>A>	AB	RANBAXY	50MG	N76409 001	SEP 16, 2003	SEP	NEWA
>A>	AB		100MG	N76409 002	SEP 16, 2003	SEP	NEWA
>A>	AB		150MG	N76409 003	SEP 16, 2003	SEP	NEWA
>A>	AB		200MG	N76409 004	SEP 16, 2003	SEP	NEWA
>A>	AB		250MG	N76409 005	SEP 16, 2003	SEP	NEWA
>A>	AB	ROXANE	50MG	N76196 001	SEP 16, 2003	SEP	NEWA
>A>	AB		100MG	N76196 002	SEP 16, 2003	SEP	NEWA
>A>	AB		150MG	N76196 003	SEP 16, 2003	SEP	NEWA
>A>	AB		200MG	N76196 004	SEP 16, 2003	SEP	NEWA
>A>	AB		250MG	N76196 005	SEP 16, 2003	SEP	NEWA
>A>	AB	TEVA	50MG	N76037 001	SEP 16, 2003	SEP	NEWA
>A>	AB		100MG	N76037 002	SEP 16, 2003	SEP	NEWA
>A>	AB		150MG	N76037 003	SEP 16, 2003	SEP	NEWA
>A>	AB		200MG	N76037 004	SEP 16, 2003	SEP	NEWA
>A>	AB		250MG	N76037 005	SEP 16, 2003	SEP	NEWA
>A>	AB	WATSON LABS	100MG	N76073 002	SEP 16, 2003	SEP	NEWA
>A>	AB		150MG	N76073 003	SEP 16, 2003	SEP	NEWA
>A>	AB		200MG	N76073 004	SEP 16, 2003	SEP	NEWA
>A>	AB		250MG	N76073 005	SEP 16, 2003	SEP	NEWA
<u>SERZONE</u>							
>D>		BRISTOL MYERS SQUIBB	50MG	N20152 001	DEC 22, 1994	SEP	CFTG
>A>	AB		50MG	N20152 001	DEC 22, 1994	SEP	CFTG
>D>			100MG	N20152 002	DEC 22, 1994	SEP	CFTG
>A>	AB		100MG	N20152 002	DEC 22, 1994	SEP	CFTG
>D>			150MG	N20152 003	DEC 22, 1994	SEP	CFTG
>A>	AB		150MG	N20152 003	DEC 22, 1994	SEP	CFTG
>D>			200MG	N20152 004	DEC 22, 1994	SEP	CFTG
>A>	AB		200MG	N20152 004	DEC 22, 1994	SEP	CFTG
>D>		+	250MG	N20152 005	DEC 22, 1994	SEP	CFTG
>A>	AB	+	250MG	N20152 005	DEC 22, 1994	SEP	CFTG

NELFINAVIR MESYLATE

TABLET; ORAL

VIRACEPT

+ AGOURON

EQ 625MG BASE

N21503 001 APR 30, 2003 APR NEWA

NIFEDIPINE

CAPSULE; ORAL

ADALAT

@ BAYER PHARMS

10MG

N19478 001 NOV 27, 1985 JUN DISC

@

20MG

N19478 002 SEP 17, 1986 JUN DISC

TABLET, EXTENDED RELEASE; ORAL

PROCARDIA XL

AB2 PFIZER

30MG

N19684 001 SEP 06, 1989 JUL CRLD

AB2

60MG

N19684 002 SEP 06, 1989 JUL CRLD

NITROFURANTOIN

TABLET; ORAL

FURADANTIN

@ PROCTER AND GAMBLE

50MG

N08693 001

APR DISC

	@	100MG		N08693 002			APR	DISC
		NITROFURANTOIN						
	@	WATSON LAB	50MG		N80447 001		APR	DISC
	@	WHITWORTH TOWN PLSN	100MG		N84085 002		APR	DISC
<u>NITROFURAZONE</u>								
OINTMENT; TOPICAL								
FURACIN								
	@	SHIRE PHARM	0.2%		N05795 001		MAR	DISC
<u>NITROGLYCERIN</u>								
FILM, EXTENDED RELEASE; TRANSDERMAL*								
NITROGLYCERIN								
AB2		MYLAN TECHNOLOGIES	0.1MG/HR		N75033 001	FEB 06, 1998	APR	CAHN
AB2 +			0.1MG/HR		N75033 001	FEB 06, 1998	AUG	CRLD
AB2			0.2MG/HR		N74609 001	AUG 30, 1996	APR	CAHN
AB2 +			0.2MG/HR		N74609 001	AUG 30, 1996	AUG	CRLD
AB2			0.4MG/HR		N74607 001	AUG 30, 1996	APR	CAHN
AB2 +			0.4MG/HR		N74607 001	AUG 30, 1996	AUG	CRLD
AB2			0.6MG/HR		N74559 001	AUG 30, 1996	APR	CAHN
AB2 +			0.6MG/HR		N74559 001	AUG 30, 1996	AUG	CRLD
TRANSDERM-NITRO								
	@	NOVARTIS	0.1MG/HR		N20144 001	FEB 27, 1996	AUG	DISC
	@		0.2MG/HR		N20144 002	FEB 27, 1996	AUG	DISC
	@		0.4MG/HR		N20144 003	FEB 27, 1996	AUG	DISC
	@		0.6MG/HR		N20144 004	FEB 27, 1996	AUG	DISC
	@		0.8MG/HR		N20144 005	FEB 27, 1996	AUG	DISC
INJECTABLE; INJECTION								
TRIDIL								
	@	FAULDING	0.5MG/ML		N18537 002	JUN 16, 1983	MAY	DISC
	@		5MG/ML		N18537 001		MAY	DISC
OINTMENT; TRANSDERMAL								
NITROGLYCERIN								
	+	FOUGERA	2%		N87355 001	JUL 08, 1988	APR	CAHN
<u>NIZATIDINE</u>								
CAPSULE; ORAL								
NIZATIDINE								
AB		TORPHARM	150MG		N76383 001	JAN 23, 2003	JAN	NEWA
AB			300MG		N76383 002	JAN 23, 2003	JAN	NEWA
<u>NOREPINEPHRINE BITARTRATE</u>								
INJECTABLE; INJECTION								
LEVOPHED								
AP	+	ABBOTT	EQ 1MG BASE/ML		N07513 001		MAR	CFTG
NOREPINEPHRINE BITARTRATE								
AP		GENSIA SICOR PHARMS	EQ 1MG BASE/ML		N40455 001	MAR 03, 2003	MAR	NEWA
<u>NORETHINDRONE ACETATE</u>								
TABLET; ORAL								
AYGESTIN								
AB	+	DURAMED PHARM BARR	5MG		N18405 001	APR 21, 1982	JUN	CAHN
AB	+	WYETH PHARMS INC	5MG		N18405 001	APR 21, 1982	MAR	CAHN

* SEE SECTION 1.3 NITROGLYCERIN, FILM, EXTENDED RELEASE; TRANSDERMAL

NORFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

CHIBROXIN

@ MERCK 0.3%

N19757 001 JUN 17, 1991 MAY DISC

NORGESTREL

TABLET; ORAL

OVRETTE

+ WYETH PHARMS INC 0.075MG

N17031 001 MAR CAHN

NYSTATIN

POWDER; ORAL

NILSTAT

@ CLONMEL HLTHCARE 100%

N50576 001 DEC 22, 1983 JUL DISC

NYSTATIN

+ PADDOCK 100%

N62613 001 NOV 26, 1985 JUL CRLD

OFLOXACIN

TABLET; ORAL

FLOXIN

>D> ORTHO MCNEIL PHARM 200MG

N19735 001 DEC 28, 1990 SEP CFTG

>A> AB 200MG

N19735 001 DEC 28, 1990 SEP CFTG

>D> 300MG

N19735 002 DEC 28, 1990 SEP CFTG

>A> AB 300MG

N19735 002 DEC 28, 1990 SEP CFTG

>D> + 400MG

N19735 003 DEC 28, 1990 SEP CFTG

>A> AB + 400MG

N19735 003 DEC 28, 1990 SEP CFTG

>A> OFLOXACIN

>A> AB PAR PHARM 200MG

N76093 001 SEP 02, 2003 SEP NEWA

>A> AB 300MG

N76093 002 SEP 02, 2003 SEP NEWA

>A> AB 400MG

N76093 003 SEP 02, 2003 SEP NEWA

>A> AB RANBAXY 200MG

N76220 001 SEP 02, 2003 SEP NEWA

>A> AB 300MG

N76220 002 SEP 02, 2003 SEP NEWA

>A> AB 400MG

N76220 003 SEP 02, 2003 SEP NEWA

>A> AB TEVA 200MG

N76182 001 SEP 02, 2003 SEP NEWA

>A> AB 300MG

N76182 002 SEP 02, 2003 SEP NEWA

>A> AB 400MG

N76182 003 SEP 02, 2003 SEP NEWA

OLANZAPINE

TABLET; ORAL

ZYPREXA

+ LILLY 5MG

N20592 002 SEP 30, 1996 MAY CRLD

20MG

N20592 006 SEP 09, 1997 MAY CRLD

TABLET, ORALLY DISINTEGRATING; ORAL

ZYPREXA ZYDIS

+ LILLY 5MG

N21086 001 APR 06, 2000 AUG CRLD

20MG

N21086 004 APR 06, 2000 AUG CRLD

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

AB LEK SVCS 10MG

N75757 001 JAN 28, 2003 JAN NEWA

AB 20MG

N75757 002 JAN 28, 2003 JAN NEWA

AB	MYLAN	10MG	N75876 001	MAY 29, 2003	MAY	NEWA
AB		20MG	N75876 002	MAY 29, 2003	MAY	NEWA
<u>ORPHENADRINE CITRATE</u>						
INJECTABLE; INJECTION						
ORPHENADRINE CITRATE						
AP	BEDFORD LABS	30MG/ML	N40463 001	MAR 04, 2003	MAR	NEWA
<u>OXYBUTYNIN</u>						
FILM, EXTENDED RELEASE; TRANSDERMAL						
OXYTROL						
+	WATSON LABS (UTAH)	3.9MG/24HR	N21351 002	FEB 26, 2003	FEB	NEWA
<u>OXYBUTYNIN CHLORIDE</u>						
TABLET, EXTENDED RELEASE; ORAL						
DITROPAN XL						
	ALZA	5MG	N20897 001	DEC 16, 1998	MAY	CRLD
		10MG	N20897 002	DEC 16, 1998	MAY	CRLD
<u>OXYTOCIN</u>						
INJECTABLE; INJECTION						
OXYTOCIN						
	@ BAXTER HLTHCARE CORP	10USP UNITS/ML	N18243 001		MAY	CAHN
<u>PALONOSETRON HYDROCHLORIDE</u>						
INJECTABLE; INTRAVENOUS						
ALOXI						
+	HELSINN HLTHCARE	EQ 0.25MG BASE/5ML(EQ 0.05MG BASE/ML)	N21372 001	JUL 25, 2003	JUL	NEWA
<u>PANCURONIUM BROMIDE</u>						
INJECTABLE; INJECTION						
PANCURONIUM BROMIDE						
AP +	GENSIA SICOR PHARMS	1MG/ML	N72759 001	JUL 31, 1990	MAY	CRLD
AP +		2MG/ML	N72760 001	JUL 31, 1990	MAY	CRLD
PAVULON						
	@ ORGANON	1MG/ML	N17015 002		MAY	DISC
	@	2MG/ML	N17015 001		MAY	DISC
<u>PANTOPRAZOLE SODIUM</u>						
INJECTABLE; IV (INFUSION)						
PROTONIX IV						
+	WYETH PHARMS INC	EQ 40MG BASE/VIAL	N20988 001	MAR 22, 2001	MAR	CAHN
TABLET, DELAYED RELEASE; ORAL						
PROTONIX						
+	WYETH PHARMS INC	EQ 20MG BASE	N20987 002	JUN 12, 2001	MAR	CAHN
		EQ 20MG BASE	N20987 002	JUN 12, 2001	APR	CRLD
+		EQ 40MG BASE	N20987 001	FEB 02, 2000	MAR	CAHN
<u>PAROMOMYCIN SULFATE</u>						
CAPSULE; ORAL						
HUMATIN						
AA +	KING PHARMS	EQ 250MG BASE	N62310 001		MAY	CAHN

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HCL

AB	TORPHARM	EQ 10MG BASE	N75356 001	JUL 30, 2003	JUL	NEWA
AB		EQ 20MG BASE	N75356 002	JUL 30, 2003	JUL	NEWA
AB		EQ 30MG BASE	N75356 003	JUL 30, 2003	JUL	NEWA
AB		EQ 40MG BASE	N75356 004	JUL 30, 2003	JUL	NEWA
PAXIL						
AB	GLAXOSMITHKLINE	EQ 10MG BASE	N20031 001	DEC 29, 1992	JUL	CFTG
AB		EQ 20MG BASE	N20031 002	DEC 29, 1992	JUL	CFTG
AB		EQ 30MG BASE	N20031 003	DEC 29, 1992	JUL	CFTG
AB	+	EQ 40MG BASE	N20031 005	DEC 29, 1992	JUL	CFTG

PAROXETINE MESYLATE

TABLET; ORAL

PAROXETINE MESYLATE

SYNTHON PHARMS

		EQ 10MG BASE	N21299 001	JUL 03, 2003	JUL	NEWA
		EQ 20MG BASE	N21299 002	JUL 03, 2003	JUL	NEWA
		EQ 30MG BASE	N21299 003	JUL 03, 2003	JUL	NEWA
	+	EQ 40MG BASE	N21299 004	JUL 03, 2003	JUL	NEWA

PEGVISOMANT

INJECTABLE; SUBCUTANEOUS

SOMAVERT

+	PHARMACIA AND UPJOHN	10MG/VIAL	N21106 001	MAR 25, 2003	MAR	NEWA
+		15MG/VIAL	N21106 002	MAR 25, 2003	MAR	NEWA
+		20MG/VIAL	N21106 003	MAR 25, 2003	MAR	NEWA

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

@	MARSAM PHARMS LLC	1,000,000 UNITS/VIAL	N62991 001	SEP 13, 1988	JUL	DISC
@		5,000,000 UNITS/VIAL	N62991 002	SEP 13, 1988	JUL	DISC
@		10,000,000 UNITS/VIAL	N62991 003	SEP 13, 1988	JUL	DISC
@		20,000,000 UNITS/VIAL	N62991 004	SEP 13, 1988	JUL	DISC

TABLET; ORAL

@	WYETH AYERST	200,000 UNITS	N60413 001		JUN	DISC
@		250,000 UNITS	N60413 002		JUN	DISC
@		400,000 UNITS	N60413 003		JUN	DISC

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

LEDERCILLIN VK

@	LEDERLE	EQ 125MG BASE/5ML	N60136 001		JUN	DISC
@		EQ 250MG BASE/5ML	N60136 002		JUN	DISC

TABLET; ORAL

@	LEDERLE	EQ 250MG BASE	N60134 001		JUN	DISC
@		EQ 500MG BASE	N60134 002		JUN	DISC
PEN-VEE K						
@	WYETH AYERST	EQ 250MG BASE	N60006 002		JUN	DISC
@		EQ 500MG BASE	N60006 003		JUN	DISC

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION

PENTAMIDINE ISETHIONATE

@ BAXTER HLTHCARE 300MG/VIAL N73617 001 DEC 18, 1995 AUG CAHN

@ ELKINS SINN 300MG/VIAL N73617 001 DEC 18, 1995 JUN DISC

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM

+ ABBOTT 50MG/ML N83246 001 JUN CTEC

SODIUM PENTOBARBITAL

@ WYETH AYERST 50MG/ML N83261 001 JUN DISC

PERGOLIDE MESYLATE

TABLET; ORAL

PERGOLIDE MESYLATE

>A> AB IVAX PHARMS EQ 0.05MG BASE N76094 001 SEP 04, 2003 SEP NEWA

>A> AB EQ 0.25MG BASE N76094 002 SEP 04, 2003 SEP NEWA

>A> AB EQ 1MG BASE N76094 003 SEP 04, 2003 SEP NEWA

PERMETHRIN

CREAM; TOPICAL

PERMETHRIN

AB CLAY PARK 5% N76369 001 APR 21, 2003 APR NEWA

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

AB + IVAX PHARMS 16MG N89457 001 SEP 10, 1987 FEB CRLD

TRILAFON

@ SCHERING 2MG N10775 001 FEB DISC

@ 4MG N10775 002 FEB DISC

@ 8MG N10775 003 FEB DISC

@ 16MG N10775 004 FEB DISC

PHEENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHEENTERMINE HCL

AA ABLE 15MG N40497 001 MAR 13, 2003 MAR NEWA

AA AMBI PHARMS 30MG N40083 001 MAR 07, 1997 MAY CAHN

AA AMIDE PHARM 15MG N40460 001 JAN 14, 2003 JAN NEWA

AA 30MG N40448 001 JAN 22, 2003 JAN NEWA

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN VC

@ WYETH AYERST 5MG/5ML;6.25MG/5ML N08604 003 APR 02, 1984 APR DISC

PROMETH VC PLAIN

AA + ALPHARMA 5MG/5ML;6.25MG/5ML N88761 001 NOV 08, 1984 APR CRLD

PHENYTOIN

SUSPENSION; ORAL

AB	PHENYTOIN VISTAPHARM	125MG/5ML	N40342 001	JAN 31, 2001	MAR	CAHN
----	-------------------------	-----------	------------	--------------	-----	------

PHENYTOIN SODIUM

INJECTABLE; INJECTION

	DILANTIN @ PARKE DAVIS	50MG/ML	N10151 001		MAR	DISC
--	---------------------------	---------	------------	--	-----	------

	PHENYTOIN + ELKINS SINN	50MG/ML	N84307 001		MAR	CRLD
--	----------------------------	---------	------------	--	-----	------

	PHENYTOIN SODIUM @ ABBOTT	50MG/ML	N89521 001	MAR 17, 1987	MAR	DISC
--	------------------------------	---------	------------	--------------	-----	------

	@	50MG/ML	N89744 001	DEC 18, 1987	MAR	DISC
--	---	---------	------------	--------------	-----	------

PHENYTOIN SODIUM, EXTENDED

CAPSULE; ORAL

	DILANTIN PARKE DAVIS	30MG	N84349 001		FEB	CRLD
--	-------------------------	------	------------	--	-----	------

	+ EXTENDED PHENYTOIN SODIUM	30MG	N84349 001		JUN	CRLD
--	--------------------------------	------	------------	--	-----	------

AB	BARR	100MG	N40435 001	JUN 20, 2003	JUN	NEWA
----	------	-------	------------	--------------	-----	------

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL

	SALAGEN MGI PHARMA INC	5MG	N20237 001	MAR 22, 1994	APR	CRLD
--	---------------------------	-----	------------	--------------	-----	------

	+ 7.5MG		N20237 002	APR 18, 2003	APR	NEWA
--	------------	--	------------	--------------	-----	------

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

	PIPRACIL + WYETH PHARMS INC	EQ 2GM BASE/VIAL	N50545 002		MAR	CAHN
--	--------------------------------	------------------	------------	--	-----	------

	@	EQ 2GM BASE/VIAL	N50545 002		JUN	DISC
--	---	------------------	------------	--	-----	------

	@	EQ 2GM BASE/VIAL	N62750 001	OCT 13, 1987	MAR	CAHN
--	---	------------------	------------	--------------	-----	------

	@	EQ 2GM BASE/VIAL	N62750 001	OCT 13, 1987	JUN	DISC
--	---	------------------	------------	--------------	-----	------

	+ @	EQ 3GM BASE/VIAL	N50545 003		MAR	CAHN
--	--------	------------------	------------	--	-----	------

	@	EQ 3GM BASE/VIAL	N50545 003		JUN	DISC
--	---	------------------	------------	--	-----	------

	+ @	EQ 3GM BASE/VIAL	N62750 002	OCT 13, 1987	MAR	CAHN
--	--------	------------------	------------	--------------	-----	------

	@	EQ 3GM BASE/VIAL	N62750 002	OCT 13, 1987	JUN	DISC
--	---	------------------	------------	--------------	-----	------

	+ @	EQ 4GM BASE/VIAL	N50545 004		MAR	CAHN
--	--------	------------------	------------	--	-----	------

	@	EQ 4GM BASE/VIAL	N50545 004		JUN	DISC
--	---	------------------	------------	--	-----	------

	+ @	EQ 4GM BASE/VIAL	N62750 003	OCT 13, 1987	MAR	CAHN
--	--------	------------------	------------	--------------	-----	------

	@	EQ 4GM BASE/VIAL	N62750 003	OCT 13, 1987	JUN	DISC
--	---	------------------	------------	--------------	-----	------

	@	EQ 4GM BASE/VIAL	N50545 006	SEP 30, 1985	MAR	CAHN
--	---	------------------	------------	--------------	-----	------

	@	EQ 40GM BASE/VIAL				
--	---	-------------------	--	--	--	--

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

	ZOSYN + WYETH PHARMS INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	N50684 001	OCT 22, 1993	MAR	CAHN
--	-----------------------------	-------------------------------------	------------	--------------	-----	------

	+ @	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	N50684 002	OCT 22, 1993	MAR	CAHN
--	--------	-------------------------------------	------------	--------------	-----	------

	+ @	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	N50684 003	OCT 22, 1993	MAR	CAHN
--	--------	-------------------------------------	------------	--------------	-----	------

	+		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	N50684 004	OCT 22, 1993	MAR	CAHN
		ZOSYN IN PLASTIC CONTAINER					
	+	WYETH PHARMS INC	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N50750 001	FEB 24, 1998	MAR	CAHN
	+		EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N50750 002	FEB 24, 1998	MAR	CAHN
	+		EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N50750 003	FEB 24, 1998	MAR	CAHN
		<u>PIRBUTEROL ACETATE</u>					
		AEROSOL, METERED; INHALATION					
		MAXAIR					
		@ 3M	EQ 0.2MG BASE/INH	N19009 001	DEC 30, 1986	MAY	DISC
		<u>POTASSIUM CHLORIDE</u>					
		INJECTABLE; INJECTION					
		POTASSIUM CHLORIDE					
		@ BAXTER HLHCARE	2MEQ/ML	N80203 001		AUG	CAHN
		TABLET, EXTENDED RELEASE; ORAL					
		KLOR-CON M15					
		UPSHER SMITH	15MEQ	N74726 003	JUN 06, 2003	JUN	NEWA
		<u>PRALIDOXIME CHLORIDE</u>					
		INJECTABLE; INJECTION					
		PRALIDOXIME CHLORIDE					
		@ BAXTER HLHCARE CORP	300MG/ML	N18799 001	DEC 13, 1982	MAR	CAHN
		PROTOPAM CHLORIDE					
	+	BAXTER HLHCARE CORP	1GM/VIAL	N14134 001		JUL	CAHN
		<u>PRAZOSIN HYDROCHLORIDE</u>					
		CAPSULE; ORAL					
		PRAZOSIN HCL					
		@ CLONMEL HLHCARE	EQ 2MG BASE	N72706 001	MAY 16, 1989	JUL	DISC
		<u>PREDNICARBATE</u>					
		CREAM; TOPICAL					
		DERMATOP E EMOLLIENT					
	+	DERMIK LABS	0.1%	N20279 001	OCT 29, 1993	APR	CTNA
		<u>PREDNISOLONE</u>					
		SYRUP; ORAL					
		PREDNISOLONE					
	AA	AXIOM PHARM	15MG/5ML	N40287 001	MAY 28, 1999	MAY	CAHN
	AA	HI TECH PHARMA	15MG/5ML	N40401 001	FEB 27, 2003	FEB	NEWA
	+	KV PHARM	5MG/5ML	N40423 001	OCT 22, 2001	JUL	CRLD
	AA		15MG/5ML	N40364 001	APR 10, 2002	JUL	CRLD
>A>	AA	MORTON GROVE	15MG/5ML	N40313 001	SEP 10, 2003	SEP	NEWA
	AA	PHARM ASSOC	15MG/5ML	N40399 001	MAR 05, 2003	MAR	NEWA
		PRELONE					
		@ MURO	5MG/5ML	N89654 001	JAN 17, 1989	JUL	DISC
	AA	+	TEVA	N89081 001	FEB 04, 1986	MAY	CAHN
	AA		15MG/5ML	N89081 001	FEB 04, 1986	JUL	CRLD

PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

ECONOPRED

@ ALCON	0.125%	N17468 001	JUN	DISC
---------	--------	------------	-----	------

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

CETAPRED

@ ALCON	0.25%;10%	N87771 001	AUG 06, 1993	JUN	DISC
---------	-----------	------------	--------------	-----	------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

AA	HI TECH PHARMA	EQ 5MG BASE/5ML	N75183 001	MAR 26, 2003	MAR	NEWA
----	----------------	-----------------	------------	--------------	-----	------

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT	ALCON	EQ 0.23% PHOSPHATE;10%	N73630 001	MAY 27, 1993	APR	CAHN
----	-------	------------------------	------------	--------------	-----	------

PREDNISON

TABLET; ORAL

PREDNISON

AB	VINTAGE PHARMS	20MG	N40392 001	FEB 12, 2003	FEB	NEWA
----	----------------	------	------------	--------------	-----	------

PRIMIDONE

TABLET; ORAL

MYSOLINE

AB +	XCEL PHARMS	50MG	N09170 003		JUL	CRLD
AB		250MG	N09170 002		JUL	CRLD

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HCL

@ BAXTER HLTHCARE	100MG/ML	N89029 001	APR 17, 1986	AUG	CAHN
@	500MG/ML	N89030 001	APR 17, 1986	AUG	CAHN
@ ELKINS SINN	100MG/ML	N89029 001	APR 17, 1986	JUN	DISC
@	500MG/ML	N89030 001	APR 17, 1986	JUN	DISC

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE

AP	BAXTER HLTHCARE	EQ 5MG BASE/ML	N87759 001	OCT 01, 1982	AUG	CAHN
	PROCHLORPERAZINE EDISYLATE					
@ BAXTER HLTHCARE	EQ 5MG BASE/ML	N89523 001	MAY 03, 1988	AUG	CAHN	
AP	GENSIA SICOR PHARMS	EQ 5MG BASE/ML	N40505 001	MAY 30, 2003	MAY	NEWA

PROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

SPARINE

@ BAXTER HLTHCARE CORP	25MG/ML	N10349 008		AUG	CAHN
@	50MG/ML	N10349 006		AUG	CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PHENERGAN

@ WYETH AYERST 25MG/ML
 @ 50MG/ML

N08857 002 JUN DISC
 N08857 003 APR DISC

PROMETHAZINE HCL

AP BAXTER HLTHCARE 25MG/ML
 AP 50MG/ML
 AP + GENSLIA SICOR PHARMS 25MG/ML
 AP + 50MG/ML
 AP PHARMAFORCE 25MG/ML

N83312 001 JUN CAHN
 N83312 002 JUN CAHN
 N40454 001 AUG 22, 2002 APR CRLD
 N40454 002 AUG 22, 2002 APR CRLD
 N40515 001 MAR 19, 2003 MAR NEWA

SUPPOSITORY; RECTAL

PHENERGAN

AB + WYETH AYERST 50MG
 AB WYETH PHARMS INC 12.5MG
 AB + 25MG
 AB + 50MG

N11689 001 FEB CTEC
 N10926 002 MAR CAHN
 N10926 001 MAR CAHN
 N11689 001 MAR CAHN

PROMETHAZINE HCL

AB ABLE 12.5MG
 AB 25MG
 AB 50MG
 AB CLAY PARK 12.5MG
 AB 25MG
 AB G AND W LABS 12.5MG
 AB PADDOCK 12.5MG
 AB 25MG

N40504 001 APR 11, 2003 APR NEWA
 N40504 002 APR 11, 2003 APR NEWA
 N40449 001 FEB 27, 2003 FEB NEWA
 N40500 001 JUN 30, 2003 JUN NEWA
 N40500 002 JUN 30, 2003 JUN NEWA
 N40428 002 MAR 31, 2003 MAR NEWA
 N40479 001 JUN 24, 2003 JUN NEWA
 N40479 002 JUN 24, 2003 JUN NEWA

SYRUP; ORAL

PHENERGAN PLAIN

@ WYETH AYERST 6.25MG/5ML

N08381 004 APR 18, 1984 JUN DISC

PROMETH PLAIN

AA + ALPHARMA 6.25MG/5ML

N85953 001 JUN CRLD

TABLET; ORAL

PHENERGAN

WYETH PHARMS INC 12.5MG
 BP 25MG
 BP + 50MG

N07935 002 MAR CAHN
 N07935 003 MAR CAHN
 N07935 004 MAR CAHN

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

RYTHMOL SR

>A> ABBOTT 225MG
 >A> 325MG
 >A> + 425MG

N21416 001 SEP 04, 2003 SEP NEWA
 N21416 002 SEP 04, 2003 SEP NEWA
 N21416 003 SEP 04, 2003 SEP NEWA

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

LARGON

@ BAXTER HLTHCARE CORP 20MG/ML

N12382 002 MAY CAHN

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DOLENE

@ CLONMEL HLTHCARE

65MG

N80530 001

AUG DISC

PROPOXYPHENE NAPSYLATE

SUSPENSION; ORAL

DARVON-N

@ AAIPHARMA LLC

50MG/5ML

N16861 001

JUL DISC

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERAL LA

WYETH PHARMS INC

60MG

N18553 004 MAR 18, 1987 MAR CAHN

BX 80MG

N18553 002 APR 19, 1983 MAR CTEC

BX 120MG

N18553 003 APR 19, 1983 MAR CTEC

+ 160MG

N18553 001 APR 19, 1983 MAR CAHN

INNOPRAN XL

RELIANT PHARMS

80MG

N21438 001 MAR 12, 2003 MAR NEWA

BX 120MG

N21438 002 MAR 12, 2003 MAR NEWA

INJECTABLE; INJECTION

INDERAL

AP + BAXTER HLTHCARE CORP

1MG/ML

N16419 001

MAY CAHN

PROPRANOLOL HCL

AP + BAXTER HLTHCARE CORP

1MG/ML

N16419 001

AUG CTNA

AP SABEX 2002

1MG/ML

N76400 001 FEB 26, 2003 FEB NEWA

TABLET; ORAL

INDERAL

AB + WYETH PHARMS INC

10MG

N16418 001

MAR CAHN

AB 20MG

N16418 003

MAR CAHN

AB 40MG

N16418 002

MAR CAHN

AB 60MG

N16418 009 OCT 18, 1982 MAR CAHN

AB + 80MG

N16418 004

MAR CAHN

@ 90MG

N16418 010 OCT 18, 1982 MAR CAHN

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

@ BAXTER HLTHCARE

10MG/ML

N89474 001 NOV 05, 1986 AUG CAHN

@ 10MG/ML

N89475 001 NOV 05, 1986 AUG CAHN

@ ELKINS SINN

10MG/ML

N89474 001 NOV 05, 1986 JUN DISC

@ 10MG/ML

N89475 001 NOV 05, 1986 JUN DISC

PROTIRELIN

INJECTABLE; INJECTION

THYREL TRH

@ FERRING

0.5MG/ML

N18087 001

JUL DISC

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION

REGONOL

@ ORGANON

5MG/ML

N17398 001

MAY DISC

	@ SABEX 2002	5MG/ML	N17398 001		JUN	CAHN	
	TABLET; ORAL						
	PYRIDOSTIGMINE BROMIDE						
AB	IMPAX LABS	60MG	N40502 001	APR 24, 2003	APR	NEWA	
	@ US ARMY	30MG	N20414 001	FEB 05, 2003	FEB	NEWA	
<u>QUETIAPINE FUMARATE</u>							
TABLET; ORAL							
SEROQUEL							
+	ASTRAZENECA	EQ 25MG BASE	N20639 001	SEP 26, 1997	MAR	CRLD	
<u>QUINAPRIL HYDROCHLORIDE</u>							
TABLET; ORAL							
ACCUPRIL							
AB	PFIZER PHARMS	EQ 5MG BASE	N19885 001	NOV 19, 1991	MAY	CFTG	
AB		EQ 10MG BASE	N19885 002	NOV 19, 1991	MAY	CFTG	
AB		EQ 20MG BASE	N19885 003	NOV 19, 1991	MAY	CFTG	
AB	+	EQ 40MG BASE	N19885 004	NOV 19, 1991	MAY	CFTG	
QUINAPRIL HCL							
AB	TEVA	EQ 5MG BASE	N75504 001	MAY 30, 2003	MAY	NEWA	
AB		EQ 10MG BASE	N75504 002	MAY 30, 2003	MAY	NEWA	
AB		EQ 20MG BASE	N75504 003	MAY 30, 2003	MAY	NEWA	
AB		EQ 40MG BASE	N75504 004	NOV 20, 1998	MAY	NEWA	
<u>QUINIDINE GLUCONATE</u>							
TABLET, EXTENDED RELEASE; ORAL							
QUINAGLUTE							
	@ BERLEX LABS	324MG	N16647 001		MAR	DISC	
QUINIDINE GLUCONATE							
BX	+	MUTUAL PHARM	324MG	N89338 001	FEB 11, 1987	APR	CRLD
	+		324MG	N89338 001	FEB 11, 1987	MAY	CTEC
	+	WATSON LABS	324MG	N87810 001	SEP 29, 1982	MAR	CRLD
BX			324MG	N87810 001	SEP 29, 1982	APR	CRLD
	@		324MG	N87810 001	SEP 29, 1982	MAY	DISC
<u>QUINIDINE SULFATE</u>							
TABLET; ORAL							
QUINIDINE SULFATE							
AB	CLONMEL HLTHCARE	200MG	N87011 001		JUL	CAHN	
TABLET, EXTENDED RELEASE; ORAL							
QUINIDEX							
AB	+	WYETH PHARMS INC	300MG	N12796 002		MAR	CAHN
	@		300MG	N12796 002		JUN	DISC
QUINIDINE SULFATE							
+	COPLEY PHARM	300MG	N40045 001	JUN 30, 1994	JUN	CTEC	
<u>RESERPINE; TRICHLORMETHIAZIDE</u>							
TABLET; ORAL							
METATENSIN #2							
	@ AVENTIS PHARMS	0.1MG;2MG	N12972 001		MAY	DISC	
METATENSIN #4							
	@ AVENTIS PHARMS	0.1MG;4MG	N12972 002		MAY	DISC	

RIBAVIRIN

SOLUTION; ORAL

REBETOL

+ SCHERING

40MG/ML

N21546 001 JUL 29, 2003 JUL NEWA

RILUZOLE

TABLET; ORAL

RILUTEK

AB + AVENTIS

50MG

N20599 001 DEC 12, 1995 JAN CFTG

RILUZOLE

AB IMPAX LABS

50MG

N76173 001 JAN 29, 2003 JAN NEWA

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

RIMANTADINE HCL

AB AMIDE PHARM

100MG

N76375 001 JAN 14, 2003 JAN NEWA

RISPERIDONE

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL

JOHNSON AND JOHNSON

0.5MG

N21444 001 APR 02, 2003 APR NEWA

+

1MG

N21444 002 APR 02, 2003 APR NEWA

2MG

N21444 003 APR 02, 2003 APR NEWA

ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDIA

SB PHARMCO

EQ 2MG BASE

N21071 002 MAY 25, 1999 APR CAHN

EQ 4MG BASE

N21071 003 MAY 25, 1999 APR CAHN

+

EQ 8MG BASE

N21071 004 MAY 25, 1999 APR CAHN

ROSUVASTATIN CALCIUM

TABLET; ORAL

CRESTOR

ASTRAZENECA

5MG

N21366 002 AUG 12, 2003 AUG NEWA

10MG

N21366 003 AUG 12, 2003 AUG NEWA

20MG

N21366 004 AUG 12, 2003 AUG NEWA

+

40MG

N21366 005 AUG 12, 2003 AUG NEWA

SACROSIDASE

SOLUTION; ORAL

SUCRAID

+ QOL MEDCL

8,500 IU/ML

N20772 001 APR 09, 1998 MAY CAHN

SECOBARBITAL SODIUM

INJECTABLE; INJECTION

SODIUM SECOBARBITAL

@ WYETH AYERST

50MG/ML

N83262 001 JUN DISC

<u>SELEGILINE HYDROCHLORIDE</u>							
CAPSULE; ORAL							
SELEGELINE HCL							
>A>	AB	AAIPHARMA LLC	5MG	N75145 001	SEP 15, 2003	SEP	NEWA
<u>SERMORELIN ACETATE</u>							
INJECTABLE; INJECTION							
GEREF							
	@	SERONO	EQ 0.5MG BASE/VIAL	N20443 001	SEP 26, 1997	JUN	DISC
	@		EQ 1MG BASE/VIAL	N20443 002	SEP 26, 1997	JUN	DISC
<u>SEVELAMER HYDROCHLORIDE</u>							
CAPSULE; ORAL							
RENAGEL							
+		GENZYME	403MG	N20926 001	OCT 30, 1998	APR	CAHN
TABLET; ORAL							
		GENZYME	400MG	N21179 001	JUL 12, 2000	APR	CAHN
+			800MG	N21179 002	JUL 12, 2000	APR	CAHN
<u>SIROLIMUS</u>							
SOLUTION; ORAL							
RAPAMUNE							
+		WYETH PHARMS INC	1MG/ML	N21083 001	SEP 15, 1999	MAR	CAHN
TABLET; ORAL							
		WYETH PHARMS INC	1MG	N21110 001	AUG 25, 2000	MAR	CRLD
+			2MG	N21110 002	AUG 22, 2002	MAR	NEWA
<u>SODIUM IODIDE, I-131</u>							
CAPSULE; ORAL							
SODIUM IODIDE I 131							
+		DRAXIMAGE	1-250mCi	N21305 002	JAN 24, 2003	JAN	NEWA
+			1-500mCi	N21305 003	JAN 24, 2003	JAN	NEWA
SOLUTION; ORAL							
SODIUM IODIDE I 131, KIT							
+		DRAXIMAGE	1-250mCi/0.25ML	N21305 002	JAN 24, 2003	FEB	CDFR
+			1-500mCi/0.5ML	N21305 003	JAN 24, 2003	FEB	CDFR
<u>SODIUM NITROPRUSSIDE</u>							
INJECTABLE; INJECTION							
NITROPRESS							
AP	+	ABBOTT	50MG/VIAL	N70566 001	JUN 09, 1986	JUN	CRLD
	+		50MG/VIAL	N70566 001	JUN 09, 1986	AUG	CTEC
SODIUM NITROPRUSSIDE							
	@	BAXTER HLTHCARE	50MG/VIAL	N18581 001	JUL 28, 1982	AUG	CAHN
	@	ELKINS SINN	50MG/VIAL	N18581 001	JUL 28, 1982	JUN	DISC
<u>SOMATROPIN RECOMBINANT</u>							
INJECTABLE; INJECTION							
BIO-TROPIN							
	@	BIO TECH GEN	4.8MG/VIAL	N19774 001	MAY 25, 1995	MAR	DISC
NORDITROPIN							
BX		NOVO NORDISK	4MG/VIAL	N19721 001	MAY 08, 1995	JUL	CMFD

		8MG/VIAL	N19721 002	MAY 08, 1995	JUL	CMFD
	TEV-TROPIN					
BX +	BIO TECH GEN	5MG/ML	N19774 002	JAN 04, 2002	FEB	CTNA
	<u>SOTALOL HYDROCHLORIDE</u>					
	TABLET; ORAL					
	BETAPACE					
AB1	BERLEX LABS	80MG	N19865 001	OCT 30, 1992	AUG	CTEC
AB1		120MG	N19865 005	APR 20, 1994	AUG	CTEC
AB1 +		160MG	N19865 002	OCT 30, 1992	AUG	CTEC
AB1		240MG	N19865 003	OCT 30, 1992	AUG	CTEC
	BETAPACE AF					
	@ BERLEX LABS	40MG	N21151 006	APR 02, 2003	MAY	DISC
		40MG	N21151 006	APR 02, 2003	APR	NEWA
	@	60MG	N21151 007	APR 02, 2003	MAY	DISC
		60MG	N21151 007	APR 02, 2003	APR	NEWA
AB2		80MG	N21151 001	FEB 22, 2000	AUG	CFTG
	@	100MG	N21151 005	MAR 14, 2003	MAY	DISC
		100MG	N21151 005	MAR 14, 2003	MAR	NEWA
AB2		120MG	N21151 002	FEB 22, 2000	AUG	CFTG
AB2 +		160MG	N21151 003	FEB 22, 2000	AUG	CFTG
	SORINE					
AB1	UPSHER SMITH	80MG	N75500 001	APR 27, 2001	AUG	CTEC
AB1		120MG	N75500 004	APR 27, 2001	AUG	CTEC
AB1		160MG	N75500 002	APR 27, 2001	AUG	CTEC
AB1		240MG	N75500 003	APR 27, 2001	AUG	CTEC
	SOTALOL HCL					
AB1	APOTEX	80MG	N76140 001	SEP 26, 2002	AUG	CTEC
AB1		120MG	N76140 002	SEP 26, 2002	AUG	CTEC
AB1		160MG	N76140 003	SEP 26, 2002	AUG	CTEC
AB1		240MG	N76140 004	SEP 26, 2002	AUG	CTEC
AB1	EON	80MG	N75366 001	MAY 01, 2000	AUG	CTEC
AB1		120MG	N75366 002	MAY 01, 2000	AUG	CTEC
AB1		160MG	N75366 003	MAY 01, 2000	AUG	CTEC
AB1		240MG	N75366 004	MAY 01, 2000	AUG	CTEC
AB1	GENPHARM	80MG	N75237 001	MAY 01, 2000	AUG	CTEC
AB1		120MG	N75237 002	MAY 01, 2000	AUG	CTEC
AB1		160MG	N75237 003	MAY 01, 2000	AUG	CTEC
AB1		240MG	N75237 004	MAY 01, 2000	AUG	CTEC
AB1	IMPAX PHARMS	80MG	N75663 001	NOV 07, 2000	AUG	CTEC
AB1		120MG	N75663 002	NOV 07, 2000	AUG	CTEC
AB1		160MG	N75663 003	NOV 07, 2000	AUG	CTEC
AB1		240MG	N75663 004	NOV 07, 2000	AUG	CTEC
AB1	MUTUAL PHARM	80MG	N75515 001	OCT 15, 2001	AUG	CTEC
AB1		120MG	N75515 004	OCT 15, 2001	AUG	CTEC
AB1		160MG	N75515 002	OCT 15, 2001	AUG	CTEC
AB1		240MG	N75515 003	OCT 15, 2001	AUG	CTEC
AB1	MYLAN	80MG	N75725 001	DEC 19, 2000	AUG	CTEC
AB1		120MG	N75725 002	DEC 19, 2000	AUG	CTEC
AB1		160MG	N75725 003	DEC 19, 2000	AUG	CTEC
AB1		240MG	N75725 004	DEC 19, 2000	AUG	CTEC
AB1	TEVA	80MG	N75429 001	MAY 01, 2000	AUG	CTEC
AB1		120MG	N75429 002	MAY 01, 2000	AUG	CTEC

AB1		160MG	N75429 003	MAY 01, 2000	AUG	CTEC
AB1		240MG	N75429 004	MAY 01, 2000	AUG	CTEC
AB2	TORPHARM	80MG	N76214 001	AUG 27, 2003	AUG	NEWA
AB2		120MG	N76214 002	AUG 27, 2003	AUG	NEWA
AB2		160MG	N76214 003	AUG 27, 2003	AUG	NEWA
AB1	WATSON LABS	80MG	N75238 001	JUL 13, 2000	AUG	CTEC
AB1		120MG	N75238 002	JUL 13, 2000	AUG	CTEC
AB1		160MG	N75238 003	JUL 13, 2000	AUG	CTEC
AB1		240MG	N75238 004	JUL 13, 2000	AUG	CTEC
<u>STANOZOLOL</u>						
TABLET; ORAL						
WINSTROL						
	+	OVATION PHARMS	2MG	N12885 001	MAY 14, 1984	JUL CAHN
	@	WINSTROL	2MG	N12885 001	MAY 14, 1984	AUG DISC
<u>STREPTOZOCIN</u>						
INJECTABLE; INJECTION						
ZANOSAR						
	+	GENSIA SICOR PHARMS	1GM/VIAL	N50577 001	MAY 07, 1982	JUN CAHN
<u>STRONTIUM CHLORIDE, SR-89</u>						
INJECTABLE; INJECTION						
METASTRON						
AP	+	AMERSHAM HLTH	1mCi/ML	N20134 001	JUN 18, 1993	JAN CFTG
		STRONTIUM CHLORIDE SR-89				
AP		BIO NUCLEONICS	1mCi/ML	N75941 001	JAN 06, 2003	JAN NEWA
<u>SUCCIMER</u>						
CAPSULE; ORAL						
CHEMET						
	+	OVATION PHARMS	100MG	N19998 002	JAN 30, 1991	JUL CAHN
<u>SULFAMETHOXAZOLE; TRIMETHOPRIM</u>						
INJECTABLE; INJECTION						
SEPTRA						
	@	MONARCH PHARMS	80MG/ML;16MG/ML	N18452 001		MAY DISC
<u>SULFANILAMIDE</u>						
>D>	SUPPOSITORY; VAGINAL					
>D>	AVC					
>D>	+	NOVAVAX	1.05GM	N06530 004	JAN 27, 1987	SEP DISC
>A>	@		1.05GM	N06530 004	JAN 27, 1987	SEP DISC
<u>SULINDAC</u>						
TABLET; ORAL						
SULINDAC						
	@	CLOMEL HLHCARE	150MG	N73261 001	SEP 06, 1991	JUN DISC
	@		200MG	N73262 001	SEP 06, 1991	JUN DISC

TAMOXIFEN CITRATE

TABLET; ORAL

NOLVADEX

AB	ASTRAZENECA	EQ 10MG BASE	N17970 001		FEB	CTEC
AB +		EQ 20MG BASE	N17970 002	MAR 21, 1994	FEB	CTEC
<u>TAMOXIFEN CITRATE</u>						
AB	AEGIS PHARMS	EQ 10MG BASE	N76398 001	MAR 31, 2003	MAR	NEWA
AB		EQ 20MG BASE	N76398 002	MAR 31, 2003	MAR	NEWA
AB	ANDRX PHARMS	EQ 10MG BASE	N76179 001	FEB 20, 2003	FEB	NEWA
AB		EQ 20MG BASE	N76179 002	FEB 20, 2003	FEB	NEWA
AB	BARR	EQ 10MG BASE	N70929 001	FEB 20, 2003	FEB	NEWA
AB		EQ 20MG BASE	N70929 002	FEB 20, 2003	FEB	NEWA
AB	IVAX PHARMS	EQ 10MG BASE	N75740 001	FEB 20, 2003	FEB	NEWA
AB		EQ 20MG BASE	N75740 002	FEB 20, 2003	FEB	NEWA
AB	MYLAN	EQ 10MG BASE	N74732 002	FEB 20, 2003	FEB	NEWA
AB		EQ 20MG BASE	N74732 001	FEB 20, 2003	FEB	NEWA
AB	PHARMACHEMIE	EQ 10MG BASE	N74539 001	MAR 31, 2003	APR	CAHN
AB		EQ 20MG BASE	N74858 001	FEB 20, 2003	FEB	NEWA
AB	ROXANE	EQ 10MG BASE	N76027 001	FEB 20, 2003	FEB	NEWA
AB		EQ 20MG BASE	N76027 002	FEB 20, 2003	FEB	NEWA
AB	TEVA	EQ 10MG BASE	N74504 001	APR 28, 2003	APR	NEWA
AB		EQ 10MG BASE	N74539 001	MAR 31, 2003	MAR	NEWA
AB		EQ 10MG BASE	N75797 001	FEB 20, 2003	FEB	NEWA
AB		EQ 20MG BASE	N74504 002	APR 28, 2003	APR	NEWA

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

TECHNISCAN MDP KIT

AP +	DRAXIMAGE	N/A	N18035 001		MAR	CRLD
------	-----------	-----	------------	--	-----	------

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

INJECTABLE; INJECTION

PYROLITE

@ CIS

N/A

N17684 001 MAY DISC

TELMISARTAN

TABLET; ORAL

MICARDIS

BOEHRINGER INGELHEIM 20MG

N20850 003 APR 04, 2000 JUL CRLD

TESTOSTERONE

GEL; TOPICAL

ANDROGEL

BX + UNIMED PHARMS 1% N21015 001 FEB 28, 2000 APR CTEC

TESTIM

BX + AUXILIUM A2 1% N21454 001 OCT 31, 2002 APR CTEC

TABLET, EXTENDED RELEASE; BUCCAL

STRIANT

+ COLUMBIA LABS 30MG N21543 001 JUN 19, 2003 JUN NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL					
ACHROMYCIN V					
	@ CLONMEL HLTHCARE	250MG	N50278 003		JUN DISC
	@	500MG	N50278 001		JUN DISC
SUMYCIN					
AB +	APOTHECON	500MG	N60429 003		JUN CRLD
TETRACYCLINE HCL					
AB	AXIOM PHARM	250MG	N60736 001		MAY CAHN
AB		500MG	N60736 002		MAY CAHN
FIBER, EXTENDED RELEASE; PERIODONTAL					
ACTISITE					
	@ ALZA	12.7MG/FIBER	N50653 001	MAR 25, 1994	JUN DISC

THALIDOMIDE

CAPSULE; ORAL					
THALOMID					
	CELGENE	50MG	N20785 001	JUL 16, 1998	AUG CRLD
		100MG	N20785 002	JAN 17, 2003	JAN NEWA
+		200MG	N20785 003	JAN 17, 2003	JAN NEWA

THEOPHYLLINE

SYRUP; ORAL					
SLO-PHYLLIN					
	@ AVENTIS	80MG/15ML	N85187 001		AUG DISC
TABLET; ORAL					
	@ AVENTIS	100MG	N85202 001		AUG DISC
	@	200MG	N85204 001		AUG DISC
TABLET, EXTENDED RELEASE; ORAL					
>D>	THEO-DUR				
>D>	AB SCHERING	100MG	N85328 001		SEP DISC
>A>	@	100MG	N85328 001		SEP DISC
>D>	AB	200MG	N86998 001		SEP DISC
>A>	@	200MG	N86998 001		SEP DISC
>D>	AB	300MG	N85328 002		SEP DISC
>A>	@	300MG	N85328 002		SEP DISC
>D>	AB	450MG	N89131 001	JUN 25, 1986	SEP DISC
>A>	@	450MG	N89131 001	JUN 25, 1986	SEP DISC
THEOPHYLLINE					
AB	PLIVA	300MG	N89763 001	APR 30, 1990	AUG CRLD
UNI-DUR					
>D>	BC SCHERING	600MG	N89823 001	JAN 04, 1995	SEP DISC
>A>	@	600MG	N89823 001	JAN 04, 1995	SEP DISC

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION					
THIAMINE HCL					
	@ WYETH AYERST	100MG/ML	N80553 001		JUN DISC

THIETHYLPERAZINE MALEATE

SUPPOSITORY; RECTAL

TORECAN

@ NOVARTIS

10MG

N13247 001

JUN DISC

THIOTEPA

INJECTABLE; INJECTION

THIOPLEX

@ IMMUNEX

15MG/VIAL

N20058 001 DEC 22, 1994 JUL DISC

THIOTEPA

AP + GENZIA SICOR PHARMS

15MG/VIAL

N75730 001 APR 20, 2001 JUL CRLD

THIOTHIXENE

CAPSULE; ORAL

NAVANE

AB PFIZER

1MG

N16584 001

FEB CAHN

AB

2MG

N16584 002

FEB CAHN

AB +

5MG

N16584 003

FEB CAHN

AB

10MG

N16584 004

FEB CAHN

20MG

N16584 005

FEB CAHN

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

AA + PFIZER

EQ 5MG BASE/ML

N16758 001

FEB CAHN

INJECTABLE; INJECTION

@ PFIZER

EQ 2MG BASE/ML

N16904 001

FEB CAHN

+

EQ 10MG BASE/VIAL

N16904 002

FEB CAHN

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HCL

AB BARR

EQ 2MG BASE

N76371 001 APR 09, 2003 APR NEWA

AB

EQ 4MG BASE

N76371 002 APR 09, 2003 APR NEWA

>A>

AB CARACO

EQ 2MG BASE

N76416 001 SEP 29, 2003 SEP NEWA

>A>

AB

EQ 4MG BASE

N76416 002 SEP 29, 2003 SEP NEWA

AB MYLAN

EQ 2MG BASE

N76354 001 MAR 28, 2003 MAR NEWA

AB

EQ 4MG BASE

N76354 002 MAR 28, 2003 MAR NEWA

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

@ BAXTER HLTHCARE

EQ 10MG BASE/ML

N63113 001 APR 26, 1991 AUG CAHN

@

EQ 10MG BASE/ML

N63128 001 NOV 27, 1991 AUG CAHN

AP

EQ 40MG BASE/ML

N63117 001 APR 26, 1991 AUG CAHN

AP

EQ 40MG BASE/ML

N63118 001 JUL 29, 1991 AUG CAHN

@

EQ 40MG BASE/ML

N63127 001 NOV 27, 1991 AUG CAHN

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

@ CLONMEL HLTHCARE

500MG

N86926 001

JUL DISC

TOLBUTAMIDE SODIUM

INJECTABLE; INJECTION

ORINASE DIAGNOSTIC

@ PHARMACIA AND UPJOHN EQ 1GM BASE/VIAL

N12095 001

JUN DISC

TORSEMIDE

TABLET; ORAL

TORSEMIDE

AB PAR PHARM

5MG

N76226 001 MAY 27, 2003 MAY NEWA

AB

10MG

N76226 002 MAY 27, 2003 MAY NEWA

AB

20MG

N76226 003 MAY 27, 2003 MAY NEWA

AB

100MG

N76226 004 MAY 27, 2003 MAY NEWA

AB PLIVA PHARM IND

5MG

N76346 001 MAY 30, 2003 MAY NEWA

AB

10MG

N76346 002 MAY 30, 2003 MAY NEWA

AB

20MG

N76346 003 MAY 30, 2003 MAY NEWA

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HCL

AB IVAX PHARMS

50MG

N75963 001 JUL 03, 2002 MAR CAHN

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; NASAL

NASACORT

@ AVENTIS

0.055MG/INH

N19798 001 JUL 11, 1991 JUL DISC

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

AT ALTANA

0.025%

N40467 001 APR 21, 2003 APR NEWA

AT

0.1%

N40467 002 APR 21, 2003 APR NEWA

SPRAY, METERED; NASAL

TRI-NASAL

@ COLLEGIUM

0.05MG/SPRAY

N20120 001 FEB 04, 2000 JUL CAHN

TRICHLORMETHIAZIDE

TABLET; ORAL

METAHYDRIN

@ AVENTIS PHARMS

2MG

N12594 001 JUN 16, 1988 MAY DISC

@

4MG

N12594 002 JUN 16, 1988 MAY DISC

TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL

ARTANE

@ LEDERLE

2MG/5ML

N06773 009

JUN DISC

TRIHEXYPHENIDYL HCL

AA + PHARM VENTURES

2MG/5ML

N89514 001 APR 07, 1989 JUN CRLD

TABLET; ORAL

ARTANE

@ LEDERLE

2MG

N06773 005

JUN DISC

@

5MG

N06773 003

JUN DISC

TRIHEXYPHENIDYL HCL

AA + WATSON LABS

2MG

N84363 001

JUN CRLD

AA +

5MG

N84364 001

JUN CRLD

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE; ORAL

TIGAN

AB +	KING PHARMS	300MG	N17531 006	DEC 13, 2001	AUG	CFTG
	TRIMETHOBENZAMIDE HCL					
AB	AMIDE PHARM	300MG	N76546 001	AUG 20, 2003	AUG	NEWA
AB	MUTUAL PHARMA	300MG	N76570 001	AUG 28, 2003	AUG	NEWA

TRIMETHOPRIM

TABLET; ORAL

PROLOPRIM

@ MONARCH PHARMS

200MG

N17943 003 JUL 14, 1982 MAY DISC

TRIMETHOPRIM

+ TEVA

200MG

N71259 001 JUN 18, 1987 MAY CRLD

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM; VAGINAL

SULTRIN

@ ORTHO MCNEIL PHARM

3.7%;2.86%;3.42%

N05794 001 AUG DISC

UREA, C-13

FOR SOLUTION; ORAL

HELICOSOL

@ METABOLIC SOLUTIONS

125MG/VIAL

N21092 001 DEC 17, 1999 MAY DISC

PYLORI-CHEK BREATH TEST

@ DXS DEVICES

100MG/VIAL

N20900 001 FEB 04, 1999 MAR CAHN

VALPROATE SODIUM

INJECTABLE; INJECTION

VALPROATE SODIUM

AP	AM PHARM	EQ 100MG BASE/ML	N76539 001	JUN 26, 2003	JUN	NEWA
----	----------	------------------	------------	--------------	-----	------

VALSARTAN

TABLET; ORAL

DIOVAN

NOVARTIS

40MG

N21283 004 AUG 14, 2002 JUL NEWA

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION; ORAL

VANCOCIN HCL

+ LILLY

EQ 250MG BASE/5ML

N61667 002 JUL 13, 1983 JUN CTEC

VANCOLED

@ LEDERLE

EQ 250MG BASE/5ML

N63321 002 OCT 15, 1993 JUN DISC

INJECTABLE; INJECTION

AP +	BAXTER HLTHCARE	EQ 500MG BASE/VIAL	N62682 001	JUL 22, 1986	AUG	CAHN
AP +		EQ 1GM BASE/VIAL	N62682 002	MAR 30, 1988	AUG	CAHN
+		EQ 2GM BASE/VIAL	N62682 003	MAY 11, 1988	AUG	CAHN
AP +		EQ 5GM BASE/VIAL	N62682 004	MAY 11, 1988	AUG	CAHN
AP +		EQ 10GM BASE/VIAL	N62682 005	MAY 11, 1988	AUG	CAHN
	VANCOMYCIN HCL					
	@ BAXTER HLTHCARE	EQ 500MG BASE/VIAL	N62879 001	AUG 02, 1988	AUG	CAHN
	@	EQ 1GM BASE/VIAL	N62879 002	AUG 02, 1988	AUG	CAHN

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

BAYER PHARMS

2.5MG

N21400 003 AUG 19, 2003 AUG NEWA

5MG

N21400 001 AUG 19, 2003 AUG NEWA

10MG

N21400 002 AUG 19, 2003 AUG NEWA

+

20MG

N21400 004 AUG 19, 2003 AUG NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION

NORCURON

@ ORGANON

10MG/VIAL

N18776 002 APR 30, 1984 MAY DISC

VECURONIUM BROMIDE

AP BAXTER HLTHCARE

10MG/VIAL

N75218 001 AUG 23, 1999 AUG CAHN

AP

20MG/VIAL

N75218 002 AUG 23, 1999 AUG CAHN

AP

+ BEDFORD

10MG/VIAL

N75549 001 JUN 13, 2000 MAY CRLD

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

WYETH PHARMS INC

EQ 37.5MG BASE

N20699 001 OCT 20, 1997 MAR CAHN

EQ 75MG BASE

N20699 002 OCT 20, 1997 MAR CRLD

@

EQ 100MG BASE

N20699 003 OCT 20, 1997 MAR CAHN

+

EQ 150MG BASE

N20699 004 OCT 20, 1997 MAR CRLD

TABLET; ORAL

EFFEXOR

@ WYETH PHARMS INC

EQ 12.5MG BASE

N20151 001 DEC 28, 1993 MAR CAHN

EQ 25MG BASE

N20151 002 DEC 28, 1993 MAR CRLD

EQ 37.5MG BASE

N20151 006 DEC 28, 1993 MAR CAHN

EQ 50MG BASE

N20151 003 DEC 28, 1993 MAR CAHN

EQ 75MG BASE

N20151 004 DEC 28, 1993 MAR CAHN

+

EQ 100MG BASE

N20151 005 DEC 28, 1993 MAR CAHN

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL

VERAPAMIL HCL

@ CLONMEL HLTHCARE

80MG

N71880 001 APR 05, 1988 JUL DISC

@

120MG

N71881 001 APR 05, 1988 JUL DISC

VIDARABINE

OINTMENT; OPHTHALMIC

VIRA-A

@ PARKEDALE

3%

N50486 001 MAY DISC

VINCRIStINE SULFATE

INJECTABLE; INJECTION

VINCASAR PFS

AP GENsIA SICOR PHARMS

1MG/ML

N71426 001 JUL 17, 1987 JUL CAHN

VINCRIStINE SULFATE PFS

AP

SICOR PHARMS

1MG/ML

N75493 001 SEP 01, 1999 JUL CAHN

VINORELBINE TARTRATE

INJECTABLE; INJECTION

NAVELBINE

AP	+	GLAXOSMITHKLINE	EQ 10MG BASE/ML	N20388 001	DEC 23, 1994	FEB	CFTG
		VINORELBINE TARTRATE					
AP		ESI LEDERLE	EQ 10MG BASE/ML	N75992 001	JUN 10, 2003	JUN	NEWA
AP		GENSIA SICOR PHARMS	EQ 10MG BASE/ML	N76028 001	FEB 03, 2003	FEB	NEWA

XENON, XE-133

GAS; INHALATION

XENON XE 133

GEN ELECTRIC

		5-100 CI/CYLINDER	N17550 001			JUL	CPOT
		0.25-5 CI/AMP	N17550 003			JUL	CPOT

ZALEPLON

CAPSULE; ORAL

SONATA

JONES PHARMA

		5MG	N20859 001	AUG 13, 1999	JUN	CAHN
	+	10MG	N20859 002	AUG 13, 1999	JUN	CAHN

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

ZOMETA

	+	NOVARTIS	EQ 4MG BASE/5ML	N21223 002	MAR 07, 2003	MAR	NEWA
--	---	----------	-----------------	------------	--------------	-----	------

ZOLMITRIPTAN

SPRAY; NASAL

ZOMIG

>A>		ASTRAZENECA	5MG/SPRAY	N21450 004	SEP 30, 2003	SEP	NEWA
-----	--	-------------	-----------	------------	--------------	-----	------

ZONISAMIDE

CAPSULE; ORAL

ZONEGRAN

DAINIPPON

		25MG	N20789 003	AUG 22, 2003	AUG	NEWA
		50MG	N20789 002	AUG 22, 2003	AUG	NEWA

ACETAMINOPHEN

TABLET, EXTENDED RELEASE; ORAL
 TYLENOL (CAPLET)

+ MCNEIL CONS SPECLT 650MG

N19872 001 JUN 08, 1994 JUN CTNA

TYLENOL (GELTAB)

+ MCNEIL CONS SPECLT 650MG

N19872 002 JAN 11, 2001 JUN NEWA

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL

FOAMICON

NOVARTIS 80MG;20MG

N72687 001 JUN 28, 1989 MAR CAHN

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE

@ CENT PHARMS 8MG;120MG

N19428 001 AUG 02, 1988 MAR DISC

CIMETIDINE

TABLET; ORAL

CIMETIDINE

@ LEK PHARMS 100MG

N75122 001 JUN 19, 1998 MAR CAHN

200MG

N75122 002 JUN 19, 1998 MAR CAHN

EPINEPHRINE

AEROSOL, METERED; INHALATION

BRONKAID MIST

@ STERLING 0.25MG/INH

N16803 001 MAY DISC

FAMOTIDINE

TABLET; ORAL

PEPCID AC

>D> + MERCK 10MG

N20325 001 APR 28, 1995 SEP CRLD

>A> 10MG

N20325 001 APR 28, 1995 SEP CRLD

>A> + 20MG

N20325 002 SEP 23, 2003 SEP NEWA

PEPCID AC (GELTAB)

MERCK 10MG

N20902 001 AUG 05, 1999 AUG CTNA

TABLET, CHEWABLE; ORAL

FAMOTIDINE

PERRIGO 10MG

N75715 001 AUG 22, 2003 AUG NEWA

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

MUCINEX

ADAMS LABS 600MG

N21282 001 JUL 12, 2002 JAN CRLD

+ 1.2GM

N21282 002 DEC 18, 2002 JAN NEWA

IBUPROFEN

TABLET; ORAL

JUNIOR STRENGTH MOTRIN

MCNEIL 100MG

N20602 001 JUN 10, 1996 JUN CRLD

>A>

LOPERAMIDE HYDROCHLORIDE

TABLET; ORAL

LOPERAMIDE HCL

LNK

2MG

N76497 001 JUN 10, 2003 JUN NEWA

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET; ORAL

IMODIUM ADVANCED

+ MCNEIL CONS SPECLT

2MG;125MG

N21140 001 NOV 30, 2000 JAN CRLD

LORATADINE

SYRUP; ORAL

CLARITIN

+ SCHERING

1MG/ML

1MG/ML

N20641 002 NOV 27, 2002 APR CRLD

N20641 002 NOV 27, 2002 MAR NEWA

TABLET; ORAL

+ SCHERING

10MG

10MG

N19658 002 NOV 27, 2002 APR CRLD

N19658 002 NOV 27, 2002 MAR NEWA

LORATADINE

GENEVA PHARMS

10MG

GENPHARM

10MG

RANBAXY

10MG

N75209 001 JAN 21, 2003 JAN NEWA

N76154 001 AUG 20, 2003 AUG NEWA

N76134 001 AUG 18, 2003 AUG NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

ALAVERT

WYETH CONS

10MG

CLARITIN REDITABS

+ SCHERING

10MG

10MG

N21375 001 DEC 19, 2002 APR CRLD

N20704 002 NOV 27, 2002 APR CRLD

N20704 002 NOV 27, 2002 MAR NEWA

LORATADINE

IMPAX LABS

10MG

WYETH CONS

10MG

N76011 001 SEP 29, 2003 SEP NEWA

N75822 001 FEB 10, 2003 FEB NEWA

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARITIN-D

+ SCHERING

5MG;120MG

5MG;120MG

N19670 002 NOV 27, 2002 APR CRLD

N19670 002 NOV 27, 2002 MAR NEWA

CLARITIN-D 24 HOUR

+ SCHERING

10MG;240MG

10MG;240MG

N20470 002 NOV 27, 2002 APR CRLD

N20470 002 NOV 27, 2002 MAR NEWA

LORATADINE AND PSEUDOEPHEDRINE HCL

ANDRX PHARMS

10MG;240MG

LORATADINE AND PSEUDOEPHEDRINE SULFATE

IMPAX LABS

5MG;120MG

N75706 001 FEB 21, 2003 FEB NEWA

N76050 001 JAN 30, 2003 JAN NEWA

MICONAZOLE NITRATE

CREAM; TOPICAL, VAGINAL

MONISTAT 3 COMBINATION PACK

+ PERSONAL PRODS

2%,4%

MONISTAT 3 COMBINATION PACK (PREFILLED)

+ PERSONAL PRODS

2%,4%

N21261 003 JUN 17, 2003 JUN NEWA

N21261 001 FEB 02, 2001 JUN CTNA

>A>

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL EXTRA STRENGTH (FOR MEN)
MORTON GROVE 5%

N75438 001 FEB 27, 2003 FEB NEWA

NICOTINE POLACRILEX

TROCHE/LOZENGE; ORAL
COMMIT

>D> GLAXOSMITHKLINE CONS 2MG
>A> EQ 2MG BASE
>D> + 4MG
>A> + EQ 4MG BASE

N21330 001 OCT 31, 2002 SEP CPOT
N21330 001 OCT 31, 2002 SEP CPOT
N21330 002 OCT 31, 2002 SEP CPOT
N21330 002 OCT 31, 2002 SEP CPOT

OMEPRAZOLE MAGNESIUM

TABLET, DELAYED RELEASE; ORAL
PRILOSEC

+ ASTRAZENECA EQ 20MG BASE

N21229 001 JUN 20, 2003 JUN NEWA

PERMETHRIN

LOTION; TOPICAL
NIX

+ INSIGHT PHARMS 1%

N19918 001 MAY 02, 1990 MAR CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 9 SEPTEMBER '03

NO SEPTEMBER 2003 APPROVALS

**This data is provided to the Office of Generic Drugs from
the Office of Orphan Products Development and it is not edited prior to publication.**

**Orphan Products Designations and Approvals List
September 2003**

Generic Name/ Trade Name (if present):	Date Designated = DD Date Approved= MA	Indication Designated:	Sponsor and Address
(+/-)-7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid	DD: 3/31/2003 MA:	Prevention of serious adverse events associated with vascular leak syndrome caused by Interleukin-2 therapy	BioMedicines, Inc. 2000 Powell Street Suite 1640 Emeryville CA 94608
(R)-N-[2-(6-Chloro-methoxy-1H-indol-3-yl)propyl]acetamide	DD: 7/3/2003 MA:	Treatment of neuroleptic-induced tardive dyskinesia in schizophrenia patients	Phase 2 Discovery, Inc. 3130 Highland Ave. Third Floor Cincinnati OH 45219
1,1'-[1,4-phenylenebis(methylene)-bis-1,4,8,11-tetraazacyclotetradecan	DD: 7/10/2003 MA:	For combination use with filgrastim to improve the yield of progenitor cells in the apheresis product for subsequent stem cell transplantation following myelosuppressive or myeloablative	AnorMED Inc. 200-20353 64th Avenue Langley, BC, V2Y 1N5 CANADA
2',3',5'-tri-o-acetyluridine	DD: 1/13/2003 MA:	Treatment of mitochondrial disease	Repligen Corporation 41 Seyon Street Building 1, Suite 100 Waltham MA 02453
2-0-Butyryl-1-0-octyl-myo-inositol 3,4,5,6-tetrakisphosphate	DD: 8/15/2003 MA:	Treatment of cystic fibrosis	Inologic, Inc. 101 Elliott Ave., West Seattle WA 98119
4,5-dibromorhodamine 123 Theralux Irradiation Device	DD: 4/10/2003 MA:	Treatment of chronic myelogenous leukemia	Celmed BioSciences Inc. 2310 boul Alfred-Nobel 2310 boul Alfred-Nobel Saint-Laurent, Quebec Canada H4S 2A4

Orphan Products Designations and Approvals List September 2003

5,5',5"-[Phosphinothiolyldyne-tris(i mino-2,1-ethanediyl)]tris[5-methylc helidoninium]trihydroide hexahydrochloride	DD: 8/20/2003	Treatment of pancreatic cancer	Now Pharm AG 241, route d'Arlon
	MA:		L-1150 Luxembourg
a-(3-aminophthalimido) Actimid	DD: 1/15/2003	Treatment of multiple myeloma	Celgene Corporation
	MA:		7 Powder Horn Drive Warren NJ 07059
a-Galactosidase A Corporation Plant-Produced Human a-Glactosidase	DD: 1/21/2003	Treatment of Fabry's disease	Large Scale Biology
	MA:		3333 Vacaville Parkway Suite 1000 Vacaville CA 95688
alendronate Fosamax	DD: 3/31/2003	Treatment of osteogenesis imperfecta in pediatric patients 4 years of age and older	Merck & Co., Inc. 126 East Lincoln Ave. 126 East Lincoln Ave. Rahway NJ 07065-0900
	MA:		
alteplase University Activase University	DD: 1/27/2003	Treatment of intraventricular hemmorage associated with intracerebral hemmorrhage	Daniel F. Hanley, MD Johns Hopkins
	MA:		Johns Hopkins
Jefferson 1-109			600 N. Wolfe St.,
			Baltimore MD 21287
AMG 531 Drive 91320-1799	DD: 3/27/2003	Treatment of immune thrombocytopenic purpura.	Amgen, Inc. One Amgen Center
	MA:		Thousand Oaks CA
anti-CD23 IgG1, kappa monoclonal Inc. antibody	DD: 2/12/2003	Treatment of chronic lymphocytic leukemia	IDEC Pharmaceuticals,
	MA:		3030 Callan Road San Diego CA 92121

Orphan Products Designations and Approvals List September 2003

Anti-CEA Sheep-human chimeric monoclonal antibody labeled Court w/iodine-131 (KAb201)	DD: 5/21/2003 MA:	Treatment of pancreatic cancer	KS Biomedix Ltd Ground Floor, 1 Occam Surrey Research Park Guilford, Surrey, GU2
7HJ UK			
antisense 20-mer phosphorothioate oligonucleotide [complementary to the coding region of R2 component of the human ribonucleotide reductase mRNA] GTI-2040	DD: 3/12/2003 MA: MA:	Treatment for renal cell carcinoma	Lorus Therapeutics, Inc 2 Meridan Road Toronto, Ontario M9W427 CANADA
arsenic trioxide Trisenox	DD: 6/13/2003 MA:	Treatment of liver cancer	Cell Therapeutics, Inc. 501 Elliott Avenue West Suite 400 Seattle WA 98119
arsenic trioxide Trisenox	DD: 5/13/2003 MA:	Treatment of chronic lymphocytic leukemia	Cell Therapeutics, Inc. 501 Elliott avenue West 501 Elliott avenue West Suite 400 Seattle WA 98119
Atomoxetine hydrochloride STRATTERA	DD: 8/26/2003 MA:	Treatment of Tourette's Syndrome	ELI LILLY & Company Lilly Corporate Center Indianapolis IN 46285
bifidobacterium longum infantis Limited 35624	DD: 1/16/2003 MA:	Treatment of pediatric Crohn's disease	Alimentary Health Guardwell, Kinsale County Cork, Ireland
bortezomib Pharmaceuticals, Inc. VELCADE	DD: 1/15/2003 MA:5/13/2003	To treat multiple myeloma	Millennium 75 Sidney Street Cambridge MA 02139
Capsaicin Park	DD: 5/2/2003 MA:	Treatment of painful HIV-associated neuropathy	NeurogesX, Inc. San Carlos Business 981F Industrial Road San Carols CA 94070-
4117			

Orphan Products Designations and Approvals List September 2003

Carboxypeptidase G2 Suite 405	DD: 8/19/2003 MA:	Treatment of patients at risk of methotrexate toxicity	Protherics, Inc. 5214 Maryland Way, Brentwood TN 37027
cholic acid (3 alpha, 7 alpha, 12 alpha trihydroxy 5-beta cholanoic acid) Falkochol	DD: 7/18/2003 MA: MA:	Treatment of inborn errors of cholesterol and bile acid synthesis and metabolism	Dr. Falk Pharma GmbH Leinenweberstrasse 5 Postfach 6529 9041 Freiburg
GERMANY			
cinacalcet Drive 91320-1799	DD: 5/12/2003 MA:	Treatment of hypercalcemia in patients with parathyroid carcinoma	Amgen, Inc. One Amgen Center Thousand Oaks CA
Combretastatin A4 Phosphate	DD: 7/23/2003 MA: MA:	Treatment of anaplastic thyroid cancer, medullary thyroid cancer, and stage IV papillary or follicular thyroid cancer	OXiGENE, Inc 321 Arsenal Street Watertown MA 02472
conjugated bile acids COBARTin 4317	DD: 7/18/2003 MA:	Treatment of steatorrhea in patients with short bowel syndrome	Jarrow Formulas, Inc. 1824 S. Robertson Blvd. 1824 S. Robertson Blvd. Los Angeles CA 90035-
cultured, partially T-Cell depleted, Center allogenic thymic tissue for Allergy & transplantation	DD: 8/15/2003 MA:	As a therapy for primary immune deficiency resulting from athymia associated with complete DiGeorge Syndrome	Duke University Medical Division of Pediatric Immunology Erwin Road Durham NC 27710
debrase Debridase Floor	DD: 8/20/2003 MA:	Debridement of acute, deep dermal burns in hospitalized patients	MediWound, Ltd. 3, Azrieli Center 3, Azrieli Center Triangular Tower 45th Tel-Aviv 67023, Israel
Defibrotide (CO)	DD: 5/21/2003 MA:	For the treatment of hepatic veno-occlusive disease	Gentium SpA Piazza XX Settembre, 2 22079 Villa Guardia ITALY

Orphan Products Designations and Approvals List September 2003

Dehydroepiandrosterone (DHEA)	DD: 8/19/2003	Replacement therapy in individuals with adrenal insufficiency	Paladin Labs, Inc. 6111 Royalmount
Avenue Suite Fidelin Avenue Suite			6111 Royalmount
	MA:		Montreal, Quebec CANADA H4P 2T4
dextran 1	DD: 3/21/2003	Treatment of cystic fibrosis	BCY LifeSciences Inc. 160 Eglinton Ave. East Suite 600
	MA:		Toronto, Ontario M4P
3B5			
DHA-paclitaxel	DD: 5/1/2003	Treatment of adenocarcinoma of the stomach or lower esophagus	Protarga, Inc. 2200 Renaissance
Boulevard Taxoprexin Boulevard			2200 Renaissance
	MA:		Suite 450 King of Prussia PA
19406			
diferuloylmethane LLC	DD: 6/13/2003	Treatment of cystic fibrosis	Seer Pharmaceuticals, P. O. Box 138 Southport CT 06890
	MA:		
diphenylcyclophenone	DD: 6/13/2003	Treatment of chronic severe forms of alopecia areata (Alopecia Totalis	Lloyd E. King, Jr. 1900 Patterson Street Suite 104
	MA:		
	MA:	[AT]/Alopecia Universalis [AU])	Nashville TN 37203
eculizumab Pharmaceuticals, Inc.	DD: 8/20/2003	Treatment of paroxysmal nocturnal hemoglobinuria	Alexion 352 Knotter Drive Cheshire CT 06410
	MA:		
Erlotinib Hydrochloride Tarceva	DD: 7/18/2003	Treatment of malignant gliomas	Genentech, Inc 1 DNA Way South San Francisco CA
	MA:		
94080-4990			
Factor XIII [A2] homodimer, recombinant DNA origin East	DD: 5/21/2003	Treatment of congenital FXIII deficiency	ZymoGenetics, Inc. 1201 Eastlake Avenue
	MA:		Seattle WA 98102

Orphan Products Designations and Approvals List September 2003

ferric hexacyanoferrate (II) "Prussian Blue"	DD: 6/26/2003 MA:	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Degussa AG Weissfrauenstr.9 D-60287 Frankfurt GERMANY
HepeX-B Biopharmaceuticals, Ltd.	DD: 7/15/2003 MA: MA:	For the prevention of hepatitis B virus (HBV) reinfection in patients who have received a liver transplantation	XTL Kiryat Weizmann Science Park Bldg 3 Rehovot 76100 ISRAEL
Human Anti-tumor Necrosis factor alpha monoclonal antibody Parkway 1307	DD: 1/16/2003 MA:	Treatment of uveitis of the posterior segment of non-infectious etiology, and uveitis of the anterior segment of non-infectious etiology and refractory to conventional therapy	Centocor, Inc. 200 Great Valley Malvern PA 19355-
IDN 6556 Inc.	DD: 8/19/2003 MA:	Treatment of patients undergoing solid organ transplantation.	Idun Pharmaceuticals, 9380 Judicial drive San Diego CA 92121
infliximab Remicade Parkway 1307	DD: 5/21/2003 MA:	Treatment of chronic sarcoidosis	Centocor, Inc. 200 Great Valley Malvern PA 19355-
infliximab Remicade Parkway 1307	DD: 5/6/2003 MA:	Treatment of giant cell arteritis	Centocor, Inc. 200 Great Valley Malvern PA 19355-
INGN 201 Inc. ADVEXIN	DD: 1/27/2003 MA: MA:	Treatment of head and neck cancer	Introgen Therapeutics, 2250 Holcombe Blvd Houston TX 77030

Orphan Products Designations and Approvals List September 2003

iron(III)-hexacyanoferrate(II) Pharmzeutische KG Radiogardase-Cs / Antidotum Republic of	DD: 5/1/2003 MA: MA:	Treatment of patients with known or sususpected internal contamination with radioactive or non-radioactive cesium or thallium	Heyl Chemisch- Fabrik GMBH & Co, Goerzallee 253 Goerzallee 253 D-14167 Berlin, Federal Germany
Lactoferrin alpha	DD: 8/20/2003 MA:	For the treatment of graft versus host disease	Agennix, Inc. Greenway Plaza Suite 910 Houston TX 77046
Lactoferrin alpha	DD: 8/20/2003 MA:	For the prevention of graft-versus-host disease	Agennix, Inc. 8 Greenway Plaza Suite 910 Houston TX 77046
Mafosfamide (formerly Oncology)	DD: 1/21/2003 MA:	Treatment of neoplastic meningitis	Baxter Oncology GmbH ASTA Medica Daimlerstrasse 40 60314 frankfurt/Main Germany
MaxAdFVIII Corporation 1113	DD: 3/3/2003 MA:	Treatment of Hemophilia A	GenStar Therapeutics 10865 Altman Row Suite 200 San Diego CA 92121-
motexafin gadolinium Xcytrin 4521	DD: 1/27/2003 MA: MA:	For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors	Pharmacyclics, Inc. 999 East Arques Avenue 999 East Arques Avenue Sunnyvale CA 94085-
Mx-dnG1 or Regin-G retroviral Corporation REXIN-G 1803W	DD: 8/15/2003 MA:	Treatment of pancreatic cancer	Epeius Biotechnologies 345 Pioneer Drive, Glendale CA 91203

Orphan Products Designations and Approvals List September 2003

myristoylated recombinant SCR1-3 of human complement reseptor Pk, type I APT070 Saffron Walden,	DD: 5/21/2003 MA: MA:	Prevention of delayed graft function in solid organ transplant	Adprotech, Ltd. Chesterford Research Little Chesterford, Essex, CB10 1XK UK
niprisan Inc. Hemoxin Technology Center Building B, Suite 08901	DD: 8/15/2003 MA:	Treatment of sickle cell disease	Xechem International, New Brunswick 100 Jersey Avenue, 310 New Brunswick NJ
polyinosinic-polycytidilic acid NW Poly-ICLC NW 3450	DD: 3/3/2003 MA: MA:	Treatment of flavivirus infections including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever, Murray valley, and Banzai viruses	Ribopharm, Inc. 3203 Cleveland Ave., 3203 Cleveland Ave., Washington DC 20008-
Protaxel Court	DD: 5/21/2003 MA:	Treatment of ovarian cancer	Biophysica, Inc. 3333 North Torrey Pines Suite 100 La Jolla CA 92037
recombinant adeno-associated Technologies Corp. virus alpha 1-antitrypsin vector rAAV-AAT	DD: 1/27/2003 MA: MA:	Treatment of alpha 1-antitrypsin deficiency	Applied Genetic 12085 Research Drive Suite 110 Alachua FL 32615
recombinant inhibitor of human plasma kallikrein	DD: 2/4/2003 MA:	Treatment of angioedema	Dyax Corp 300 Technology Square Cambridge MA 02139

Orphan Products Designations and Approvals List September 2003

Recombinant T-cell receptor Square Road	DD: 5/2/2003 MA: MA:	Treatment of multiple sclerosis patients who are both HLA-DR2 positive and glycoprotein residues 35-55 autoreactive to myelin oligodendrocyte	Virogenomics, Inc. 9020 SW Washington Suite 380 Tigard, OR 97223-4332
repertaxin	DD: 1/27/2003 MA:	Prevention of delayed graft function in solid organ transplant	Dompe s.p.a. Via Campo di Pile 67100 - L'Aquila Italy
repository corticotropin or Pharmaceuticals, Inc. adrenocorticotrophic hormone H.P. Acthar Gel 1217	DD: 5/21/2003 MA: MA:	Treatment of infantile spasms	Questcor 3260 Whipple Road Union City CA 94587-
resiniferatoxin	DD: 5/13/2003 MA: DASS/PPCS/NIDCR/NIH	Treatment of intractable pain at end-stage disease	Andrew J. Mannes, Md Bldg 10/Rm 2N236 - 10 Convent Drive Bethesda MD 20892
ribavirin Road REBETOL Road	DD: 4/4/2003 MA:7/29/2003	Treatment of chronic hepatitis C in pediatric patients	Schering Corporation 2000 Galloping Hill 2000 Galloping Hill Kenilworth NJ 07033
SGN-30 (anti-CD30 mAb) Southeast	DD: 7/18/2003 MA:	Treatment of Hodgkin's disease	Seattle Genetics, Inc 21823 30th Drive, Bothell WA 98021
siplizumab Inc. Road	DD: 7/15/2003 MA:	Treatment of T-cell lymphomas	MedImmune Oncology, 35 W. Watkins Mill Gaithersburg Md 20878
sodium dichloroacetate	DD: 7/3/2003 MA: MA:	Use as an antidote in the management of systemic monochloroacetic acid poisoning	EBD Group 6120 Paseo del Norte Suite J2 Carlsbad CA 92009

Orphan Products Designations and Approvals List September 2003

Sodium pyruvate	DD: 3/31/2003 MA:	Treatment of cystic fibrosis	Cellular Sciences, Inc. 84 Park Avenue P. O. Box 968 Flemington NJ 08822
suberoylanilide hydroxamic acid Road 6717	DD: 6/12/2003 MA:	Treatment of multiple myeloma	Aton Pharma, Inc. 777 Old Saw Mill River Tarrytown NY 10591-
Tezacitabine 2916	DD: 1/27/2003 MA:	Treatment of adenocarcinoma of the esophagus and stomach	Chiron Corporation 4560 Horton Street Emeryville CA 94608-
Tinidazole Inc. 60004	DD: 8/20/2003 MA:	For the treatment of amebiasis	Presutti Laboratories, 1607 N. Douglas Avenue Arlington Heights IL
Tretinoin ATRA-IV	DD: 4/11/2003 MA:	Treatment of T-cell non-Hodgkin's lymphoma	Antigenics, Inc. 34 Commerce Way 34 Commerce Way Woburn MA 01801

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO SEPTEMBER 2003 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL./PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL. EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020977 001	ABACAVIR SULFATE; ZIAGEN	#5034394	DEC 18, 2011			
		#5034394*PED	JUN 18, 2012			
020978 001	ABACAVIR SULFATE; ZIAGEN	#5034394	DEC 18, 2011			
		#5034394*PED	JUN 18, 2012			
020213 001	ACETYLCOLINE CHLORIDE; MIOCHOL-E	#6261546	APR 29, 2019	U-506		
021478 001	ACYCLOVIR; ZOVIRAX	#4963555	OCT 16, 2007			
020899 001	ALBUMIN HUMAN; OPTISON	#5573751	APR 25, 2012			
		#5529766	JUN 25, 2013	U-505		
		#5558094	FEB 28, 2012	U-505		
020560 001	ALENDRONATE SODIUM; FOSAMAX	#5358941	DEC 02, 2012		I-309	SEP 29, 2003
		#4621077	AUG 06, 2007	U-114	PED	MAR 29, 2004
		#5681590	DEC 02, 2012			
		#5849726	JUN 06, 2015			
		#6008207	JUN 06, 2015	U-303		
		#6194004	DEC 02, 2012			
		#4621077*PED	FEB 06, 2008	U-114		
		#5358941*PED	JUN 02, 2013			
		#5681590*PED	JUN 02, 2013			
		#5849726*PED	DEC 06, 2015			
		#6008207*PED	DEC 06, 2015	U-303		
		#6090410*PED	JUN 02, 2013			
		#6194004*PED	JUN 02, 2013			
		#5358941	DEC 02, 2012			
		#4621077	AUG 06, 2007	U-114		
020560 002	ALENDRONATE SODIUM; FOSAMAX	#5681590	DEC 02, 2012			
		#5849726	JUN 06, 2015			
		#6008207	JUN 06, 2015	U-303		
		#6090410	DEC 02, 2012			
		#4621077*PED	FEB 06, 2008	U-114		
		#5358941*PED	JUN 02, 2013			
		#5681590*PED	JUN 02, 2013			
		#5849726*PED	DEC 06, 2015			
		#6008207*PED	JUN 06, 2015	U-303		
		#6090410*PED	JUN 02, 2013			
		#5358941	DEC 02, 2012			
		#4621077	AUG 06, 2007	U-114		
		#5681590	DEC 02, 2012			
		#5849726	JUN 06, 2015			
		#6008207	JUN 06, 2015	U-303		
		#6090410	DEC 02, 2012			
		#4621077*PED	FEB 06, 2008	U-114		
		#5358941*PED	JUN 02, 2013			
		#5681590*PED	JUN 02, 2013			
		#5849726*PED	DEC 06, 2015			
		#6008207*PED	DEC 06, 2015	U-303		
020560 003	ALENDRONATE SODIUM; FOSAMAX	#6090410*PED	JUN 02, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020560 004	ALENDRONATE SODIUM; FOSAMAX	#6015801	JUL 17, 2018	U-353	NS	OCT 20, 2003
		#4621077	AUG 06, 2007	U-114	D-61	OCT 20, 2003
		#5358941	DEC 02, 2012		D-62	OCT 20, 2003
		#5681590	DEC 02, 2012		PED	APR 20, 2004
		#5849726	JUN 06, 2015		PED	APR 20, 2004
		#6008207	JUN 06, 2015		PED	APR 20, 2004
		#6090410	DEC 02, 2012			
		#5994329	JUL 17, 2018			
		#6225294	JUL 17, 2018			
		#4621077*PED	FEB 06, 2008	U-114		
		#5358941*PED	JUN 02, 2013			
		#5681590*PED	JUN 02, 2013			
		#5849726*PED	DEC 16, 2015			
		#5994329*PED	JAN 17, 2019			
		#6008207*PED	DEC 06, 2015			
		#6015801*PED	JAN 17, 2019	U-353		
		#6090410*PED	JUN 02, 2013			
		#6225294*PED	JAN 17, 2019			
020560 005	ALENDRONATE SODIUM; FOSAMAX	#6015801	JUL 17, 2018	U-353	NS	OCT 20, 2003
		#4621077	AUG 06, 2007	U-114	D-61	OCT 20, 2003
		#5358941	DEC 02, 2012		D-62	OCT 20, 2003
		#5681590	DEC 02, 2012		PED	APR 20, 2004
		#5849726	JUN 06, 2015		PED	APR 20, 2004
		#5994329	JUL 17, 2018		PED	APR 20, 2004
		#6008207	JUN 06, 2015			
		#6090410	DEC 02, 2012			
		#6225294	JUL 17, 2018			
		#4621077*PED	FEB 06, 2008	U-114		
		#5358941*PED	JUN 02, 2013			
		#5681590*PED	JUN 02, 2013			
		#5849726*PED	DEC 06, 2015			
		#5994329*PED	JAN 17, 2019			
		#6008207*PED	DEC 06, 2015			
		#6015801*PED	JAN 17, 2019	U-353		
		#6090410*PED	JUN 02, 2013			
		#6225294*PED	JAN 17, 2019			
		#4661491	MAY 27, 2006		NCE	JUN 12, 2008
		#6149940	AUG 22, 2017			
021287 001	ALFUZOSIN HYDROCHLORIDE; UROXATRAL					
021434 001	ALPRAZOLAM; XANAX XR					
021434 002	ALPRAZOLAM; XANAX XR					
021434 003	ALPRAZOLAM; XANAX XR					
021434 004	ALPRAZOLAM; XANAX XR					
020221 002	AMIFOSTINE; ETHYOL					
020965 001	AMINOLEVULINIC ACID HYDROCHLORIDE; LEVULAN					
		#5424471	JUL 31, 2012			
		#5954703	OCT 31, 2017			
				U-289		
					NDF	JAN 17, 2006
					NDF	JAN 17, 2006
					NDF	JAN 17, 2006
					NDF	JAN 17, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/ PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020364 002	AMLODIPINE BESYLATE; LOTREL	#4410520	AUG 11, 2003			
		#4410520*PED	FEB 11, 2004			
020364 003	AMLODIPINE BESYLATE; LOTREL	#4410520	AUG 11, 2003			
		#4410520*PED	FEB 11, 2004			
020364 004	AMLODIPINE BESYLATE; LOTREL	#4410520	AUG 11, 2003			
		#4410520*PED	FEB 11, 2004			
020364 005	AMLODIPINE BESYLATE; LOTREL	#4410520	AUG 11, 2003		NS	JUN 20, 2005
		#4410520*PED	FEB 11, 2004		PED	DEC 20, 2005
021303 001	AMPHETAMINE ASPARTATE; ADDERALL XR 10	#6322819	OCT 21, 2018			
		#6605300	OCT 21, 2018			
021303 006	AMPHETAMINE ASPARTATE; ADDERALL XR 15	#6322819	OCT 21, 2018			
		#6605300	OCT 21, 2018			
021303 002	AMPHETAMINE ASPARTATE; ADDERALL XR 20	#6322819	OCT 21, 2018			
		#6605300	OCT 21, 2018			
021303 004	AMPHETAMINE ASPARTATE; ADDERALL XR 25	#6322819	OCT 21, 2018			
		#6605300	OCT 21, 2018			
021303 003	AMPHETAMINE ASPARTATE; ADDERALL XR 30	#6322819	OCT 21, 2018			
		#6605300	OCT 21, 2018			
021303 005	AMPHETAMINE ASPARTATE; ADDERALL XR 5	#6605300	OCT 21, 2018			
040422 005	AMPHETAMINE ASPARTATE; DEXTROAMP SACCHARATE				PC	SEP 15, 2003
040422 006	AMPHETAMINE ASPARTATE; DEXTROAMP SACCHARATE				PC	SEP 15, 2003
040422 007	AMPHETAMINE ASPARTATE; DEXTROAMP SACCHARATE				PC	SEP 15, 2003
021007 001	AMPRENAVIR; AGENERASE					
021549 001	APREPITANT; EMEND			U-257	NCE	MAR 26, 2008
021549 002	APREPITANT; EMEND					
		#5723490	MAR 03, 2015			
		#5719147	JUN 29, 2012			
		#5538982	JUL 23, 2013			
		#6048859	JUN 29, 2012			
		#6096742	JUL 01, 2018			
		#6235735	JUN 29, 2012			
		#5719147	JUN 29, 2012			
		#5538982	JUL 23, 2013			
		#6048859	JUN 29, 2012			
		#6096742	JUL 01, 2018			
		#6235735	JUN 29, 2012			
		#4734416	MAR 29, 2005		I-401	AUG 28, 2006
		#5006528	OCT 20, 2009		I-401	AUG 28, 2006
		#4734416	MAR 29, 2005		I-401	AUG 28, 2006
		#5006528	OCT 20, 2009		I-401	AUG 28, 2006
		#4734416	MAR 29, 2005		I-401	AUG 28, 2006
		#5006528	OCT 20, 2009		I-401	AUG 28, 2006
		#4734416	MAR 29, 2005		I-401	AUG 28, 2006
		#5006528	OCT 20, 2009		I-401	AUG 28, 2006
		#4734416	MAR 29, 2005		I-401	AUG 28, 2006
		#5006528	OCT 20, 2009		I-401	AUG 28, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL. EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021436 006	ARIPRAZOLE;ABILIFY	#4734416	MAR 29, 2005		I-401	AUG 28, 2006
		#5006528	OCT 20, 2009			
021387 001	ASPIRIN;PRAVIGARD PAC (COPAC)	#4346227	OCT 20, 2005			
		#4346227*PED	APR 20, 2006			
		#5030447	JUL 09, 2008			
		#5030447*PED	JAN 09, 2009			
		#5180589	JUL 09, 2008			
		#5180589*PED	JAN 09, 2009			
		#5622985	APR 22, 2014	U-335		
021387 002	ASPIRIN;PRAVIGARD PAC (COPAC)	#5622985*PED	OCT 22, 2014	U-335		
		#4346227	OCT 20, 2005			
		#4346227*PED	APR 20, 2006			
		#5030447	JUL 09, 2008			
		#5030447*PED	JAN 09, 2009			
		#5622985	APR 22, 2014	U-335		
021387 003	ASPIRIN;PRAVIGARD PAC (COPAC)	#5622985*PED	OCT 22, 2014	U-335		
		#4346227	OCT 20, 2005			
		#4346227*PED	APR 20, 2006			
		#5030447	JUL 09, 2008			
		#5030447*PED	JAN 09, 2009			
		#5180589	JUL 09, 2008			
		#5180589*PED	JAN 09, 2009			
		#5622985	APR 22, 2014	U-335		
021387 004	ASPIRIN;PRAVIGARD PAC (COPAC)	#5622985*PED	OCT 22, 2014	U-335		
		#4346227	OCT 20, 2005			
		#4346227*PED	APR 20, 2006			
		#5030447	JUL 09, 2008			
		#5030447*PED	JAN 09, 2009			
		#5180589	JUL 09, 2008			
		#5180589*PED	JAN 09, 2009			
		#5622985	APR 22, 2014	U-335		
021387 005	ASPIRIN;PRAVIGARD PAC (COPAC)	#5622985*PED	OCT 22, 2014	U-335		
		#4346227	OCT 20, 2005			
		#4346227*PED	APR 20, 2006			
		#5030447	JUL 09, 2008			
		#5030447*PED	JAN 09, 2009			
		#5180589	JUL 09, 2008			
		#5180589*PED	JAN 09, 2009			
		#5622985	APR 22, 2014	U-335		
021387 006	ASPIRIN;PRAVIGARD PAC (COPAC)	#5622985*PED	OCT 22, 2014	U-335		
		#4346227	OCT 20, 2005			
		#4346227*PED	APR 20, 2006			
		#5030447	JUL 09, 2008			
		#5030447*PED	JAN 09, 2009			
		#5180589	JUL 09, 2008			
		#5180589*PED	JAN 09, 2009			
		#5622985	APR 22, 2014	U-335		
		#5622985*PED	OCT 22, 2014	U-335		
		#4346227	OCT 20, 2005			
		#4346227*PED	APR 20, 2006			
		#5030447	JUL 09, 2008			
		#5030447*PED	JAN 09, 2009			
		#5180589	JUL 09, 2008			
		#5180589*PED	JAN 09, 2009			
		#5622985	APR 22, 2014	U-335		
		#5622985*PED	OCT 22, 2014	U-335		
		#4346227	OCT 20, 2005			
		#4346227*PED	APR 20, 2006			
		#5030447	JUL 09, 2008			
		#5030447*PED	JAN 09, 2009			
		#5180589	JUL 09, 2008			
		#5180589*PED	JAN 09, 2009			
		#5622985	APR 22, 2014	U-335		
		#5622985*PED	OCT 22, 2014	U-335		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL. EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021567 001	ATAZANAVIR SULFATE; REYATAZ	#5849911	APR 09, 2017		NCE	JUN 20, 2008
		#6087383	DEC 21, 2018			
021567 002	ATAZANAVIR SULFATE; REYATAZ	#5849911	APR 09, 2017		NCE	JUN 20, 2008
		#6087383	DEC 21, 2018			
021567 003	ATAZANAVIR SULFATE; REYATAZ	#5849911	APR 09, 2017		NCE	JUN 20, 2008
		#6087383	DEC 21, 2018			
021411 001	ATOMOXETINE HYDROCHLORIDE; STRATTERA	#5658590	JAN 11, 2015	U-494	NCE	NOV 26, 2007
		#5658590*PED	JUL 11, 2015	U-494	PED	MAY 26, 2008
021411 002	ATOMOXETINE HYDROCHLORIDE; STRATTERA	#5658590	JAN 11, 2015	U-494	NCE	NOV 26, 2007
		#5658590*PED	JUL 11, 2015	U-494	PED	MAY 26, 2008
021411 003	ATOMOXETINE HYDROCHLORIDE; STRATTERA	#5658590	JAN 11, 2015	U-494	NCE	NOV 26, 2007
		#5658590*PED	JUL 11, 2015	U-494	PED	MAY 26, 2008
021411 004	ATOMOXETINE HYDROCHLORIDE; STRATTERA	#5658590	JAN 11, 2015	U-494	NCE	NOV 26, 2007
		#5658590*PED	JUL 11, 2015	U-494	PED	MAY 26, 2008
021411 005	ATOMOXETINE HYDROCHLORIDE; STRATTERA	#5658590	JAN 11, 2015	U-494	NCE	NOV 26, 2007
		#5658590*PED	JUL 11, 2015	U-494	PED	MAY 26, 2008
021411 006	ATOMOXETINE HYDROCHLORIDE; STRATTERA	#5658590	JAN 11, 2015	U-494	NCE	NOV 26, 2007
		#5658590*PED	JUL 11, 2015	U-494	PED	MAY 26, 2008
021078 001	ATOVAQUONE; MALARONE	#6166046	NOV 25, 2013	U-406	NC	JUL 14, 2003
		#5053432	OCT 01, 2008		PED	JAN 14, 2004
		#6291488	NOV 25, 2013			
		#5053432*PED	APR 01, 2009			
		#6166046*PED	MAY 25, 2014			
		#6291488*PED	MAY 25, 2014			
021078 002	ATOVAQUONE; MALARONE PEDIATRIC	#6166046	NOV 25, 2013		NC	JUL 14, 2003
		#5053432	OCT 01, 2008		PED	JAN 14, 2004
		#6291488	NOV 25, 2013	U-406		
		#5053432*PED	APR 01, 2009			
		#6166046*PED	MAY 25, 2014			
		#6291488*PED	MAY 25, 2014			
020259 001	ATOVAQUONE; MEPRON	#4981874	AUG 15, 2009	U-69		
		#5053432	OCT 01, 2008			
		#5053432*PED	APR 01, 2009			
		#4981874*PED	FEB 15, 2010			
020500 001	ATOVAQUONE; MEPRON	#4981874	AUG 15, 2009	U-69		
		#5053432	OCT 01, 2008	U-69	ODE	JAN 05, 2006
		#5053432*PED	APR 01, 2009		PED	JUL 05, 2006
		#4981874*PED	FEB 15, 2010			
021470 001	AZELAIC ACID; FINACEA	#6534070	NOV 18, 2018			
019851 001	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	#4410520	AUG 11, 2003			
		#4410520*PED	FEB 11, 2004			
019851 002	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	#4410520	AUG 11, 2003			
		#4410520*PED	FEB 11, 2004			
019851 003	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	#4410520	AUG 11, 2003			
		#4410520*PED	FEB 11, 2004			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021485 001	CARBIDOPA; STALEVO 50	#5446194 #5135950 #4963590 #6500867 #5112861 #4657927 #4657927 #4789724 #4757128	AUG 29, 2012 OCT 31, 2010 NOV 27, 2007 JUN 29, 2020 MAY 12, 2009 APR 14, 2004 APR 14, 2004 APR 14, 2004 AUG 01, 2006 AUG 01, 2006	U-175 U-175 U-175	NCE	OCT 19, 2004
020452 001	CARBOPLATIN; PARAPLATIN					
020452 002	CARBOPLATIN; PARAPLATIN					
020452 003	CARBOPLATIN; PARAPLATIN					
020637 001	CARMUSTINE; GLIADEL					
020297 001	CARVEDILOL; COREG				I-382	FEB 25, 2006
020297 002	CARVEDILOL; COREG				I-388	MAR 27, 2006
020297 003	CARVEDILOL; COREG				I-388	MAR 27, 2006
020297 004	CARVEDILOL; COREG				I-388	MAR 27, 2006
021227 001	CASPOFUNGIN ACETATE; CANCIDAS				I-399	JAN 07, 2006
021227 002	CASPOFUNGIN ACETATE; CANCIDAS				I-399	JAN 07, 2006
021150 001	CETIRIZINE HYDROCHLORIDE; ZYRTEC-D 12 HOUR	#4525358 #4525358*PED #6469009 #6489329 #5002769 #5023082	JUN 25, 2007 DEC 25, 2007 JUL 13, 2019 APR 08, 2016 MAR 16, 2006 MAR 30, 2005	U-295 U-295 U-295		
020774 001	CHLORHEXIDINE GLUCONATE; PERIOCHIP					
021159 001	CYCLOPIROX; LOPROX					
021473 001	CIPROFLOXACIN; CIPRO XR					
021473 002	CIPROFLOXACIN; CIPRO XR					
021537 001	CIPROFLOXACIN; CIPRODEX					
>ADD>						
020822 004	CITALOPRAM HYDROBROMIDE; CELEXA	#4670444	DEC 09, 2003		NDF	FEB 28, 2006
021535 001	CLOBETASOL PROPIONATE; CLOBEX	#6359016	AUG 10, 2020		NDF	DEC 13, 2005
020839 001	CLOPIDOGREL BISULFATE; PLAVIX	#4844902	FEB 11, 2008		NDF	DEC 13, 2005
019758 001	CLOZAPINE; CLOZARIL	#6284804	AUG 10, 2020		NC	JUL 18, 2006
019758 002	CLOZAPINE; CLOZARIL					
021141 001	COLESEVELAM HYDROCHLORIDE; WELCHOL					
021176 001	COLESEVELAM HYDROCHLORIDE; WELCHOL					
017821 001	CYCLOBENZAPRINE HYDROCHLORIDE; FLEXERIL					
020705 002	DELAVIRDINE MESYLATE; RESCRIPTOR					
021271 001	DESTURDIN; IPRIVASK	#6066678 #6066678	JUN 10, 2014 JUN 10, 2014	U-323 U-323	I-380 I-380	DEC 18, 2005 DEC 18, 2005
021165 001	DESLOMATADINE; CLARINEX	#5563142 #6177101 #4745177 #4801576 #5733874 #4659716 #4863931 #4804666 #5595997 #6100274 #4659716*PED #4804666*PED #4863931*PED #5595997*PED #6100274*PED	OCT 08, 2013 JUN 11, 2018 MAY 17, 2005 JAN 31, 2006 MAR 31, 2015 APR 21, 2004 SEP 15, 2008 FEB 14, 2006 DEC 30, 2014 JUL 07, 2019 OCT 21, 2004 AUG 14, 2006 MAR 15, 2009 JUN 30, 2015 JAN 07, 2020	U-427 U-428 U-429 U-427 U-428 U-428 U-429	NCE PED	DEC 21, 2006 JUN 21, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>						
020796 001	ENTACAPONE; COMTAN	6599530	SEP 14, 2018			
021437 001	EPLERENONE; INSPRA	#6534093	DEC 08, 2019	U-3		
021437 002	EPLERENONE; INSPRA	#6534093	DEC 08, 2019	U-3		
021437 003	EPLERENONE; INSPRA	#6534093	DEC 08, 2019	U-3		
021365 001	ESCITALOPRAM OXALATE; LEXAPRO	#RE34712	JUN 08, 2009			
		#RE34712*PED	DEC 08, 2009			
		#4593119	JUN 03, 2003			
019386 002	ESMOLOL HYDROCHLORIDE; BREVIBLOC	#5017609	MAY 21, 2008			
		5017609*PED	NOV 21, 2008			
		4593119*PED	DEC 03, 2003			
019386 003	ESMOLOL HYDROCHLORIDE; BREVIBLOC	#5017609	MAY 21, 2008			
		#4593119	JUN 03, 2003			
		5017609*PED	NOV 21, 2008			
		4593119*PED	DEC 03, 2003			
019386 004	ESMOLOL HYDROCHLORIDE; BREVIBLOC	#6528540	JAN 12, 2021			
		#4593119	JUN 03, 2003			
		#6310094	JAN 12, 2021			
		6528540*PED	JUL 12, 2021			
		6310094*PED	JUL 12, 2021			
		4593119*PED	DEC 03, 2003			
019386 006	ESMOLOL HYDROCHLORIDE; BREVIBLOC	#6528540	JAN 12, 2021			
		#4593119	JUN 03, 2003			
		#6310094	JAN 12, 2021			
		6528540*PED	JUL 12, 2021			
		6310094*PED	JUL 12, 2021			
		4593119*PED	DEC 03, 2003			
019386 007	ESMOLOL HYDROCHLORIDE; BREVIBLOC	#4593119	JUN 03, 2003			
		#6310094	JAN 12, 2021			
		#6528540	JAN 12, 2021			
		6528540*PED	JUL 12, 2021			
		6310094*PED	JUL 12, 2021			
		4593119*PED	DEC 03, 2003			
019386 005	ESMOLOL HYDROCHLORIDE; BREVIBLOC DOUBLE STR	#6528540	JAN 12, 2021			
		#4593119	JUN 03, 2003			
		#6310094	JAN 12, 2021			
		6528540*PED	JUL 12, 2021			
		6310094*PED	JUL 12, 2021			
		4593119*PED	DEC 03, 2003			
021367 001	ESTRADIOL ACETATE; FEMRING	#5855906	DEC 19, 2015	U-508	NP	MAR 20, 2006
021367 002	ESTRADIOL ACETATE; FEMRING	#5855906	DEC 19, 2015	U-508	NP	MAR 20, 2006
020375 005	ESTRADIOL; CLIMARA	#5223261	JUN 29, 2010			
020375 006	ESTRADIOL; CLIMARA	#5223261	JUN 29, 2010			
004782 003	ESTROGENS, CONJUGATED; PREMARIN	#5223261	JUN 29, 2010			
004782 006	ESTROGENS, CONJUGATED; PREMARIN	#5223261	JUN 29, 2010			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020527 002	ESTROGENS, CONJUGATED;PREMPHASE 14/14	#RE36247	MAY 02, 2006			
020527 001	ESTROGENS, CONJUGATED;PREMPRO	#5547948	JAN 17, 2015		D-79	MAR 12, 2006
020527 003	ESTROGENS, CONJUGATED;PREMPRO	#5210081	FEB 26, 2012		D-79	MAR 12, 2006
020527 004	ESTROGENS, CONJUGATED;PREMPRO	#RE36247	FEB 26, 2012		D-81	JUN 04, 2006
020527 005	ESTROGENS, CONJUGATED;PREMPRO	#5547948	MAY 02, 2006		NS	JUN 04, 2006
021180 001	ETHINYL ESTRADIOL;ORTHO EVRA	#5876746	JAN 17, 2015	U-514	D-81	JUN 04, 2006
021544 001	ETHINYL ESTRADIOL;SEASONALE	#5972377	JUN 07, 2015	U-514		
021203 001	FENOFIBRATE;TRICOR	#6589552	JAN 09, 2018		NP	SEP 05, 2006
021203 003	FENOFIBRATE;TRICOR	#6589552	JAN 09, 2018			
020747 001	FENTANYL CITRATE;ACTIQ	#4863737	SEP 05, 2006			
020747 002	FENTANYL CITRATE;ACTIQ	#5785989	SEP 05, 2006			
020747 003	FENTANYL CITRATE;ACTIQ	#4863737	SEP 05, 2006			
020747 004	FENTANYL CITRATE;ACTIQ	#5785989	SEP 05, 2006			
020747 005	FENTANYL CITRATE;ACTIQ	#4863737	SEP 05, 2006			
020747 006	FENTANYL CITRATE;ACTIQ	#5785989	SEP 05, 2006			
019813 001	FENTANYL;DURAGESIC	#4863737	SEP 05, 2006			
019813 002	FENTANYL;DURAGESIC	#4588580	JUL 23, 2004	U-43	NPP	MAY 20, 2006
019813 003	FENTANYL;DURAGESIC	#4588580*PED	JAN 23, 2005	U-43	PED	NOV 20, 2006
019813 004	FENTANYL;DURAGESIC	#4588580*PED	JAN 23, 2005	U-43	PED	MAY 20, 2006
020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	#4588580*PED	JUL 23, 2004	U-43	NPP	MAY 20, 2006
		#5578610	JAN 23, 2005	U-43	PED	NOV 20, 2006
		#5855912	NOV 26, 2013	U-192	M-25	MAY 12, 2006
		#5738872	FEB 28, 2015		PED	NOV 12, 2006
		#5932247	FEB 28, 2015			
		#6037353	MAR 14, 2017	U-138		
		#6113942	FEB 28, 2015			
		#6187791	MAY 11, 2012	U-138		
		#6399632	MAY 11, 2012	U-468		
		#5578610*PED	MAY 26, 2014	U-192		
		#5738872*PED	AUG 28, 2015			
		#5855912*PED	AUG 28, 2015			
		#5932247*PED	AUG 28, 2015			
		#6037353*PED	SEP 14, 2017	U-138		
		#6113942*PED	AUG 28, 2015			
		#6187791*PED	NOV 11, 2012	U-138		
		#6399632*PED	NOV 11, 2012	U-468		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020872 001	FEXOFENADINE HYDROCHLORIDE; ALLEGRA	#5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
		#5932247	FEB 28, 2015		PED	AUG 25, 2003
		#5855912	FEB 28, 2015		M-25	MAY 12, 2006
		#6037353	MAR 14, 2017		PED	NOV 12, 2006
		#6113942	FEB 28, 2015			
		#6187791	MAY 11, 2012			
		#6399632	MAY 11, 2012			
		#5578610*PED	MAY 26, 2014			
		#5855912*PED	AUG 28, 2015			
		#5932247*PED	AUG 28, 2015			
		#6037353*PED	SEP 14, 2017			
		#6113942*PED	AUG 28, 2015			
		#6187791*PED	NOV 11, 2012			
		#6399632*PED	NOV 11, 2012			
020872 002	FEXOFENADINE HYDROCHLORIDE; ALLEGRA	#5578610	NOV 26, 2013	U-138	NDF	FEB 25, 2003
		#5932247	FEB 28, 2015		PED	AUG 25, 2003
		#5855912	FEB 28, 2015		M-25	MAY 12, 2006
		#6037353	MAR 14, 2017		PED	NOV 12, 2006
		#6113942	FEB 28, 2015			
		#6187791	MAY 11, 2012			
		#6399632	MAY 11, 2012			
		#5578610*PED	MAY 26, 2014			
		#5855912*PED	AUG 28, 2015			
		#5932247*PED	AUG 28, 2015			
		#6037353*PED	SEP 14, 2017			
		#6113942*PED	AUG 28, 2015			
		#6187791*PED	NOV 11, 2012			
		#6399632*PED	NOV 11, 2012			
020872 004	FEXOFENADINE HYDROCHLORIDE; ALLEGRA	#5578610	NOV 26, 2013	U-138	NDF	FEB 25, 2003
		#5932247	FEB 28, 2015		PED	AUG 25, 2003
		#5855912	FEB 28, 2015		M-25	MAY 12, 2006
		#6037353	MAR 14, 2017		PED	NOV 12, 2006
		#6113942	FEB 28, 2015			
		#6187791	MAY 11, 2012			
		#6399632	MAY 11, 2012			
		#5578610*PED	MAY 26, 2014			
		#5855912*PED	AUG 28, 2015			
		#5932247*PED	AUG 28, 2015			
		#6037353*PED	SEP 14, 2017			
		#6113942*PED	AUG 28, 2015			
		#6187791*PED	NOV 11, 2012			
		#6399632*PED	NOV 11, 2012			
020786 001	FEXOFENADINE HYDROCHLORIDE; ALLEGRA-D	#5578610	NOV 26, 2013	U-138	M-25	MAY 12, 2006
		#5932247	FEB 28, 2015		PED	NOV 12, 2006
		#5855912	FEB 28, 2015			
		#6037353	MAR 14, 2017			
		#6113942	FEB 28, 2015			
		#6187791	MAY 11, 2012			
		#6399632	MAY 11, 2012			
		#5578610*PED	MAY 26, 2014			
		#5855912*PED	AUG 28, 2015			
		#5932247*PED	AUG 28, 2015			
		#6037353*PED	SEP 14, 2017			
		#6113942*PED	AUG 28, 2015			
		#6187791*PED	NOV 11, 2012			
		#6399632*PED	NOV 11, 2012			

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 # represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/ PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020180 001	FINASTERIDE; PROSCAR	#6187791*PED	NOV 11, 2012	U-138	NPP	JAN 03, 2006
020038 001	FLUDARABINE PHOSPHATE; FLUDARA	#6399632*PED	NOV 11, 2012	U-468	PED	JUL 03, 2006
020101 001	FLUOXETINE HYDROCHLORIDE; PROZAC	#6046183	MAR 20, 2011		NPP	JAN 03, 2006
020974 001	FLUOXETINE HYDROCHLORIDE; PROZAC	#4357324	FEB 24, 2003		PED	JUL 03, 2006
020974 002	FLUOXETINE HYDROCHLORIDE; PROZAC	#4357324*PED	AUG 24, 2003		NPP	JAN 03, 2006
021077 001	FLUTICASON PROPIONATE; ADVAIR DISKUS 100/50	#4335121	NOV 14, 2003		PED	JUL 03, 2006
		#5270305	SEP 07, 2010	U-387	NC	AUG 24, 2003
		#4992474	FEB 12, 2008	U-211		
		#5225445	FEB 12, 2008	U-211		
		#5126375	FEB 12, 2008			
		#5290815	MAR 01, 2011	U-386		
		#4335121*PED	MAY 14, 2004			
021077 002	FLUTICASON PROPIONATE; ADVAIR DISKUS 250/50	#4335121	NOV 14, 2003		NC	AUG 24, 2003
		#5270305	SEP 07, 2010	U-387		
		#4992474	FEB 12, 2008	U-211		
		#5225445	FEB 12, 2008	U-211		
		#5126375	FEB 12, 2008			
		#5290815	MAR 01, 2011	U-386		
		#4335121*PED	MAY 14, 2004			
021077 003	FLUTICASON PROPIONATE; ADVAIR DISKUS 500/50	#4335121	NOV 14, 2003		NC	AUG 24, 2003
		#5270305	SEP 07, 2010	U-387		
		#4992474	FEB 12, 2008	U-211		
		#5225445	FEB 12, 2008	U-211		
		#5126375	FEB 12, 2008			
		#5290815	MAR 01, 2011	U-386		
		#4335121*PED	MAY 14, 2004			
019957 001	FLUTICASON PROPIONATE; CUTIVATE	#4335121	NOV 14, 2003			
		#5270305	SEP 07, 2010	U-387		
		#4992474	FEB 12, 2008	U-211		
		#5225445	FEB 12, 2008	U-211		
		#5126375	FEB 12, 2008			
		#5290815	MAR 01, 2011	U-386		
		#4335121*PED	MAY 14, 2004			
019958 001	FLUTICASON PROPIONATE; CUTIVATE	#4335121	NOV 14, 2003			
		#5270305	SEP 07, 2010	U-387		
		#4992474	FEB 12, 2008	U-211		
		#5225445	FEB 12, 2008	U-211		
		#5126375	FEB 12, 2008			
		#5290815	MAR 01, 2011	U-386		
		#4335121*PED	MAY 14, 2004			
020121 001	FLUTICASON PROPIONATE; FLONASE	#4335121	NOV 14, 2003			
		#5270305	SEP 07, 2010	U-387		
		#4992474	FEB 12, 2008	U-211		
		#5225445	FEB 12, 2008	U-211		
		#5126375	FEB 12, 2008			
		#5290815	MAR 01, 2011	U-386		
		#4335121*PED	MAY 14, 2004			
020548 001	FLUTICASON PROPIONATE; FLOVENT	#4335121	NOV 14, 2003			
		#5270305	SEP 07, 2010	U-387		
		#4992474	FEB 12, 2008	U-211		
		#5225445	FEB 12, 2008	U-211		
		#5126375	FEB 12, 2008			
		#5290815	MAR 01, 2011	U-386		
		#4335121*PED	MAY 14, 2004			
020548 002	FLUTICASON PROPIONATE; FLOVENT	#4335121	NOV 14, 2003			
		#5270305	SEP 07, 2010	U-387		
		#4992474	FEB 12, 2008	U-211		
		#5225445	FEB 12, 2008	U-211		
		#5126375	FEB 12, 2008			
		#5290815	MAR 01, 2011	U-386		
		#4335121*PED	MAY 14, 2004			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA *PED and PED represent Pediatric Exclusivity

represents patent information submitted prior to 08/18/03

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020548 003	FLUTICASONE PROPIONATE; FLOVENT	#4335121	NOV 14, 2003			
		#4335121*PED	MAY 14, 2004			
020549 001	FLUTICASONE PROPIONATE; FLOVENT	#4335121	NOV 14, 2003	U-409		
		#4335121*PED	MAY 14, 2004	U-409		
020549 002	FLUTICASONE PROPIONATE; FLOVENT	#4335121	NOV 14, 2003	U-409		
		#4335121*PED	MAY 14, 2004	U-409		
020549 003	FLUTICASONE PROPIONATE; FLOVENT	#4335121	NOV 14, 2003	U-409		
		#4335121*PED	MAY 14, 2004	U-409		
020833 001	FLUTICASONE PROPIONATE; FLOVENT DISKUS 50	#4335121	NOV 14, 2003	U-409		
		#4335121*PED	MAY 14, 2004	U-409		
020833 002	FLUTICASONE PROPIONATE; FLOVENT DISKUS 100	#4335121	NOV 14, 2003	U-409		
		#4335121*PED	MAY 14, 2004	U-409		
020833 003	FLUTICASONE PROPIONATE; FLOVENT DISKUS 250	#4335121	NOV 14, 2003	U-409		
		#4335121*PED	MAY 14, 2004	U-409		
020261 001	FLUVASTATIN SODIUM; LESCOL	#5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
		#5354772	OCT 11, 2011	U-413		
020261 002	FLUVASTATIN SODIUM; LESCOL	#5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
		#5354772	OCT 11, 2011	U-413		
021192 001	FLUVASTATIN SODIUM; LESCOL XL	#5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
		#5354772	OCT 11, 2011	U-109		
020961 001	FOMIVIRSEN SODIUM; VITRAVENE PRESERVATI	#5442049	AUG 15, 2012	U-522		
		#5595978	AUG 15, 2012	U-522		
		#4689320	OCT 15, 2004	U-522		
		#5264423	NOV 23, 2010	U-522		
		#5276019	JAN 04, 2011	U-522		
		#6488027	MAR 08, 2019			
021345 001	FONDAPARINUX SODIUM; ARIXTRA	#4337201	DEC 04, 2002		I-397	JUN 17, 2006
020831 001	FORMOTEROL FUMARATE; FORADIL	#5006344	JUL 10, 2009		I-342	SEP 25, 2004
		#5006344*PED	JAN 10, 2010		NPP	JUN 27, 2006
019915 002	FOSINOPRIL SODIUM; MONOPRIL	#4337201	JUN 04, 2003		NPP	MAY 27, 2006
		#4337201*PED	DEC 04, 2002		PED	NOV 27, 2006
		#5006344	JUL 10, 2009			
		#5006344*PED	JAN 10, 2010			
019915 003	FOSINOPRIL SODIUM; MONOPRIL	#4337201	JUN 04, 2003		NPP	MAY 27, 2006
		#4337201*PED	DEC 04, 2002		PED	NOV 27, 2006
		#5006344	JUL 10, 2009			
		#5006344*PED	JAN 10, 2010			
019915 004	FOSINOPRIL SODIUM; MONOPRIL	#4337201	JUN 04, 2003		NPP	MAY 27, 2006
		#4337201*PED	DEC 04, 2002		PED	NOV 27, 2006
		#5006344	JUL 10, 2009			
		#5006344*PED	JAN 10, 2010			
020286 001	FOSINOPRIL SODIUM; MONOPRIL-HCT	#4337201	JUN 04, 2003		NPP	MAY 27, 2006
		#4337201*PED	DEC 04, 2002		PED	NOV 27, 2006
		#5006344	JUL 10, 2009			
		#5006344*PED	JAN 10, 2010			
		#4337201*PED	JUN 04, 2003			

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 # represents patent information submitted prior to 08/18/03

*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020286 002	FOSINOPRIL SODIUM; MONOPRIL-HCT	#4337201	DEC 04, 2002			
		#5006344	JUL 10, 2009			
		#5006344*PED	JAN 10, 2010			
		#4337201*PED	JUN 04, 2003			
076457 001	GANCICLOVIR; GANCICLOVIR				PC	FEB 16, 2004
076457 002	GANCICLOVIR; GANCICLOVIR				PC	FEB 16, 2004
021061 001	GATIFLOXACIN; TEQUIN				I-329	OCT 17, 2005
021061 002	GATIFLOXACIN; TEQUIN				I-329	OCT 17, 2005
021062 001	GATIFLOXACIN; TEQUIN				I-329	OCT 17, 2005
021062 002	GATIFLOXACIN; TEQUIN				I-329	OCT 17, 2005
021062 003	GATIFLOXACIN; TEQUIN				I-329	OCT 17, 2005
021062 004	GATIFLOXACIN; TEQUIN				I-329	OCT 17, 2005
021493 001	GATIFLOXACIN; ZYMAR				I-329	OCT 17, 2005
021399 001	GEFITINIB; IRESSA	#5880283	DEC 05, 2015		NDF	OCT 17, 2005
		#4980470	DEC 15, 2009		NCE	MAR 28, 2006
		#5457105	JAN 19, 2013		NCE	DEC 17, 2004
		#5616582	JAN 19, 2013		NCE	MAY 05, 2008
		#5770599	APR 26, 2016			
		#6262071	SEP 21, 2019			
		#6331550	SEP 21, 2019	U-513	NCE	APR 04, 2008
		#6340689	SEP 14, 2019	U-511		
		#6455540	SEP 21, 2019	U-512		
		#5633262	SEP 21, 2019	U-511		
		#5776944	JUN 15, 2015			
		#5962468	JUN 15, 2015			
		#6362161	JUN 15, 2015			
		#5981589	MAY 24, 2014	U-282		
		#6054430	MAY 24, 2014	U-441	ODE	DEC 20, 2003
		#6342476	MAY 24, 2014			
>ADD>	GLATIRAMER ACETATE; COPAXONE			U-441		
076467 001	GLIPIZIDE; GLIPIZIDE	#5091190	SEP 05, 2009			
020329 001	GLIPIZIDE; GLUCOTROL XL	#5545413	JUL 21, 2008	U-111	PC	OCT 19, 2003
020329 002	GLIPIZIDE; GLUCOTROL XL	#5091190	SEP 05, 2009	U-111		
020329 003	GLIPIZIDE; GLUCOTROL XL	#5545413	JUL 21, 2008	U-111		
		#4612008	SEP 16, 2003			
		#5024843	SEP 05, 2009			
		#5082668	SEP 16, 2003			
		#5091190	SEP 05, 2009	U-111		
		#5545413	JUL 21, 2008	U-111		
		#5591454	JAN 07, 2014	U-111		
		#5952340	SEP 14, 2016	U-519		
		#5952340	SEP 14, 2016	U-519		
		#6372252	APR 28, 2020	U-489		
		#4619921	DEC 16, 2004			
		#5616599	APR 01, 2014	U-500	NC	JUN 05, 2006
					NCE	APR 25, 2007
>ADD>	GRANISETRON HYDROCHLORIDE; KYTRIL					
020239 001	GRANISETRON HYDROCHLORIDE; KYTRIL					
020239 002	GRANISETRON HYDROCHLORIDE; KYTRIL					
021282 002	GUAFENESIN; MUCINEX					
019968 001	HALOBETASOL PROPIONATE; ULTRAVATE					
021532 002	HYDROCHLOROTHIAZIDE; BENICAR HCT					

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021532 003	HYDROCHLOROTHIAZIDE; BENICAR HCT	#5616599	APR 01, 2014	U-500	NC	JUN 05, 2006
021532 005	HYDROCHLOROTHIAZIDE; BENICAR HCT	#5616599	APR 01, 2014	U-500	NCE	APR 25, 2007
020818 003	HYDROCHLOROTHIAZIDE; DIOVAN HCT	#5399578	MAR 21, 2012	U-3	NC	JUN 05, 2006
021162 001	HYDROCHLOROTHIAZIDE; MICARDIS HCT	#6294197	JUN 18, 2017	U-3	NCE	APR 25, 2007
021162 002	HYDROCHLOROTHIAZIDE; MICARDIS HCT	#6358986	JAN 10, 2020		NC	JUN 05, 2006
020716 001	HYDROCODONE BITARTRATE; VICOPROFEN	#6358986	JAN 10, 2020		NCE	APR 25, 2007
020453 001	HYDROCORTISONE PROBUATE; PANDEL	#6599531	JUN 10, 2017			
021455 001	IBANDRONATE SODIUM; BONIVA	#4794106	AUG 28, 2006			
		#4927814	JUL 09, 2007	U-520	NCE	MAY 16, 2008
		#6143326	APR 21, 2017	U-520		
021472 001	IBUPROFEN; IBUPROFEN	#6294196	OCT 07, 2019			
021321 001	ICODextrin; EXTRANEAL	#6251426	JUN 25, 2018			
		#6248726	JUN 19, 2018	U-495	ODE	DEC 20, 2009
		#4761237	AUG 02, 2005	U-495		
		#4886789	DEC 12, 2006	U-495		
		#6077836	JUN 20, 2017	U-495		
		#5521184	MAY 28, 2013			
021588 002	IMATINIB MESYLATE; GLEEVEC	#5521184	MAY 28, 2013			
					I-392	MAY 20, 2006
					I-392	MAY 20, 2006
					NCE	MAY 10, 2006
					I-376	MAY 10, 2006
					ODE	FEB 01, 2009
					ODE	MAY 10, 2008
					I-392	MAY 20, 2006
					NCE	MAY 10, 2006
					I-376	DEC 20, 2005
					ODE	FEB 01, 2009
					ODE	MAY 10, 2008
021081 001	INSULIN GLARGINE; LANTUS	#4364921	MAR 06, 2005	U-498		
021425 001	IOPROMIDE; ULTRAVIST (PHARMACY)	#4364921	MAR 06, 2005	U-498		
021425 002	IOPROMIDE; ULTRAVIST (PHARMACY)	#5110493	MAY 05, 2009			
021528 001	KETOROLAC TROMETHAMINE; ACULAR LS	#5110493*PED	NOV 05, 2009			
		#5047407*PED	MAY 17, 2010			
		#5047407	NOV 17, 2009			
020857 001	LAMIVUDINE; COMBIVIR	#5047407	NOV 17, 2009			
		#5047407*PED	MAY 17, 2010			
		#5047407	NOV 17, 2009			
021003 001	LAMIVUDINE; EPIVIR-HBV	#5047407*PED	MAY 17, 2010			
		#5047407	NOV 17, 2009			
021004 001	LAMIVUDINE; EPIVIR-HBV	#5047407	MAY 17, 2010			
		#5047407*PED	NOV 17, 2009			
020241 001	LAMOTRIGINE; LAMICTAL	#5047407*PED	MAY 17, 2010			
		#5047407	NOV 17, 2009			
020241 002	LAMOTRIGINE; LAMICTAL	#5047407*PED	MAY 17, 2010			
					I-387	JAN 17, 2006
					I-404	JUN 20, 2006
					I-387	JAN 17, 2006
					I-404	JUN 20, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020241 003	LAMOTRIGINE; LAMICTAL	#4628098	MAY 10, 2009		I-387	JAN 17, 2006
020241 004	LAMOTRIGINE; LAMICTAL	#4689333	JUL 29, 2005	U-126	I-404	JUN 20, 2006
020241 005	LAMOTRIGINE; LAMICTAL	#5013743	FEB 12, 2010	U-452	I-387	JAN 17, 2006
020241 006	LAMOTRIGINE; LAMICTAL	#5026560	JUN 25, 2008		I-404	JUN 20, 2006
020764 001	LAMOTRIGINE; LAMICTAL CD	#5045321	SEP 03, 2008		I-387	JAN 17, 2006
020764 002	LAMOTRIGINE; LAMICTAL CD	#5093132	SEP 03, 2008		I-404	JUN 20, 2006
020764 003	LAMOTRIGINE; LAMICTAL CD	#5433959	SEP 03, 2008		I-387	JAN 17, 2006
020764 004	LAMOTRIGINE; LAMICTAL CD	#4628098	MAY 10, 2009		I-404	JUN 20, 2006
021281 001	LANSOPRAZOLE; PREVACID	#4689333	JUL 29, 2005	U-126	I-387	JAN 17, 2006
021281 002	LANSOPRAZOLE; PREVACID	#5013743	FEB 12, 2010	U-452	I-404	JUN 20, 2006
020905 001	LEFLUNOMIDE; ARAVA	#5026560	JUN 25, 2008		I-387	JAN 17, 2006
020905 002	LEFLUNOMIDE; ARAVA	#5045321	SEP 03, 2008		I-404	JUN 20, 2006
020905 003	LEFLUNOMIDE; ARAVA	#5093132	SEP 03, 2008		I-387	JAN 17, 2006
021488 001	LEUPROLIDE ACETATE; ELIGARD	#5433959	SEP 03, 2008		I-404	JUN 20, 2006
020837 001	LEVAlBUTEROL HYDROCHLORIDE; XOPENEX	#4938763	OCT 03, 2008		I-395	JUN 13, 2006
021035 001	LEVETIRACETAM; KEPPRA	#5278201	JAN 11, 2011		I-395	JUN 13, 2006
021035 002	LEVETIRACETAM; KEPPRA	#324519	OCT 20, 2011		I-395	JUN 13, 2006
021035 003	LEVETIRACETAM; KEPPRA	#5599552	FEB 04, 2014		NP	FEB 13, 2006
021505 001	LEVETIRACETAM; KEPPRA	#5733950	OCT 03, 2008			
		#5739176	OCT 03, 2008			
		#5362755	NOV 08, 2011	U-332		
		#4943639	JUN 06, 2006			
		#4943639	JUN 06, 2006			
		#4943639	JUN 06, 2006			
		#4873223	JUN 06, 2006		NCE	NOV 30, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL. EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020634 001	LEVOFLOXACIN; LEVAQUIN	#5503407	DEC 20, 2010		I-393	MAY 23, 2006
020634 002	LEVOFLOXACIN; LEVAQUIN	#555581	FEB 15, 2022		I-393	MAY 23, 2006
020634 003	LEVOFLOXACIN; LEVAQUIN	#555581	FEB 15, 2022		I-393	MAY 23, 2006
020635 001	LEVOFLOXACIN; LEVAQUIN	#555581	FEB 15, 2022		I-393	MAY 23, 2006
020635 002	LEVOFLOXACIN; LEVAQUIN IN DEXTROSE	#555581	FEB 15, 2022		I-393	MAY 23, 2006
020635 003	LEVOFLOXACIN; LEVAQUIN IN DEXTROSE	#555581	FEB 15, 2022		I-393	MAY 23, 2006
021199 001	LEVOFLOXACIN; QUIXIN	#555581	FEB 15, 2022		I-393	MAY 23, 2006
021301 001	LEVOTHYROXINE SODIUM; LEVOXYL	#555581	FEB 15, 2022			
021301 002	LEVOTHYROXINE SODIUM; LEVOXYL	#555581	FEB 15, 2022			
021301 003	LEVOTHYROXINE SODIUM; LEVOXYL	#555581	FEB 15, 2022			
021301 004	LEVOTHYROXINE SODIUM; LEVOXYL	#555581	FEB 15, 2022			
021301 005	LEVOTHYROXINE SODIUM; LEVOXYL	#555581	FEB 15, 2022			
021301 006	LEVOTHYROXINE SODIUM; LEVOXYL	#555581	FEB 15, 2022			
021301 007	LEVOTHYROXINE SODIUM; LEVOXYL	#555581	FEB 15, 2022			
021301 008	LEVOTHYROXINE SODIUM; LEVOXYL	#555581	FEB 15, 2022			
021301 009	LEVOTHYROXINE SODIUM; LEVOXYL	#555581	FEB 15, 2022			
021301 010	LEVOTHYROXINE SODIUM; LEVOXYL	#555581	FEB 15, 2022			
021301 011	LEVOTHYROXINE SODIUM; LEVOXYL	#555581	FEB 15, 2022			
021301 012	LEVOTHYROXINE SODIUM; LEVOXYL	#555581	FEB 15, 2022			
020612 001	LIDOCAINE; LIDODERM	#5589180	MAR 17, 2009	U-485		
		#5411738	MAY 02, 2012			
		#5827529	OCT 27, 2015	U-486		
		#5709869	MAR 17, 2009	U-485		
		#5601838	MAY 02, 2012	U-488		
		#6559305	JAN 29, 2021			
021130 001	LINEZOLID; ZYVOX	#6559305	JAN 29, 2021		NPP	DEC 19, 2005
021130 002	LINEZOLID; ZYVOX	#6559305	JAN 29, 2021		I-402	JUL 22, 2006
021131 001	LINEZOLID; ZYVOX	#6559305	JAN 29, 2021		I-402	JUL 22, 2006
021132 001	LINEZOLID; ZYVOX	#6559305	JAN 29, 2021		I-402	JUL 22, 2006
019558 001	LISINAPRIL; PRINIVIL				NPP	DEC 19, 2005
019558 002	LISINAPRIL; PRINIVIL				I-402	JUL 22, 2006
019558 003	LISINAPRIL; PRINIVIL				NPP	DEC 19, 2005
019558 004	LISINAPRIL; PRINIVIL				I-402	JUL 22, 2006
019558 006	LISINAPRIL; PRINIVIL				NPP	DEC 19, 2005
019777 001	LISINAPRIL; ZESTRIL				NPP	DEC 19, 2005

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019777 002	LISINAPRIL; ZESTRIL	#6521651	NOV 01, 2017		PED	NOV 29, 2006
019777 003	LISINAPRIL; ZESTRIL	#4659716	APR 21, 2004	U-142	NPP	MAY 29, 2006
019777 004	LISINAPRIL; ZESTRIL	#4659716*PED	OCT 21, 2004	U-142	PED	NOV 29, 2006
019777 005	LISINAPRIL; ZESTRIL	#4863931	SEP 15, 2008		NPP	MAY 29, 2006
019777 006	LISINAPRIL; ZESTRIL	#4863931*PED	MAR 15, 2009		PED	NOV 29, 2006
021226 001	LOPINAVIR; KALETRA	#4659716	APR 21, 2004	U-142	NPP	MAY 29, 2006
019658 002	LORATADINE; CLARITIN	#4863931	OCT 21, 2004	U-142	PED	NOV 29, 2006
020641 002	LORATADINE; CLARITIN	#4659716*PED	SEP 15, 2008		NPP	NOV 29, 2003
020704 002	LORATADINE; CLARITIN REDITABS	#4863931*PED	MAR 15, 2009		PED	MAY 29, 2006
019670 002	LORATADINE; CLARITIN-D	#6132758	JUN 01, 2018	U-142		
020470 002	LORATADINE; CLARITIN-D 24 HOUR	#4659716*PED	APR 21, 2004	U-142		
075209 001	LORATADINE; LORATADINE	#4863931	SEP 15, 2008			
075822 001	LORATADINE; LORATADINE	#4863931*PED	MAR 15, 2009			
075706 001	LORATADINE; LORATADINE AND PSEUD	#4659716	APR 21, 2004	U-142		
076050 001	LORATADINE; LORATADINE AND PSEUD	#4863931	SEP 15, 2008			
020386 001	LOSARTAN POTASSIUM; COZAAR	#4659716*PED	MAR 15, 2009			
020386 002	LOSARTAN POTASSIUM; COZAAR	#4863931*PED	APR 21, 2004	U-496	PC	JUL 21, 2003
020386 003	LOSARTAN POTASSIUM; COZAAR	#5314697	OCT 23, 2012	U-496	PC	AUG 09, 2003
		#5210079	MAY 11, 2010	U-496	PC	NOV 29, 2003
		#5210079*PED	NOV 11, 2010	U-496	PC	JUL 30, 2003
		#5210079*PED	MAY 11, 2010	U-496	I-383	SEP 17, 2005
		#5210079*PED	NOV 11, 2010	U-496	I-383	SEP 17, 2005
		#5210079*PED	MAY 11, 2010	U-496	I-383	SEP 17, 2005
		#5210079*PED	NOV 11, 2010	U-496	I-383	SEP 17, 2005

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021410 001	METFORMIN HYDROCHLORIDE; AVANDAMET	#6475521	MAR 19, 2018		NCE	MAY 25, 2004
021410 002	METFORMIN HYDROCHLORIDE; AVANDAMET	#6344215	OCT 27, 2020		NCE	MAY 25, 2004
021410 003	METFORMIN HYDROCHLORIDE; AVANDAMET	#6344215	OCT 27, 2020		NCE	MAY 25, 2004
021410 004	METFORMIN HYDROCHLORIDE; AVANDAMET	#6344215	OCT 27, 2020		NCE	MAY 25, 2004
021410 005	METFORMIN HYDROCHLORIDE; AVANDAMET	#6344215	OCT 27, 2020		NCE	MAY 25, 2004
021202 004	METFORMIN HYDROCHLORIDE; GLUCOPHAGE XR	#5472969	MAY 22, 2007		NDF	OCT 13, 2003
021259 002	METHYLPHENIDATE HYDROCHLORIDE; METADATE CD	#5472969	MAY 22, 2007		NDF	APR 03, 2004
021259 003	METHYLPHENIDATE HYDROCHLORIDE; METADATE CD	#5472969	MAY 22, 2007		NDF	APR 03, 2004
019962 003	METOPROLOL SUCCINATE; TOPROL-XL	#5525616	MAY 13, 2013		NCE	JUL 31, 2008
021348 001	MIGLUSTAT; ZAVESCA	#5525616	JUN 11, 2013		ODE	JUL 31, 2010
076119 001	MIRTAZAPINE; MIRTAZAPINE				PC	JUN 16, 2003
076119 002	MIRTAZAPINE; MIRTAZAPINE				PC	JUN 16, 2003
076204 001	MOEXIPRIL HYDROCHLORIDE; MOEXIPRIL HCL				PC	SEP 21, 2003
076204 002	MOEXIPRIL HYDROCHLORIDE; MOEXIPRIL HCL				PC	SEP 21, 2003
021085 001	MOXIFLOXACIN HYDROCHLORIDE; AVELOX				I-385	FEB 28, 2006
021277 001	MOXIFLOXACIN HYDROCHLORIDE; AVELOX IN SODIUM CHL				I-385	FEB 28, 2006
021598 001	MOXIFLOXACIN HYDROCHLORIDE; VIGAMOX	#4990517	JUN 30, 2009	U-298	NDF	APR 15, 2006
		#5607942	MAR 04, 2014	U-298	PED	OCT 15, 2006
		#5849752	DEC 05, 2016			
		#4990517	JUN 30, 2009			
		#5607942	MAR 04, 2014			
		#5849752	DEC 05, 2016			
		#4990517*PED	DEC 30, 2009			
		#5607942*PED	SEP 04, 2014			
		#5849752*PED	JUN 05, 2017			
		#6559188	SEP 17, 2019			
		#6559188	SEP 17, 2019			
		#5484926	SEP 17, 2019			
		#5952343	OCT 07, 2013			
		#6162812	OCT 07, 2013	U-257		
		5952343*PED	OCT 07, 2013	U-248		
		5484926*PED	APR 07, 2014	U-257		
		6162812*PED	APR 07, 2014	U-248		
		5484926	OCT 07, 2013			
		#5952343	OCT 07, 2013			
		#6162812	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		5952343*PED	APR 07, 2014			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			
		5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		#5952343	OCT 07, 2013			
		5952343*PED	OCT 07, 2013			
		6162812*PED	APR 07, 2014			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020007 003	ONDANSETRON HYDROCHLORIDE; ZOPRAN PRESERVATIVE	#4695578	JAN 25, 2005			
		#4753789	JUN 24, 2006	U-44		
020766 001	ORLISTAT; XENICAL	#4598089	JUN 18, 2009		NCE	APR 23, 2004
		#6004996	JAN 06, 2018		PED	OCT 23, 2004
		4598089*PED	DEC 18, 2009			
		6004996*PED	JUL 06, 2018			
		#6030643	MAY 16, 2017	U-497		
020776 001	OXAPROZIN POTASSIUM; DAYPRO ALTA				NPP	APR 15, 2006
017577 001	OXYBUTYNYN CHLORIDE; DITROPAN				PED	OCT 15, 2006
018211 001	OXYBUTYNYN CHLORIDE; DITROPAN				NPP	APR 15, 2006
020897 001	OXYBUTYNYN CHLORIDE; DITROPAN XL				PED	OCT 15, 2006
020897 002	OXYBUTYNYN CHLORIDE; DITROPAN XL				NPP	APR 15, 2006
020897 003	OXYBUTYNYN CHLORIDE; DITROPAN XL				PED	OCT 15, 2006
021351 002	OXYBUTYNYN; OXYTROL				NPP	APR 15, 2006
		#5164190	DEC 11, 2010		NDF	OCT 15, 2006
		#5601839	APR 26, 2015			
		#5834010	APR 26, 2015			
		#5202333	APR 13, 2010	U-528	NCE	JUL 25, 2008
		#4758579	JUL 19, 2010			
		#4758579	JUL 19, 2010			
021372 001	PALMOSETRON HYDROCHLORIDE; ALOXI					
020987 001	PANTOPRAZOLE SODIUM; PROTONIX					
020987 002	PANTOPRAZOLE SODIUM; PROTONIX					
020988 001	PANTOPRAZOLE SODIUM; PROTONIX IV					
075356 001	PAROXETINE HYDROCHLORIDE; PAROXETINE HCL				PC	MAR 06, 2004
075356 002	PAROXETINE HYDROCHLORIDE; PAROXETINE HCL				PC	MAR 06, 2004
075356 003	PAROXETINE HYDROCHLORIDE; PAROXETINE HCL				PC	MAR 06, 2004
075356 004	PAROXETINE HYDROCHLORIDE; PAROXETINE HCL				PC	MAR 06, 2004
020936 001	PAROXETINE HYDROCHLORIDE; PAXIL CR					
020936 002	PAROXETINE HYDROCHLORIDE; PAXIL CR	#6548084	JUL 19, 2016			
		#6548084*PED	JAN 19, 2017			
		#6548084	JUL 19, 2016			
020936 003	PAROXETINE HYDROCHLORIDE; PAXIL CR	#6548084*PED	JAN 19, 2017			
		#6548084	JUL 19, 2016			
021299 001	PAROXETINE MESYLATE; PAROXETINE MESYLATE	#6548084*PED	JAN 19, 2017			
		#5874447	JUN 10, 2017	U-286		
		#5874447	JUN 10, 2017	U-518		
021299 002	PAROXETINE MESYLATE; PAROXETINE MESYLATE	#5874447	JUN 10, 2017	U-46		
		#5874447	JUN 10, 2017	U-286		
		#5874447	JUN 10, 2017	U-518		
021299 003	PAROXETINE MESYLATE; PAROXETINE MESYLATE	#5874447	JUN 10, 2017	U-46		
		#5874447	JUN 10, 2017	U-286		
		#5874447	JUN 10, 2017	U-518		
021299 004	PAROXETINE MESYLATE; PAROXETINE MESYLATE	#5874447	JUN 10, 2017	U-46		
		#5874447	JUN 10, 2017	U-286		
		#5874447	JUN 10, 2017	U-518		
		#5874447	JUN 10, 2017	U-46		
		#5874447	JUN 10, 2017	U-286		
		#5874447	JUN 10, 2017	U-518		

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 # represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021106 001	PEGVISOMANT; SOMAVERT	#6057292 #5849535 #5958879 #5350836 #5681809 #6583115 #6057292 #5849535 #5958879 #5350836 #5681809 #6583115 #6057292 #5849535 #5958879 #5350836 #5681809 #6583115 #6469015 #6573378 #6579981	SEP 21, 2015 SEP 21, 2015 SEP 27, 2011 SEP 27, 2011 SEP 27, 2011 SEP 27, 2011 SEP 21, 2015 SEP 21, 2015 SEP 27, 2011 SEP 27, 2011 SEP 27, 2011 SEP 27, 2011 SEP 21, 2015 SEP 21, 2015 SEP 27, 2011 SEP 27, 2011 SEP 27, 2011 SEP 27, 2011 OCT 22, 2019 SEP 24, 2010 JUN 17, 2020	U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-501 U-501	NCE ODE	MAR 25, 2008 MAR 25, 2010
021106 002	PEGVISOMANT; SOMAVERT	#6057292 #5849535 #5958879 #5350836 #5681809 #6583115 #6057292 #5849535 #5958879 #5350836 #5681809 #6583115 #6057292 #5849535 #5958879 #5350836 #5681809 #6583115 #6469015 #6573378 #6579981	SEP 21, 2015 SEP 21, 2015 SEP 27, 2011 SEP 27, 2011 SEP 27, 2011 SEP 27, 2011 SEP 21, 2015 SEP 21, 2015 SEP 27, 2011 SEP 27, 2011 SEP 27, 2011 SEP 27, 2011 SEP 21, 2015 SEP 21, 2015 SEP 27, 2011 SEP 27, 2011 SEP 27, 2011 SEP 27, 2011 OCT 22, 2019 SEP 24, 2010 JUN 17, 2020	U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-501 U-501	NCE ODE	MAR 25, 2008 MAR 25, 2010
021106 003	PEGVISOMANT; SOMAVERT	#6057292 #5849535 #5958879 #5350836 #5681809 #6583115 #6057292 #5849535 #5958879 #5350836 #5681809 #6583115 #6057292 #5849535 #5958879 #5350836 #5681809 #6583115 #6469015 #6573378 #6579981	SEP 21, 2015 SEP 21, 2015 SEP 27, 2011 SEP 27, 2011 SEP 27, 2011 SEP 27, 2011 SEP 21, 2015 SEP 21, 2015 SEP 27, 2011 SEP 27, 2011 SEP 27, 2011 SEP 27, 2011 SEP 21, 2015 SEP 21, 2015 SEP 27, 2011 SEP 27, 2011 SEP 27, 2011 SEP 27, 2011 OCT 22, 2019 SEP 24, 2010 JUN 17, 2020	U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-507 U-501 U-501	NCE ODE	MAR 25, 2008 MAR 25, 2010
020629 001	PENCICLOVIR SODIUM; DENAVIR	#4687777 #4687777 #6150384	JAN 17, 2011 JAN 17, 2011 JUN 19, 2016	U-419	PC PC PC	MAY 31, 2003 MAY 31, 2003 MAY 31, 2003
020451 001	PORFIMER SODIUM; PHOTOFRIN	#6500454 #6500454 #5045552 #5403856 #5403856 #5403856 #5403856 #6524570* #6524570* #6524570*	DEC 31, 2022 DEC 31, 2022 MAY 08, 2013 MAY 08, 2013 APR 04, 2012 APR 04, 2012 APR 04, 2012 APR 04, 2012 MAY 01, 2016 MAY 01, 2017	U-385 U-385 U-71 U-71 U-71 U-71 U-499 U-499	I-391 ODE PC NDF NDF NDF NP NP	AUG 01, 2006 AUG 01, 2010 DEC 24, 2003 SEP 04, 2006 SEP 04, 2006 SEP 04, 2006 MAR 12, 2006 MAR 12, 2006
074726 003	POTASSIUM CHLORIDE; Klor-Con M15					
021416 001	PROPAFENONE HYDROCHLORIDE; RYTHMOL SR					
021416 002	PROPAFENONE HYDROCHLORIDE; RYTHMOL SR					
021416 003	PROPAFENONE HYDROCHLORIDE; RYTHMOL SR					
021438 001	PROPRANOLOL HYDROCHLORIDE; INNOPRAN XL					
021438 002	PROPRANOLOL HYDROCHLORIDE; INNOPRAN XL					
020973 001	RABEPRAZOLE SODIUM; ACIPHEX					
020973 002	RABEPRAZOLE SODIUM; ACIPHEX					
019901 001	RAMIPRIL; ALTACE					
019901 002	RAMIPRIL; ALTACE					
019901 003	RAMIPRIL; ALTACE					
019901 004	RAMIPRIL; ALTACE					
020903 001	RIBAVIRIN; REBETOL					

>ADD>
 >ADD>

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020903 002	RIBAVIRIN;REBETOL	#6472373	SEP 21, 2017	U-521	M-26	MAR 06, 2005
		#6472373*PED	MAR 21, 2018	U-521	ODE	JUL 29, 2010
		#6461605	NOV 01, 2016	U-521	PED	JAN 29, 2011
		#6461605*PED	MAY 01, 2017	U-521	NDF	JUL 29, 2006
		#6172046	SEP 21, 2017	U-521	ODE	JUL 29, 2010
		#6172046*PED	MAR 21, 2018	U-521	PED	JAN 29, 2011
		#6063772	JAN 23, 2016	U-521		
		#6063772*PED	JUL 23, 2016	U-521		
		#5767097	JAN 23, 2016	U-521		
		#5767097*PED	JUL 23, 2016	U-521		
020835 001	RISEDRONATE SODIUM;ACTONEL	#6096342	NOV 22, 2011			
020835 002	RISEDRONATE SODIUM;ACTONEL	#6096342	NOV 22, 2011			
020835 003	RISEDRONATE SODIUM;ACTONEL	#5583122	DEC 10, 2013	U-222		
		#6096342	NOV 22, 2011			
		#6165513	JUN 10, 2018		M-15	MAR 03, 2005
021444 001	RISPERIDONE;RISPERDAL	#4804663	DEC 29, 2007	U-516		
		#5648093	JUL 15, 2014			
		#6224905	JUN 10, 2017	U-516		
021444 002	RISPERIDONE;RISPERDAL	#4804663	DEC 29, 2007	U-516		
		#5648093	JUL 15, 2014			
		#6224905	JUN 10, 2017	U-516		
021444 003	RISPERIDONE;RISPERDAL	#4804663	DEC 29, 2007		M-15	MAR 03, 2005
		#5648093	JUL 15, 2014			
		#6224905	JUN 10, 2017	U-516		
021042 001	ROFECOXIB;VIOXX	#4824860	MAY 19, 2008		M-27	AUG 06, 2006
021042 002	ROFECOXIB;VIOXX	#4824860	MAY 19, 2008		M-27	AUG 06, 2006
021042 003	ROFECOXIB;VIOXX				M-27	AUG 06, 2006
021052 001	ROFECOXIB;VIOXX				M-27	AUG 06, 2006
021052 002	ROFECOXIB;VIOXX				M-27	AUG 06, 2006
020658 006	ROPINIROLE HYDROCHLORIDE;REQUIP					
020658 007	ROPINIROLE HYDROCHLORIDE;REQUIP					
021071 002	ROSIGLITAZONE MALEATE;AVANDIA				I-384	FEB 27, 2006
021071 003	ROSIGLITAZONE MALEATE;AVANDIA				I-384	FEB 27, 2006
021071 004	ROSIGLITAZONE MALEATE;AVANDIA				I-384	FEB 27, 2006
021366 002	ROSUVASTATIN CALCIUM;CRESTOR				NCE	AUG 12, 2008
021366 003	ROSUVASTATIN CALCIUM;CRESTOR				NCE	AUG 12, 2008

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021366 004	ROSUVASTATIN CALCIUM;CRESTOR	#RE37314 #6589959 #6316460	JUN 12, 2012 DEC 23, 2019 AUG 04, 2020		NCE	AUG 12, 2008
021366 005	ROSUVASTATIN CALCIUM;CRESTOR	#RE37314 #6589959 #6316460 #4562829	JUN 12, 2012 DEC 23, 2019 AUG 04, 2020 MAY 01, 2004	U-503	NCE	AUG 12, 2008
019414 001	RUBIDIUM CHLORIDE RB-82;CARDIOGEN-82					
019839 001	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
019839 002	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
019839 003	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
019839 004	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
019839 005	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
020925 001	SEVELAMER HYDROCHLORIDE;RENAGEL					
021179 001	SEVELAMER HYDROCHLORIDE;RENAGEL					
021179 002	SEVELAMER HYDROCHLORIDE;RENAGEL					
019766 001	SIMVASTATIN;ZOCOR	#6509013 #6509013 #6509013	AUG 13, 2013 AUG 13, 2013 AUG 13, 2013			
019766 002	SIMVASTATIN;ZOCOR					
019766 003	SIMVASTATIN;ZOCOR					
019766 004	SIMVASTATIN;ZOCOR					
019766 005	SIMVASTATIN;ZOCOR					
021083 001	SIROLIMUS;RAPAMUNE					
021110 001	SIROLIMUS;RAPAMUNE					
021110 002	SIROLIMUS;RAPAMUNE					
020231 001	SODIUM FLUORIDE;COLGATE TOTAL					
020280 007	SOMATROPIN RECOMBINANT;GENOTROPIN	#5100899 #5212155 #5308847 #5403833 #5989591 #5286840	JUN 06, 2009 MAY 18, 2010 MAY 03, 2011 APR 04, 2012 MAR 11, 2018 JUL 16, 2008	U-290 U-291 U-292 U-293	NCE I-386	APR 16, 2006 APR 16, 2006 APR 16, 2006 APR 16, 2006 APR 11, 2006 APR 11, 2006 SEP 15, 2004 APR 11, 2006
020280 001	SOMATROPIN RECOMBINANT;GENOTROPIN					
020280 002	SOMATROPIN RECOMBINANT;GENOTROPIN					
020280 003	SOMATROPIN RECOMBINANT;GENOTROPIN					
020280 005	SOMATROPIN RECOMBINANT;GENOTROPIN					
020280 008	SOMATROPIN RECOMBINANT;GENOTROPIN					
020280 009	SOMATROPIN RECOMBINANT;GENOTROPIN					
020280 010	SOMATROPIN RECOMBINANT;GENOTROPIN					
020280 011	SOMATROPIN RECOMBINANT;GENOTROPIN					
020280 012	SOMATROPIN RECOMBINANT;GENOTROPIN					
020280 013	SOMATROPIN RECOMBINANT;GENOTROPIN					
019640 001	SOMATROPIN RECOMBINANT;HUMATROPE					
019640 004	SOMATROPIN RECOMBINANT;HUMATROPE					
019640 005	SOMATROPIN RECOMBINANT;HUMATROPE					
019640 006	SOMATROPIN RECOMBINANT;HUMATROPE					

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019640 007	SOMATROPIN RECOMBINANT; HUMATROPE	#5633352	MAY 27, 2014		I-398	JUL 25, 2006
021148 001	SOMATROPIN RECOMBINANT; NORDITROPIN	#5849700	DEC 15, 2015	U-340		
		#5849704	DEC 15, 2015			
021148 002	SOMATROPIN RECOMBINANT; NORDITROPIN	#5633352	MAY 27, 2014			
		#5849700	DEC 15, 2015	U-340		
021148 003	SOMATROPIN RECOMBINANT; NORDITROPIN	#5849704	DEC 15, 2015			
		#5633352	MAY 27, 2014	U-340		
		#5849700	DEC 15, 2015			
021151 005	SOTALOL HYDROCHLORIDE; BETAPACE AF				NP	FEB 22, 2003
021151 006	SOTALOL HYDROCHLORIDE; BETAPACE AF				PED	AUG 22, 2003
021151 007	SOTALOL HYDROCHLORIDE; BETAPACE AF				NP	FEB 22, 2003
					PED	AUG 22, 2003
020413 001	STAVUDINE; ZERIT				NP	FEB 22, 2003
					PED	AUG 22, 2003
021453 001	STAVUDINE; ZERIT XR	#4978655	JUN 24, 2008		NDF	DEC 31, 2005
		#4978655*PED	DEC 24, 2008	U-248		
021453 002	STAVUDINE; ZERIT XR	#4978655	JUN 24, 2008		PED	JUL 01, 2006
		#4978655*PED	DEC 24, 2008	U-248		
021453 003	STAVUDINE; ZERIT XR	#4978655	JUN 24, 2008		NDF	DEC 31, 2005
		#4978655*PED	DEC 24, 2008	U-248		
021453 004	STAVUDINE; ZERIT XR	#4978655	JUN 24, 2008		PED	JUL 01, 2006
		#4978655*PED	DEC 24, 2008	U-248		
020600 001	TAZAROTENE; TAZORAC	#5914334	JUN 07, 2014	U-517		
		#6258830	JUN 07, 2014	U-517		
020600 002	TAZAROTENE; TAZORAC	#5914334	JUN 07, 2014			
		#6258830	JUN 07, 2014	U-517		
020372 001	TECHNETIUM TC-99M TETROFOSMIN KIT; MYOVIEW				I-396	FEB 28, 2006
020850 001	TELMISARTAN; MICARDIS	#6358986	JAN 10, 2020			
020850 002	TELMISARTAN; MICARDIS	#6358986	JAN 10, 2020			
020850 003	TELMISARTAN; MICARDIS	#5591762	JAN 07, 2014	U-3	NCE	NOV 10, 2003
		#6358986	JAN 10, 2020			
021356 001	TENOFOVIR DISOPROXIL FUMARATE; VIREAD				NPP	AUG 15, 2006
020749 001	TERBINAFINE HYDROCHLORIDE; LAMISIL	#6121314	MAY 18, 2012	U-502		
021124 001	TERBINAFINE HYDROCHLORIDE; LAMISIL AT	#6121314	MAY 18, 2012	U-504		
020489 001	TESTOSTERONE; ANDRODERM	#4863970	NOV 14, 2006			
		#4983395	NOV 12, 2007			
		#5152997	DEC 11, 2010	U-490		
		#5164190	DEC 11, 2010			
		#4849224	NOV 12, 2007			
		#4855294	SEP 06, 2008			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020489 002	TESTOSTERONE; ANDRODERM	#4849224 #4855294 #4863970 #4983395 #5152997 #5164190 #4615697 #6248358	NOV 12, 2007 SEP 06, 2008 NOV 14, 2006 NOV 12, 2007 DEC 11, 2010 DEC 11, 2010 OCT 07, 2003 AUG 23, 2019	U-490 U-527	NP NP	JUN 19, 2006 OCT 31, 2005
021454 001	TESTOSTERONE; TESTIM	#6561977	OCT 23, 2020	U-371		
020785 001	THALIDOMIDE; THALOMID	#6561976 #6045501 #6315720 #6561977 #6561976 #6045501 #6315720 #6561977	AUG 28, 2018 AUG 28, 2018 OCT 23, 2020 OCT 23, 2020 AUG 28, 2018 AUG 28, 2018 OCT 23, 2020 OCT 23, 2020	U-371 U-371 U-442 U-371 U-371 U-371 U-442 U-371	ODE NCE	JUL 16, 2005 JUL 16, 2003
020785 002	THALIDOMIDE; THALOMID	#6561976	AUG 28, 2018	U-371		
020785 003	THALIDOMIDE; THALOMID	#6045501 #6315720 #6561977 #6561976	AUG 28, 2018 OCT 23, 2020 OCT 23, 2020 AUG 28, 2018	U-371 U-442 U-371 U-371	ODE NCE	JUL 16, 2005 JUL 16, 2003
020771 001	TOLTERODINE TARTRATE; DETROL	#5382600	MAR 25, 2012	U-371		
020771 002	TOLTERODINE TARTRATE; DETROL	#5382600	MAR 25, 2012	U-371		
021228 001	TOLTERODINE TARTRATE; DETROL IA	#5382600	MAR 25, 2012	U-371		
021228 002	TOLTERODINE TARTRATE; DETROL IA	#5382600	MAR 25, 2012	U-371		
020505 001	TOPIRAMATE; TOPAMAX	#4513006	SEP 26, 2004	U-530		
020505 002	TOPIRAMATE; TOPAMAX	#4513006	SEP 26, 2004	U-530		
020505 003	TOPIRAMATE; TOPAMAX	#4513006	SEP 26, 2004	U-530		
020505 004	TOPIRAMATE; TOPAMAX	#4513006	SEP 26, 2004	U-530		
020505 005	TOPIRAMATE; TOPAMAX	#4513006	SEP 26, 2004	U-530		
020505 006	TOPIRAMATE; TOPAMAX	#4513006	SEP 26, 2004	U-530		
020844 001	TOPIRAMATE; TOPAMAX SPRINKLE	#4513006	SEP 26, 2004	U-530		
020844 002	TOPIRAMATE; TOPAMAX SPRINKLE	#4513006	SEP 26, 2004	U-530		
020844 003	TOPIRAMATE; TOPAMAX SPRINKLE	#4513006	SEP 26, 2004	U-530		
021257 001	TRAVOPROST; TRAVATAN	#4513006	SEP 26, 2004	U-530		
021108 001	TRETINOIN; RENOVA	#6531141	MAR 07, 2020	U-530		
020487 001	VALACYCLOVIR HYDROCHLORIDE; VALTREX	#4957924 #5879706 #6107302 #5879706 #6107302 #4957924 #4957924 #5879706 #6107302 #4957924 #6107302	JUN 23, 2009 JAN 19, 2016 JAN 19, 2016 JAN 19, 2016 JAN 19, 2016 JUN 23, 2009 JUN 23, 2009 JAN 19, 2016 JAN 19, 2016 JUN 23, 2009 JAN 19, 2016	U-530 U-530 U-530 U-530 U-530 U-530 U-530 U-530 U-530 U-530 U-530	M-23	FEB 13, 2006
020487 002	VALACYCLOVIR HYDROCHLORIDE; VALTREX	#4957924 #5879706 #6107302 #5879706 #6107302 #4957924 #4957924 #5879706 #6107302 #4957924 #6107302	JUN 23, 2009 JAN 19, 2016 JAN 19, 2016 JAN 19, 2016 JAN 19, 2016 JUN 23, 2009 JUN 23, 2009 JAN 19, 2016 JAN 19, 2016 JUN 23, 2009 JAN 19, 2016	U-530 U-530 U-530 U-530 U-530 U-530 U-530 U-530 U-530 U-530 U-530		
020550 001	VALACYCLOVIR HYDROCHLORIDE; VALTREX	#4957924 #5879706 #6107302 #4957924 #6107302	JUN 23, 2009 JAN 19, 2016 JAN 19, 2016 JUN 23, 2009 JAN 19, 2016	U-530 U-530 U-530 U-530 U-530	I-381 I-389 I-403	SEP 09, 2005 APR 01, 2006 AUG 29, 2006
020550 002	VALACYCLOVIR HYDROCHLORIDE; VALTREX	#4957924 #6107302 #4957924 #6107302	JUN 23, 2009 JAN 19, 2016 JUN 23, 2009 JAN 19, 2016	U-530 U-530 U-530 U-530	I-381 I-389 I-403 I-381	SEP 09, 2005 APR 01, 2006 AUG 29, 2006 SEP 09, 2005
021257 001	TRAVOPROST; TRAVATAN	#4513006	SEP 26, 2004	U-530		
021108 001	TRETINOIN; RENOVA	#6531141	MAR 07, 2020	U-530		
020487 001	VALACYCLOVIR HYDROCHLORIDE; VALTREX	#4957924 #5879706 #6107302 #5879706 #6107302 #4957924 #4957924 #5879706 #6107302 #4957924 #6107302	JUN 23, 2009 JAN 19, 2016 JAN 19, 2016 JAN 19, 2016 JAN 19, 2016 JUN 23, 2009 JUN 23, 2009 JAN 19, 2016 JAN 19, 2016 JUN 23, 2009 JAN 19, 2016	U-530 U-530 U-530 U-530 U-530 U-530 U-530 U-530 U-530 U-530 U-530		

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 # represents patent information submitted prior to 08/18/03 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021400 001	VARDENAFIL HYDROCHLORIDE; LEVITRA	#4612008	SEP 16, 2003			
021400 002	VARDENAFIL HYDROCHLORIDE; LEVITRA	#6146662	AUG 14, 2007	U-366	NCE	AUG 19, 2008
021400 003	VARDENAFIL HYDROCHLORIDE; LEVITRA	#4612008	SEP 16, 2003		NCE	AUG 19, 2008
021400 004	VARDENAFIL HYDROCHLORIDE; LEVITRA	#6146662	AUG 14, 2007		NCE	AUG 19, 2008
020699 001	VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR	#5116844	AUG 11, 2009		NCE	AUG 19, 2008
020699 002	VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR	#5364938	NOV 15, 2011		I-261	FEB 11, 2006
020699 003	VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR	#5567817	OCT 22, 2013		I-261	FEB 11, 2006
020699 004	VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR	#5773443	JAN 25, 2011		I-261	FEB 11, 2006
020552 001	VERAPAMIL HYDROCHLORIDE; COVERA-HS	#5116844	AUG 11, 2009		I-261	FEB 11, 2006
020552 002	VERAPAMIL HYDROCHLORIDE; COVERA-HS	#5364938	NOV 15, 2011	U-366		
021266 001	VORICONAZOLE; VFEND	#5567817	OCT 22, 2013	U-366		
021266 002	VORICONAZOLE; VFEND	#5773443	NOV 15, 2011			
021267 001	VORICONAZOLE; VFEND	#5773443	JAN 25, 2011			
020859 001	ZALEPLON; SONATA	#5116844	AUG 11, 2009			
020859 002	ZALEPLON; SONATA	#5364938	NOV 15, 2011			
021223 002	ZOLEDRONIC ACID; ZOMETA	#5567817	OCT 22, 2013			
021231 002	ZOLMITRIPTAN; ZOMIG-ZMT	#5773443	JAN 25, 2011			
020789 002	ZONISAMIDE; ZONEGRAN	#4626538	JUN 06, 2008			
020789 003	ZONISAMIDE; ZONEGRAN	#4777163	JUN 06, 2008			
		#4939130	JUL 24, 2007	U-53	NCE	AUG 20, 2006
			NOV 13, 2007		I-361	FEB 22, 2005
					ODE	AUG 20, 2008
					NDF	FEB 13, 2004
					NCE	MAR 27, 2005
					NCE	MAR 27, 2005

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 23RD EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

PATENT & EXCLUSIVITY ABBREVIATIONS

RTO RX TO OTC SWITCH OR OTC USE

EXCLUSIVITY DOSING SCHEDULE

- D-78 USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS
- D-79 NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE
- D-80 CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING
- D-81 NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-82 USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS

EXCLUSIVITY INDICATION

- I-380 TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR
- I-381 TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER
- I-382 FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION
- I-383 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
- I-384 USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES
- I-385 MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD "INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML" TO STREPTOCOCCUS PNEUMONIAE
- I-386 RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION
- I-387 ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAT OR EQUAL TO 2 YEARS OF AGE
- I-388 TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
- I-389 SUPPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS
- I-390 USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE, DIABETES, PERIPHERAL VESSEL DISEASE, STROKE HISTORY, OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH, REDUCE NONFATAL MI & STROKE.....
- I-391 INTENTIONALLY LEFT BLANK
- I-392 TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT OR RESIST TO INTERFERON ALPHA THERAPY.NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL
- I-393 CHRONIC BACTERIAL PROSTATITIS
- I-394 USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES
- I-395 TO IMPROVE PHYSICAL FUNCTION

- I-396 EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION
- I-397 EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY
- I-398 IDIOPATHIC SHORT STATURE
- I-399 TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSSES, PERITONITIS AND PLEURAL SPACE INFECTIONS
- I-400 USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-401 LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA
- I-402 DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS
- I-403 USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE
- I-404 MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY

EXCLUSIVITY MISCELLANEOUS

- M-23 INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT
- M-24 INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION
- M-25 ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PKG INSERT
- M-26 INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01
- M-27 INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY

PATENT USE

- U-494 TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
- U-495 PERITONEAL DIALYSIS SOLUTION
- U-496 METHOD FOR TREATING CHRONIC RENAL FAILURE
- U-497 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS
- U-498 INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST
- U-499 METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION
- U-500 USE AS AN ANTIHYPERTENSIVE AGENT
- U-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS
- U-502 PITYRIASIS VERSICOLOR
- U-503 GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR
- U-504 TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS
- U-505 ULTRASOUND CONTRAST AGENT
- U-506 PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE, BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..
- U-507 ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
- U-508 METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS
- U-509 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
- U-510 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES
- U-511 USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA
- U-512 USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA
- U-513 METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA

- U-514 PREVENTION OF OVULATION IN A WOMAN
- U-515 TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY
- U-516 METHOD OF TREATING A PSYCHOTIC DISEASE
- U-517 STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS
- U-518 OBSESSIVE COMPULSIVE DISORDER
- U-519 POST OPERATIVE NAUSEA AND VOMITING
- U-520 PREMENOPAUSAL OSTEOPOROSIS
- U-521 METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
- U-522 TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA
- U-523 METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED
- U-524 METHOD OF TREATING DIARRHEA
- U-525 METHOD OF TREATING PARASITIC INFECTIONS
- U-526 METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION
- U-527 METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE
- U-528 PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
- U-529 ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE
- U-530 TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES

